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Overall results will be discussed in the forthcoming chapters, and 
have been published in the papers listed below: 
 
1 Armando Zarrelli, Valeria Romanucci, Marina Della Greca, Lorenzo De 
Napoli, Lucio Previtera and Giovanni Di Fabio. “New Silybin Scaffold for 
Chemical Diversification: Synthesis of Novel 23-Phosphodiester Silybin 
Conjugates” Synlett 24, no. 01 (December 04, 2013): 45–48, doi:10.1055/s-
0032-1317688. 
Abstract: Silybin is the major component (ca. 30%) of the silymarin 
complex extracted from the seeds of Silybum marianum, with multiple 
biological activities operating at various cell levels. As an ongoing effort 
toward the exploitation of natural products as scaffolds for chemical 
diversification at readily accessible positions, we present here an efficient 
synthetic procedure to obtain new 23-phosphodiester silybin conjugates 
with different labels. A key point in our approach is the new 3,5,7,20-
tetra-O-acetylsilybin-23-phosphoramidite, useful for a variety of 
derivatizations following a reliable and well-known chemistry. The 
feasibility of the procedure has been demonstrated by preparing new 23-
silybin conjugates, exploiting standard phosphoramidite chemistry. 
2 Giovanni Di Fabio, Valeria Romanucci, Cinzia Di Marino, Lorenzo De 
Napoli and Armando Zarrelli. “A Rapid and Simple Chromatographic 
Separation of Diastereomers of Silibinin and Their Oxidation to Produce 
2,3-Dehydrosilybin Enantiomers in an Optically Pure Form” Planta 
Medica 79, no. 12 (August 2013): 1077–80, doi:10.1055/s-0032-1328703. 
Abstract: Silybin A and B were separated from commercial silibinin using 
the preparative HPLC method. The described method is rapid and 
effective in obtaining gram-scale amounts of two diastereoisomers with 
minimal effort. In our approach, silibinin was dissolved in THF (solubility 
greater than 100mg/mL), an alternative solvent to H2O or MeOH in which 
silibinin has a very low solubility (ca 0.05–1.5mg/mL), and then separated 
into its two components using preparative RP-HPLC. By starting with 
purified diastereoisomers, it was possible to obtain the two enantiomers 
of 2,3-dehydrosilybin in good yields and optically pure using an efficient 
oxidation procedure. All of the purified products were fully characterised 
using NMR (1H, 13C), CD, [α]D, and ESI-MS analyses. The purities of the 
products, which were evaluated using analytical HPLC, were greater 
than 98% in all cases. 
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3 Giovanni Di Fabio, Valeria Romanucci, Mauro De Nisco, Silvana 
Pedatella, Cinzia Di Marino and Armando Zarrelli. “Microwave-Assisted 
Oxidation of Silibinin: A Simple and Preparative Method for the 
Synthesis of Improved Radical Scavengers” Tetrahedron Letters 54, no. 
46 (November 2013): 6279–82, doi:10.1016/j.tetlet.2013.09.035. 
Abstract: A new and preparative oxidation of silibinin has been developed 
to give access to two different silibinin derivatives known for their 
enhanced antioxidant properties. Conventional heating methods were 
com- pared with results obtained from microwave (MW) heating. The 
base-catalysed oxidation of silibinin under MW heating is a very efficient 
method for the preparation of 2,3-dehydrosilybin and a related silybin 
rearrangement product. This latter compound shows enhanced radical 
scavenging properties. Optimised conditions were used to prepare 2,3-
dehydrosilybins A and B from optically pure silybins A and B. An 
efficient, preparative purification method was also developed to enable 
isolation of different products in high purity. 
4 Valeria Romanucci, Armando Zarrelli, Lorenzo De Napoli, Cinzia Di 
Marino, and Giovanni Di Fabio. “Synthesis of Oligonucleotide Conjugates 
and Phosphorylated Nucleotide Analogues: An Improvement to a Solid 
Phase Synthetic Approach” Journal of Chemistry, 2013, 
doi:10.1155/2013/469470. 
Abstract:  An improvement to our solid phase strategy to generate 
pharmacologically interesting molecule libraries is proposed here. The 
synthesis of new o-chlorophenol-functionalised solid supports with very 
high loading (0.18–0.22meq/g for control pore glass (CPG) and 0.25–
0.50meq/g for TG) is reported. To test the efficiency of these supports, we 
prepared nucleotide and oligonucleotide models, and their coupling yields 
and the purity of the crude detached materials were comparable to 
previously available results. These supports allow the facile and high 
yield preparation of highly pure phosphodiester and phosphoramidate 
monoester nucleosides, conjugated oligonucleotides, and other yet 
unexplored classes of phosphodiester and phosphoramidate molecules. 
5 Maria Gaglione, Nicoletta Potenza, Giovanni Di Fabio, Valeria 
Romanucci, Nicola Mosca, Aniello Russo, Ettore Novellino, Sandro 
Cosconati and Anna Messere. “Tuning RNA Interference by Enhancing 
siRNA/PAZ Recognition” ACS Medicinal Chemistry Letters 4, no. 1 
(January 10, 2013): 75–78, doi:10.1021/ml300284b. 
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Abstract: Chemically modified siRNAs were synthesized to enhance 
siRNA/PAZ interactions. These modifications allowed obtaining siRNAs 
endowed with high silencing potential, long persistence and better serum 
resistance. Theoretical data allowed correlating the observed siRNAs 
interfering performance with the peculiar interactions with PAZ. 
6 Valeria Romanucci, Danilo Milardi, Tiziana Campagna, Maria Gaglione, 
Anna Messere, Alessandro D’Urso, Emanuela Crisafi, Carmelo La Rosa, 
Armando Zarrelli, Jan Balzarini and Giovanni Di Fabio. “Synthesis, 
Biophysical Characterization and Anti-HIV Activity of d(TG3AG) 
Quadruplexes Bearing Hydrophobic Tails at the 5’-End” Bioorganic & 
Medicinal Chemistry 22, no. 3 (February 01, 2014): 960–66, 
doi:10.1016/j.bmc.2013.12.051. 
Abstract:  Novel conjugated G-quadruplex-forming d(TG3AG) 
oligonucleotides, linked to hydrophobic groups through phosphodiester 
bonds at 5’-end, have been synthesized as potential anti-HIV aptamers, 
via a fully automated, online phosphoramidite-based solid-phase strategy. 
Conjugated quadruplexes showed pronounced anti-HIV activity with 
some preference for HIV-1, with inhibitory activity invariably in the low 
micromolar range. The CD and DSC monitored thermal denaturation 
studies on the resulting quadruplexes, indicated the insertion of lipophilic 
residue at the 5’-end, conferring always improved stability to the 
quadruplex complex (20 <Tm< 40°C). The data suggest no direct 
functional relationship between the thermal stability and anti-HIV 
activity of the folded conjugated G-quartets. It would appear that the 
nature of the residue at 5’ end of the d(TG3AG) quadruplexes plays an 
important role in the thermodynamic stabilization but a minor influence 
on the anti-HIV activity. Moreover, a detailed CD and DSC analyses 
indicate a monophasic behaviour for sequences I and V, while for ODNs 
(II–IV) clearly show that these quadruplex structures deviate from simple 
two-state melting, supporting the hypothesis that inter- mediate states 
along the dissociation pathway may exist. 
7 Armando Zarrelli, Valeria Romanucci, Concetta Tuccillo, Alessandro 
Federico, Carmela Loguercio, Raffaele Gravante and Giovanni Di Fabio. 
“New Silibinin Glyco-Conjugates: Synthesis and Evaluation of 
Antioxidant Properties” Bioorganic & Medicinal Chemistry Letters 24, no. 
22 (2014): 5147–49, doi:10.1016/j.bmcl.2014.10.023. 
Abstract: New silibinin glyco-conjugates have been synthesized by 
efficient method and in short time. Exploiting our solution phase strategy, 
several structurally diverse silibinin glyco-conjugates (gluco, manno, 
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galacto, and lacto-) were successfully realized in very good yields and in 
short time. In preliminary study to evaluate their antioxidant and 
neuroprotective activities new derivatives were subjected to DPPH free 
radical scavenging assay and the Xanthine oxidase (XO) inhibition 
models assay. Irrespective of the sugar moiety examined, new glyco-
conjugates are more than 50 times water-soluble of silibinin. In the other 
hand they exhibit a radical scavenging activities slightly higher than to 
silibinin and XO inhibition at least as silibinin. 
8 Armando Zarrelli, Valeria Romanucci, Lorenzo De Napoli, Lucio 
Previtera and Giovanni Di Fabio. “Synthesis of New Silybin Derivatives 
and Evaluation of Their Antioxidant Properties” Helvetica Chimica Acta 
98 (2015): 399–409, doi:10.1002/hlca.201400282. 
Abstract: Silibinin, the major flavonolignan of silymarin, displays a broad 
spectrum of biological features that are generally ascribed to its 
antioxidant properties. Silibinin occurs in two diastereoisomeric forms, 
i.e., silybins A and B, in a ratio of ca. 1:1. With a simple and robust 
purification method, it is now possible to obtain silybins A and B in pure 
forms, in g-scale amounts, and within a short period of time. Herein, we 
describe an efficient synthesis strategy to obtain a variety of new and 
more H2O-soluble derivatives from the single silybins in which the 9"-OH 
group was converted to a sulfate, N3, phosphodiester, or NH2 group via a 
solution-phase approach. Thus, eight new compounds have been 
synthesized, purified by HPLC analysis, and characterized by NMR and 
MS analyses. To conduct experiments to clarify the many biological 
properties of pure silibinin diastereoisomers and their derivatives, the 
synthetic compounds were tested by using the DPPH assay to evaluate 
their antioxidant activities. The results, even if only for a small number of 
derivatives, revealed that some of these compounds are much more active 
than their parent compounds. It is also interesting to consider the 
synergetic effects. 
9 Valeria Romanucci, Maria Gaglione, Anna Messere, Nicoletta Potenza, 
Armando Zarrelli, Sam Noppen, Sandra Liekens, Jan Balzarini and 
Giovanni Di Fabio “Hairpin Oligonucleotides Forming G-Quadruplexes: 
New Aptamers with Anti-HIV Activity” European Journal of Medicinal 
Chemistry 89 (2015): 51–58, doi:10.1016/j.ejmech.2014.10.030. 
Abstract: We describe the facile syntheses of new modified 
oligonucleotides based on d(TG3AG) that form bimolecular G-
quadruplexes and possess a HEG loop as an inversion of polarity site 3’-3’ 
or 5’-5’ and aromatic residues conjugated to the 5’-end through 
 
vi 
phosphodiester bonds. The conjugated hairpin G-quadruplexes exhibited 
parallel orientation, high thermal stability, elevated resistance in human 
serum and high or moderate anti-HIV-1 activity with low cytotoxicity. 
Further, these molecules showed significant binding to HIV envelope 
glycoproteins gp120, gp41 and HSA, as revealed by SPR assays. As a 
result, these conjugated hairpins represent the first active anti-HIV-1 
bimolecular G-quadruplexes based on the d(TG3AG) sequence. 
During the three years of PhD, Valeria is committed on issues 
concerning the isolation and characterization of natural products. 
The list of the papers published in this field, which will not be 
discussed in the forthcoming chapters of the thesis, is reported 
below: 
1. Giovanni Di Fabio,Valeria Romanucci, Mauro Zarrelli, Michele Giordano 
and Armando Zarrelli, “C-4 Gem-Dimethylated Oleanes of Gymnema 
Sylvestre and Their Pharmacological Activities” Molecules, 2013, 
doi:10.3390/molecules181214892. 
 
2. Giovanni Di Fabio, Valeria Romanucci, Anna De Marco and Armando 
Zarrelli “Triterpenoids from Gymnema Sylvestre and Their 
Pharmacological Activities” Molecules (Basel, Switzerland) 19, no. 8 
(2014): 10956–81, doi:10.3390/molecules190810956. 
 
3. Armando Zarrelli, Valeria Romanucci, Raffaele Gravante, Cinzia Di 
Marino and Giovanni Di Fabio “History of Gymnemic Acid, a Molecule 
That Does Not Exist” Natural Product Communications 9, no. 10 (October 
2014): 1429–32, http://www.ncbi.nlm.nih.gov/pubmed/25522530. 
 
4. Giovanni Di Fabio, Valeria Romanucci, Cinzia Di Marino, Antonio Pisanti 
and Armando Zarrelli “Gymnema Sylvestre R. Br., an Indian Medicinal 
Herb: Traditional Uses, Chemical Composition, and Biological Activity” 
Current Pharmaceutical Biotechnology 16, no. 6 (2015). 
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Long Abstract 
DNA G-quadruplexes are very appealing structures for their 
variety of pharmacological applications. G-quadruplex structures are 
involved as targets in antitumour therapies1 and as scaffolds of 
oligonucleotides (ONs) able to specifically inhibit proteins (aptamers). 
In the last 30 years, there has been growing interest in the 
potentiality of G-quadruplexes as novel aptamers2. 
In ‘90s, Hotoda et al. identified a variety of tetramolecular G-
quadruplexes based on the sequence d(TGGGAG), targeting the 
glycoprotein of HIV-1, gp1203,4. This sequence d(TGGGAG), showed a 
high anti-HIV-1 activity only with conjugated with an aromatic group 
at the 5’-end. Structure–activity relationship analysis on Hotoda 
modified sequences, indicated that G-quadruplex formation, as well 
as the presence of large aromatic groups at the 5′-end, were both 
essential for the antiviral activity5,6. In 2011 Di Fabio et al. reported 
the synthesis and characterization of a new mini-library of 
d(TGGGAG) ODNs carrying aryl groups at the 5’-end7. The results 
obtained, showed that all 5’-end-modified sequences formed G-
quadruplexes with strongly increased thermal stability and are 
endowed with high anti-HIV activity. As is it known both 
thermodynamic and kinetic aspects are relevant into G-quadruplex 
folding, so it is necessary to explore both of them to get a more 
complete picture of structure-activity relationship8. 
In my PhD project, we focused our attention on the synthesis and 
biophysically and biologically characterization of a new mini-library 
of d(TGGGAG) oligomers as potential anti-HIV9. In addition, in order 
to have more information on the G-quadruplex folding depending on 
the modifications at 5’-end of d(TGGGAG), we are started kinetic 
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studies of G-quadruplex formation by ESI-MS with the precious 
collaboration of Valérie Gabelica, Research Director in Inserm/Univ. 
Bordeaux, (France), pioneer of the study of non-covalent DNA 
complexes by ESI-MS10–12. In the first part of my PhD project, we 
developed an efficient procedure to synthesize a new mini-library of 
d(TGGGAG) oligomers carrying hydrophobic and aromatic groups at 
the 5’-end by a phosphodiester bond (Fig.1). The choice of conjugated 
groups aim to improve cellular uptake, to extend the half-life of these 
molecules in plasma and especially to stabilize DNA structures by 
hydrophobic interactions. 
 
Figure 1 
CD analysis was undertaken on oligomers I–V in comparison with 
the corresponding unmodified d(TGGGAG). Thermal denaturation 
studies on the resulting G-quadruplexes, suggested that the insertion 
of lipophilic residue at the 5’-end, involves always, in stability 
enhancement of G-quadruplex complexes (20<∆Tm<40°C). 
Moreover, detailed CD and DSC analysis indicated a monophasic 
behaviour for sequences I and V, while II–IV deviated from simple 
two-state melting, supporting the hypothesis that intermediate states 
along the dissociation pathway may exist. All heating runs were fully 
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irreversible. Therefore, neither an extrapolation of the 
thermodynamic parameters ∆G and ∆S from the melting curves nor a 
deconvolution of the Cp curves by statistical mechanic methods were 
possible. Consequently, in these non-equilibrium conditions only the 
enthalpy change relative to the G-quadruplex dissociation process 
may be directly obtained13. 
In the second part of PhD project, aiming to improve the kinetic of 
G-quadruplex formation using d(TGGGAG) as a lead sequence, and 
therefore to enhance the anti-HIV activity of these aptamers, we 
designed and synthesized, for the first time, bimolecular G-
quadruplex based on d(TGGGAG) sequence containing a HEG loop as 
a 3’-3’ or 5’-5’ inversion of polarity site (Fig 2)14. 
 
Figure 2 
CD studies assessed that the introduction of a HEG loop, produces 
an improvement of the thermal stability of H1-H5 ODNs compared to 
d(TGGGAG) tetramolecular G-quadruplexes and that this insertion 
has no effect on the original parallel folding of the G-quadruplex 
structure. This thermal stabilization was further increased, once 
more time, by introduction of different aromatic residues at the 5’-end 
of oligonucleotides H2-4. Moreover, only compounds H2-4, have proven 
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to exhibit significant anti-HIV activity in cell culture. Besides the 
moderate anti-HIV activity, the conjugated hairpin G-quadruplexes 
exhibited interesting properties in terms of slight cytotoxicity, 
favorable CC50/EC50 (selectivity index) ratio and increased stability in 
human serum. Finally, the good affinity of the synthetic conjugated 
G-quadruplexes H2-4 for HSA is an interesting result due to the 
increased use of albumin as a versatile drug carrier in anti- HIV 
strategy. 
In attempt to investigate if there is an influence of the end 
conjugated moiety on the kinetics of G4 formation and also to have 
more details about the G-quadruplex formed; ESI-MS studies are 
conducted on more active 5’-end modified ODNs in comparison with 
unmodified sequence d(TGGGAG). By ESI-MS experiments, it is 
possible to have information about the number of strands, and the 
cations inside each structure, moreover it is possible to detect all 
possible intermediate complexes (Fig.3) and to determine equilibrium 
binding constants of non-covalent complexes10,15. 
 
Figure 3 
To study the kinetic of G-quadruplex formation, we recorded ESI-
MS spectra as a function of the time after addition of cation in the 
ODN solutions, at room temperature. All modified sequences shown 
the same spectra profile, in terms of distribution of complexes and 
relative charge states. Overall data, reported a rapid conversion of the 
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single strand into dimer and trimer species, in agreement with the 
association pathways proposed by Stefl et al.16, then the tetramer 
begins to form quite quickly and continues to increase up to 14 days 
but more slowly. An unexpected result is the detection of an octameric 
specie, the formation of this begins simultaneously to tetramer, but 
their concentration remains, in all cases, lower than that of tetramer. 
In over years, some G-rich DNA sequences, potentially G-
quadruplex structures, are found at the chromosomal extremities 
(telomeres) and also in several important oncogenes17,18. Last year, 
the research group of Prof. S. Balasubramanian, has published an 
interesting article, describing a method for the quantitative 
visualization of G-quadruplexes in vivo, direct evidence of their 
natural formation in the human genome19. Many antitumor strategies 
have been developed on the inhibition of telomerase activity (enzyme 
overexpressed in cancer cells), as consequence of decrease in length of 
telomeric DNA20. In this frame, there is a huge interest against of a 
variety of small organic molecules, capable to induce the formation of 
G-quadruplex in G-rich sequences found in telomeres21. 
The main important characteristics of ligands are an aromatic core 
that favours stacking interactions with the G-tetrads and basic side 
chains that interact with DNA grooves22. A class of molecules that 
displays these features are flavonoids. 
Over the years, flavonoids has reported a variety of therapeutic 
activities against cancers, tumors, AIDS, etc23–25. Many examples of 
telomerase inhibitors within the family of flavonoids (silibinin, 
epigallocatechin gallate and apigenin) have been also reported26,27. 
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In this frame, my PhD project is focused on the study of silibinin, a 
flavonolignan isolated from the fruits of the milk thistle Silybum 
marianum, as potential anti-telomerase drug. silibinin is the major 
flavonolignan found in silymarin, isolated from the fruits of the milk 
thistle Silybum marianum28. Structurally silibinin is a 
diastereoisomeric mixture of two flavonolignans, namely silybin A 
and silybin B in a ratio of approximately 1:1, hardly separable (Fig.4). 
O
O
OH
OH
OCH3
Silybin A
(2R, 3R, 7''R, 8''R)
Silybin B
(2R, 3R, 7''S, 8''S)
O
OH
O
O
OH
O
OH
OCH3
HO
OH
2
345
8
6
8''
7''
5'
2'
6'
1" 5"
2"
9''
Silibinin
O
O
OH
OH
OCH3
+
1
7
1'
4'
3'
6"
4"
3"
A      C E
B      D
 
Figure 4 
Recently, this metabolite has received attention due to its 
anticancer and chemopreventive actions29,30, as well as 
hypocholesterolemic, cardioprotective, and neuroprotective 
activities31. In addition to the activity of silibinin, other constituents 
of sylimarin such as isosilybin, silychristin and 2,3-dehydrosilybin, 
have been shown an attractive pharmacological properties. In 
particular, the oxidized form of silibinin, the 2,3- dehydrosilybin 
(DHS), displays major antioxidant and anticancer properties than 
silibinin suggesting that DHS may be useful therapeutically32. 
In an effort to investigate the ability of silibinin and DHS to induce 
inter- and intramolecular G-quadruplex structures, the 
stereochemistry of these metabolites may play an extremely 
important role with interesting structural implications. For this 
reason we firstly, performed a new HPLC preparative method to 
 
xiii 
separate diasteroisomers of silibinin, with minimal effort and in a 
short time33. Because of the low content of DHS in its natural state 
(silymarin extract), this compound was practically neglected in 
studies on the biological activity of silymarin. Therefore in order to 
obtain a large amount of DHS useful to test as therapeutics agent, a 
base-catalyzed oxidation of silybins A and B is carried out using 
microwave (MW). Moreover by starting with each diastereoisomer, 
sylibin A and B, have been produced two enantiomers of DHS in an 
optically pure form; the use of microwaves has facilitated the reaction 
time (few minutes) and the yields34. 
While remaining within of chemistry of silininin, during my PhD, 
we also dealt with the low water solubility of silibinin that 
dramatically limits its pharmacological use. In this frame, in order to 
overcome these drawbacks, we developed a synthetic strategy to 
obtain new silibinin derivatives linking suitable chemical 
modifications able to improve its applications in biomedicine and 
biochemisty35–37. 
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CHAPTER 1 
Biological interest of non canonical DNA structures: 
"G-quadruplexes" 
1.1 General introduction on the G-quadruplexes 
A few years ago, Alexander Rich wrote: ‘DNA comes in many 
forms’1. Since many years we have learned that Nucleic Acids are 
highly flexible molecules that can adopt a wide range of structures in 
addition to the major double-helical conformation. One of the most 
attractive “unusual” DNA structures are the G-quadruplex2,3. G-
quadruplexes are a polymorphic class of secondary DNA structures 
formed from G-rich sequences. They are characterized by the stacking 
of units, known as G-tetrads4. 
 
Figure 1. Representation of a G-tetrad stabilized by K+ cation. 
The G-tetrads are formed by a planar arrangement of four 
guanines that are stabilized by Hoogsteen hydrogen bonds and from 
the coordination of monovalent cations, preferentially Na+ and K+ 
(Figure 1). From many years the DNA G-quadruplex structures have 
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been studied because they are involved in genome function including 
transcription, recombination and replication5 (Figure 2). 
 
Figure 2. Current 3D structural understanding of G-quadruplexes and their possible 
biological role in human diseases. (a) Thrombin binding aptamer (PDB Id 148D), (b) 
DNA G-quadruplex formed from a sequence located in the c-KIT1 promoter region 
(PDB Id 2O3M), (c) human telomeric intramolecular G-quadruplex (PDB Id 1KF1). 
Colour scheme: adenine, red; thymine, cyan; guanine, green; cytosine, beige; 
phosphate backbone, grey ribbon. 
Moreover, some G-rich DNA sequences, potentially G-quadruplex 
structures, are found at the chromosomal extremities (the telomeres) 
and also in several important oncogenes6 (Figure 2). In this regard, 
last year, the research group of Prof. S. Balasubramanian and G. 
Biffi, published an interesting paper describing a method for the 
quantitative visualization of G-quadruplexes in vivo, providing a 
direct evidence of their natural formation in the human genome7. The 
scientific interest in G4 structures has increased also for their 
biophysical proprieties among which, their high thermodynamic 
stability. 
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DNA quadruplex structures are very appealing from a 
pharmacological point of view, both as targets in antitumour 
therapies8,9 and as scaffolds of oligonucleotides (ONs) able to 
specifically inhibit proteins (aptamers). In the last 30 years, there has 
been growing interest in the potentiality of G-quadruplexes as novel 
aptamers, able to bind and recognize specific targets, ranging from 
small molecules (amino acids, antibiotics) to proteins or nucleic acid 
structures10,11. The best known example of aptamer is the thrombin-
binding aptamer (TBA), a single-stranded 15-mer DNA that was 
found to be a potent inhibitor of thrombin, the key enzyme of 
coagulation cascade12,13. Furthermore, G-quadruplex have resulted to 
be potent inhibitors of the HIV-infection. In this way, the G-
quadruplex structures may have important applications in medicinal 
chemistry research, in which they can be used as building blocks for 
the development of new DNA-based therapeutic agents. 
In the last few years, a new field for the applications of nucleic 
acids is growing very quickly: the nanotecnologies by DNA. Nucleic 
acids can be optimal building blocks for their capacity to form 
predictable bidimensional and tridimensional structures. The first 
example of nanostructures by DNA are reported and called “DNA 
origamis,” by Paul Rothemund in 2006. Next, several groups 
investigating in this field reported many potential applications as 
sensors, electrical transportators and cellular carriers14,15. In this 
context, some examples of G-quadruplexes used for the construction 
of DNA-based nanostructures are the G-wires, Frayed wires and 
Synapses (Figure 3). 
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G-wires are obtained by the stacking of tetramolecular G-
quadruplex formed by telomeric sequence of some ciliates (d-G4T2G4)16 
or by poly-dG sequences17. 
 
Figure 3. Models of G-wires and Frayed wires. 
MacGregor and co-workers first identified the structure of frayed 
wires formed by d-A15G15 or d-T15G15 sequences18. These frayed wires 
are distinguished from G-wires by their flexible A15/T15 tails that 
radiate from a guanine core. “Synapsable” DNA was described by Sen 
and co-workers in 199619. It results from the interaction between two 
DNA duplexes containing mismatched regions of repeating G–G base 
pairs. The repeating G–G mismatches facilitate the formation of G-
quartets that leads to the dimerization of the duplex. 
1.2 Topologies of G-quadruplex structures 
The G-quadruplexes display a fascinating array of polymorphic 
structures that contain a number of common variables (Figure 4): 
orientation and length of the loops (lateral, diagonal or external), 
geometry and sequence, number of quartets, relative orientation of 
strands (parallel, antiparallel), and glycosidic bond angles (anti or 
syn)20 (Figure 5d). 
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In function of these variables, we can classify G-quadruplexes as 
intramolecular (one strand), bimolecular (two strands), or 
tetramolecular (four strands), in which the strands may run in a 
parallel (anti guanosine’s conformation) or in antiparallel (syn and 
anti guanosine’s conformations) direction21,22 (Figure 4 and 5). 
 
 
 
Figure 4. Schematic diagram shows three different side loops: lateral side loop (L); 
external side loop (E) and diagonal side loop (D). Orientation of strands: parallel, 
alternating anti-parallel strands, two groups of adjacent parallel strands and three 
parallel strands and one anti-parallel strand. Tetramolecular G4 (four strands), 
bimolecular G4 (two strands), and intramolecular G4 (one strand). Arrows indicate 
5′–3′direction of DNA molecule. 
Generally, tetramolecular G-quadruplexes adopt a well-defined 
structure, in which all strands are parallel with anti-conformation of 
bases23; indeed intramolecular G-quadruplexes formed by single DNA 
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strand, form faster and are more complex, showing a wide 
conformational diversity24. In addition, G-quadruplex can also 
multimerize by non-covalent stacking with the quartets or with base-
pairing of flanking. The elevate structural polymorphism of G-
quadruplex structures depends strongly on sequence but they can be 
also regulated or modulated by experimental conditions, such as the 
nature and concentration of cations, temperature, and pH. 
Fortunately, these structures can be studied with different techniques 
because they exhibit a specific profile; in particular, they show an 
unusual mobility under gel electrophoresis conditions, a characteristic 
CD spectrum, a signature cation-dependent stability to thermal 
denaturation, and distinctive imino resonances in the 1H-NMR 
spectrum24. 
1.2.1 Grooves and metal ion coordination 
The G-quadruplex structures are not stacked linearly, but adopt a 
right-handed helix in which are defined the internal grooves. The 
variation of groove-widths of the G-quadruplex is related to the 
conformation of base glycosidic torsion angles (Figure 5d) and so to 
the type of G-quadruplex. In a parallel four-stranded G-quadruplex 
with anti conformation of guanine, the grooves have medium width23. 
On the other hand, in a monomolecular structure, syn-anti-syn-anti 
guanosine’s conformation, will resulting in grooves of alternating 
wide-small-wide-small widths. Each groove, lined with the guanine 
O6 carbonyl oxygens, forms a specific binding site for metal ions. The 
order of cation ability to stabilize and/or to induce G-quadruplex 
structures is as follows : K+> NH4+> Rb+> Na+> Cs+> Li+ for 
monovalent cations25 and Sr2+> Ba2+> Ca2+> Mg2+ for divalent 
cations26. The coordination of potassium, sodium, and strontium all 
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provide both thermodynamic and kinetic stability to the G-
quadruplex structure. 
 
Figure 5. Guanine and G-quartet. (a) Chemical formula of canonical guanine and two 
hydrogen bonding faces (Watson–Crick and Hoogsteen) which are implicated in G-
quartet formation. Arrows indicate H-bond donors (in black) and acceptors (in gray). 
(b) Classical G-quartet structure with anticlockwise rotation (-) of the donor NH to 
the acceptor C=O hydrogen bonds. (c) Two most favorable sugar conformations of 
guanine of quartet: C2’- or C3‘-endo. (d) Two torsion angles of guanine glycosidic bond 
(syn and anti) that determine groove dimension of G-quartet: wide, medium and 
small. 
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In the case of K+, the stacked G-tetrads in G-quadruplex DNA 
provide a bipyramidyl antiprismatic coordination geometry, with each 
of eight carbonyl oxygens interacting equally with the cation27. 
1.3 Quadruplexes in telomeres or quadruplexes everywhere? 
Sixty years ago, we learned that the DNA can also adopt many 
conformation in addition to the well-known duplex structure, and 
mainly that these conformations are involved in the gene regulation. 
Today, the study of these conformations represents a major biological 
opportunity to understand the role of non-coding DNA sequences. 
Since the discovery that G-quadruplexes DNA can form in the G-rich 
regions of telomeric oligonucleotides in the late 1980s28, there has 
been a growing number of studies focusing on the structures and 
possible biological functions of these fascinating DNA motifs29. 
Many years ago it was reported that the phenomenon of cellular 
senescence is regulated by telomere shortening30. Telomeres are 
overhang non-coding DNA present at the ends of human 
chromosomes and they are essential for the preservation of genetic 
material following successive DNA replications. Telomeric DNA is 
normally single-stranded, so in principle it could readily fold into 
intramolecular DNA quadruplex structures. In normal somatic cells, 
telomere length decreases with each cell division event by DNA 
polymerase on the contrary telomere shortening is absent in cancer 
cells due to telomere maintenance mechanism. The telomere 
maintenance mechanism is provided by a telomerase enzyme, a 
reverse transcriptase that is over-expressed in cancer cells31. Many 
antitumor strategies have been developed aiming at the telomere 
maintenance mechanism. 
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The classic model consists in the inhibition of telomerase in cancer 
cells in order to decrease the length of telomeric DNA32. 
 
Figure 6. Mechanism of telomere shortening and telomere damage by telomerase 
activity. 
The mechanism of  telomerase inhibition, is based on the ability of 
a ligand molecule to induce or stabilize the fold into a G-quadruplex 
structure from a single-stranded telomeric DNA, that is not 
recognized by telomerase enzyme (Figure 6). 
The formation of a quadruplex–ligand complex at telomere ends 
appears to be equivalent to the exposure of damaged DNA, since it 
elicits a rapid DNA damage response that is lethal to the affected 
cells33. Since recent proved existence of G-quadruplex structures in 
repeat d(TTAGGG) sequences of human telomeric DNA7, the studies 
of G-quadruplexes as potential anti-telomerase have grown 
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exponetially. All these facts make G-quadruplexes an attractive 
target for drug design. Recently, structural studies on telomeric G-
quadruplex have revealed a diversity of topologies, which are 
particular sensitive to the nature of the cations present and to the 
flanking sequences34. In this context, it is reported the polymorphic 
nature of truncated human telomeric sequence, Tel22 
(d[AG3(T2AG3)3]), whose NMR structure in Na+ solution35 revealed an 
antiparallel topology, contrary to its crystal structure, obtained from 
a K+ solution which shows a parallel topology36 (Figure 7).  
 
Figure 7. Folding topology of the basket-type intramolecular G-quadruplex formed by 
wtTel22 in Na+ solution as determined by NMR. Folding topology of the propeller-
type parallel-stranded intramolecular Gquadruplex formed by wtTel22 in the 
presence of K+ in crystalline state. 
The elevate polymorphism of telomeric G-quadruplex DNA structures 
could have important implications in the drug design of ligands as 
anti-telomerase drugs. 
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1.3.1 G-Quadruplex-binding ligands as anticancer drug 
Natural and synthetic molecules (protein, ligands, and polymers ) 
may act as molecular chaperones for G-quadruplex assembly. In these 
years, many molecules have been identified as ligands for G4 
structures, and for their development as potential anticancer 
agents37,38. So far, the rational design of G-quadruplex-interacting 
compounds has been guided by two criteria (-stacking and 
electrostatics) but also by empirical approaches. 
The majority of G-quadruplex ligands in literature contains a 
polycyclic hetero-aromatic core, because it is clear that the main G-
quadruplex stabilization occurs via stacking and electrostatic 
interactions resulting in the binding of the ligand (usually a flat 
aromatic molecule) on the G-quartet constitutive of the external-face 
of the G-quadruplex. 
 
Figure 8. Different binding modes of G-quadruplex-ligand. 
This binding mode (external stacking) has been thoroughly 
discussed since it represents a unique feature of quadruplex 
recognition as compared to other DNA forms39. In order to design 
drug ligands able to bind selectively G-quadruplex structures, the 
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understanding of target G-quadruplex structures and their topologies 
is a key point40. Actually few molecules distinguish between the 
various classes of G quadruplexes (intra- or inter-molecular, parallel 
or antiparallel). The particular geometry of the G-quadruplex 
structure is thought to allow specific recognition by small ligands 
through various binding modes (Figure 8): by an external stacking 
with the terminal quartet, by an intercalation between the G-tetrads, 
and finally through groove binding mode. In many studies, 
investigating the G-quadruplex-ligand complexes, it has been 
reported that the stacking of the drug on the outer planes of G-tetrads 
appears to be more energetically favorable and probable according 
with the rationale design supposed many years before. 
The only ligand discovered so far, binding the groove of G-
quadruplex is Distamycin A41. Martino et al. investigated the 
interaction of Distamycin A with d[TGGGGT]4 and found that the 
ligand binds with a 4/1 ratio to the quadruplex (Figure 9). 
 
Figure 9. Side view of the superimposition of the 10 best structures of the 4:1 complex 
Dist-A/[d(TGGGGT)]4. Dist-A is reported in yellow, and DNA is colored in magenta. 
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So far, knowing that the binding mode of ligand-G-quadruplex is 
mainly controlled by hydrophobic and Van der Waals interaction, the 
design of ligands is based on the same general features. Generally, G4 
ligands, are characterized by a planar aromatic core able to stack 
with the G-tetrads, and by basic side chains which interact with the 
grooves/loops and the negatively charged phosphate backbone of G-
quadruplexes42,43. The aim of the basic side chains is the stabilization 
of G-quadruplex structures by electrostatic interactions, and also the 
increase of water solubility of ligands. 
 
Figure 10. Some structures of G-quadruplex ligands. 
In order to increase the selectivity of ligands for G4 compared with 
duplex, the size of the aromatic core is crucial, as much large core 
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improves the aromatic–aromatic overlap and provides selectivity for 
G-quadruplexes. Following these general structural features, in these 
years, many G-quadruplex-ligands have been identified. Some 
examples of the first generation of telomerase inhibitors are 
anthraquinones44, 3,6-disubstituted acridines45; these have a planar 
aromatic electron-deficient core, and thus it was originally 
hypothesized that these are able to stack efficiently onto the planar 
surface of a G-tetrad. Subsequently, the second generation of ligands, 
has continued to exhibit this feature with some enhancements and it 
included the trisubstituted acridines46, the most important is BRACO-
1947, the porphyrins, among which TMPyP448 (Figure 10), and a non-
polycyclic aromatic ligands, such as bis-triazole derivative49. Ongoing 
research has revealed a large number of telomerase inhibitors from 
natural products displaying remarkable diversity in molecular 
structure. More recently, Kim et al. reported the high anti-telomerase 
activity of Telomestatin50, a natural metabolite extracted from 
Streptomyces annulatus (Figure 10). Also some semi-synthetic 
derivatives of berberine, another natural product, was reported as 
anticancer drugs associated with down-regulation of telomerase 
activity. In this frame, the Quarfloxin, a specific G4 ligand for myc 
G-quadruplex, is in Phase II clinical trials, as anticancer drug51,52. 
1.4 G-quadruplexes: new class of aptamers 
Aptamers are short single strand oligonucleotides (< 100 bases) 
able to bind different targets, ranging from small molecules (amino 
acids, antibiotics) to proteins, with high affinity and specificity. These 
peculiar features are related to a tertiary structure, which presents a 
good shape complementarity with target molecules53. In this frame, 
these oligonucleotides, ‘aptamers’, are an emergent class of molecules 
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that rival antibodies in both therapeutic and diagnostic application54. 
Thank to their oligonucleotide structure, the aptamers offer a number 
of advantages in comparison with antibodies, including an 
inexpensive, rapid, and reproducible synthesis pathway, easily 
implemented chemical modifications, long-term stability and very low 
immunology. Usually, they are selected from a huge combinatorial 
library using the “systematic evolution of ligands by exponential 
enrichment” (SELEX), reported for the first time in the 199055. The 
SELEX method makes use of the powerful amplification capability of 
PCR in which a random mixture of DNA sequences with fixed 5’ and 
3’-end sequences are screened for binding with a specific target. The 
few selected DNA sequences that exhibit strong binding with the 
target are then PCR amplified and screened for the strong target 
binding again. This process is repeated many times to obtain a few 
final sequences that usually contain well-conserved consensus 
sequences. Recently, two oligonucleotides have been validated as 
therapeutics: a phosphorothioate antisense oligonucleotide ISIS 2922 
(Formivirsen), approved to treat retinitis caused by 
Cytomegalovirus56 and Pegaptanib sodium, 2’-fluoropyrimidine RNA-
based, for the treatement of neovascular age-related macular 
degeneration57. On the way of the search for ever more specific 
aptamers, particular interest has been growing for G-quadruplex 
structures, in particular for their very specific three-dimensional 
shapes. In this frame, the G-quadruplex aptamers, recently involved 
in clinical trials are the thrombin-binding aptamer (TBA)12,13 and 
AS141158. The TBA is a DNA 15-mer sequence, discovered in 1992 
through the SELEX methodology in order to search new therapeutic 
agents to prevent thrombosis. 
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The solution structure of TBA was determined by NMR, by Wang 
and coworker in 1993. It consists in an unimolecular antiparallel G-
quadruplex, with a chair-like conformation13 (Figure 11). 
 
Figure 11. G-quadruplex structure of thrombin binding aptamer, solved by NMR in 
1993. 
The second one is AS1411, 26-mer oligonucleotide, implicated in 
the proliferation of cancer cells with nucleolin as its specific target. 
The nucleolin is a protein marker expressed at high levels in human 
cancer cells59. Very recently AS1411 completed phase II clinical trials 
as anti-cancer drug with low toxicity and high therapeutic potential60. 
1.5 G-quadruplexes against HIV infection 
Recently, G-quadruplexes have been exploited as therapeutic 
strategies in cancer chemotherapy and as anti-HIV agents due to 
their in vivo activity, playing important roles in controlling gene 
expression via protein recognition of their structures61. G-quadruplex 
based aptamers have been successfully designed to target the HIV 
virus at different stages of its life cycle. The potential targets of HIV 
infection are HIV-1 reverse transcriptase62, HIV RNase H63, HIV-1 
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integrase64 (IN) and viral surface glycoprotein know as gp12065. 
Among the first G-quadruplex aptamer against HIV-1 integrase, is a 
parallel stranded G-quadruplex: T30177 (Figure 12a). This aptamer 
was the first IN inhibitor tested in clinical trials (ZintevirTM 
developed by Aronex Pharmaceuticals in 1996) showing a high 
inhibition against the HIV-1 integrase at nanomolar levels66. 
 
Figure 12.  a) Intramolecular parallel G4 structure with three tetrads for the T30177 
anti-HIV aptamer (PDB ID: 2M4P); b) Interlocked bimolecular parallel G4 structure 
with six tetrads for the 93del anti-HIV aptamer (PDB ID: 1Y8D); c) Two stacked 
parallel G4 structures with three tetrads each observed for the T30923 anti-HIV 
aptamer (PDB ID: 2LE6). 
Subsequently, similar to T30177, other G-quadruplex aptamers, a 
16-mer oligonucleotides (93del and T30923) have been proved 
effective for inhibiting HIV-1 integrase67,68 (Figure 12b, 12c). In 
particular, the aptamer 93del shows a remarkably unique quadruplex 
arrangement with two quadruplex subunits strongly interlocked in 
dimer parallel structure69, which is stable even at temperatures over 
90 °C. Infection of human immunodeficiency virus type-I (HIV-1) to 
susceptible cell is initiated by the binding of the positively charged V3 
loop of the viral envelope glycoprotein (gpl20), to the cellular receptor, 
CD4, which is then followed by fusion of the virus particle with the 
cell membrane (Figure 13). Although the precise mechanism of virus 
entry is unclear, it is believed that specific regions of gpl20 and the 
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transmembrane glycoprotein gp41 are involved in this process. 
Therefore, sequences able to recognize target proteins, such as gp120 
and gp41, are potential antiviral drugs70. 
 
Figure 13. Model of the multi-step process of HIV entry. The CD4 and coreceptor 
molecules are located in the host membrane (bottom), while the gp120 and gp41 
proteins are associated with the viral membrane (curved, top). HIV entry is initiated 
by attachment of gp120 to CD4, which results in conformational changes in gp120 
that result in the formation of the bridging sheet mini-domain and extension of the 
V3 loop. 
Among these, the aptamer phosphorothioate ISIS-5320 formed by 
tetramolecular G-quadruplex structure71, has been reported to target 
glycoprotein gp120 of HIV virus. Based on these evidences, 
tetramolecular parallel G-quadruplexes, thank to their shorter 
sequences and simpler strand arrangements, could be a potential 
building block for the modifications requirement for its enhancement 
of pharmacokinetic and pharmacodynamic properties. 
In this frame, in the ‘90s, Hotoda et al. identified a tetramolecular 
G-quadruplex  based on the sequence d(TGGGAG), and able to target 
the gp120 of HIV-172,73. This sequence showed a high anti- HIV-1 
activity only if conjugated with an aromatic group at the 5’-end. 
d(TGGGAG) sequence came to the precursor sequence 
d(TGGGAGGTGGGTCTG), both 5′-end modified sequences showed 
the same anti-HIV-1 activity by unique mechanism of action. The first 
modified active against HIV-1 infection, reported by Hotoda, was with 
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4,4′-dimethoxytrityl (DMT) group at the 5′-end of 6-mer, subsequently 
from the screening of the various modified 6-mer, was discovered the 
most potent inhibitor, R-95288, with high anti- HIV-1 activity and low 
toxicity (Figure 14).  
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Figure 14. Structures of DBB-d(TGGGAG) and R-95288, potent aptamers against 
HIV infection discovered by Hotoda in 1997.  
The sequence R-95288 is modified to bear a 3,4-dibenzyloxybenzyl 
(DBB) group at 5'-end and a 2-hydroxy-ethylphosphate at the 3'-
end74,75 (Figure 14). Analysis on these Hotoda modified 6-mer, have 
indicated that G-quadruplex formation, as well as the presence of 
large aromatic groups at the 5′-end, were both essential for the 
antiviral activity. In this context, since the structural stability of G-
quadruplex forming aptamers is closely related to their biological 
activities, a biophysical and structural investigation of Hotoda’s 
modified sequences, was provided by D’onofrio and co-workers in 
200776. They reported CD, DSC and molecular modeling studies on 
some representative anti-HIV 5’-modified Hotoda’s 6-mers, in 
comparison with unmodified sequence d(TGGGAG). They concluded 
that the insertion of large aromatic groups, as DMT and DBB (Figura 
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14) at the 5′-end of the d(TGGGAG) sequence has dramatic effects on 
the thermodynamic of G-quadruplex formation. Indeed both 5′-
modified G-quadruplexes, showed higher thermal stability than 
unmodified sequence. Moreover, they reported the thermodynamic 
origins of this stabilization, defining that the G-quadruplex with 5’-
DBB is entropically stabilized for its hydrophobic interactions in 
comparison with G4 by d(TGGGAG). 
In 2008 D’onofrio et al., aiming at ODNs endowed with potential 
anti-HIV activity, investigated the end-conjugation with sugars on 
d(TGGGAG) sequence, as a strategy to improve the pharmacological 
profile of these oligonucleotides77. They reported from CD-monitored 
thermal denaturation studies on the resulting quadruplexes that the 
insertion of a single monosaccharide at the 3′-end improves the 
stability of G-quadruplex complex and also confers an anti-HIV 
activity to unmodified sequence. On the contrary, the 5′-tethering 
with same monosaccharides, in all cases decreases the G-quadruplex 
stability and did not improve the biological activity. Overall reported 
studies underline the crucial role of aromatic groups at the 5’-end in 
the stability of G-quadruplexes. 
1.6 Aim of research work 
In this context, my research activity is focused on the design, 
synthesis and structural characterization of several biomolecules, 
such as DNA modified sequences based on G-quadruplex structures 
as anti-HIV aptamers and G-quadruplex-ligands of natural origin 
with potential anti-telomerase activity. Notably, I mainly focused my 
attention on: 
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 G-quadruplex aptamers based on d(TGGGAG) endowed with 
anti-HIV activity 
The first goal of this research was to achieve more potential anti-
HIV aptamers based on Hotoda's sequences in order to get a more 
complete picture of their structure-activity relationships depending 
on the modifications at 5’-end of d(TGGGAG). 
In this frame, in 2011 Di Fabio et al reported the synthesis and 
characterization of a new mini-library of d(TGGGAG) ODNs carrying 
aryl groups at the 5’-end connected by phosphodiester bond78. The 
main goal of this work was to expand the repertoire of accessible end-
modified G-rich ODNs, using a simpler and more general synthetic 
strategy to link the aryl groups at the 5’-end of ODNs. The results 
obtained showed that all 5’-end modified sequences formed G-
quadruplexes with strongly increased thermal stability and that these 
sequences are endowed with high anti-HIV activity and high binding 
affinity for the HIV-1 envelope proteins gp120 and gp41. 
Furthermore, we can summarize that the biological activity of 
modified d(TGGGAG) is related to two main factors: 1. the extent of 
interaction with the positively charged V3 loop of gp120 and 2. the 
amount of G4 able to interact with the target, that in turn it is 
dependent on the G-quadruplex thermal stability, the kinetics of 
formation and the resistance to nucleases. 
Starting from these considerations, we focused our attention on the 
synthesis and biophysically and biologically characterization of a 
mini-library of new d(TGGGAG) oligomers as potential anti-HIV 
aptamers. In this frame, aiming at extending the number of more 
effective oligonucleotide-based antivirals, we developed an efficient 
procedure to synthesize a new mini-library of d(TGGGAG) oligomers 
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carrying hydrophobic and aromatic groups at the 5’-end by a 
phosphodiester bond79. The choice of conjugated groups aim to 
improve cellular uptake, extend the half-life of these molecules in 
plasma and most of all to stabilize DNA structures by hydrophobic 
interactions. In addition, in attempt to enhance the kinetic of G-
quadruplex formation, we synthesized bimolecular G-quadruplex 
aptamers based on Hotoda's sequence, essentially different from the 
quadruplexes reported before for the number of strands, the number 
of aromatic moieties at 5’-end and for the presence of 
hexaethylenglycol (HEG) as a linker between two strands80. 
In order to achieve a more complete picture of structure-activity 
relationship, we started kinetic studies on the most active 5’-end 
modified d(TGGGAG) oligomers in collaboration with Valérie 
Gabelica, Reseach Director Inserm/Univ. Bordeaux (France). Notably, 
during the period that I spent to IECB in Bordeaux in the Gabelica’s 
group, I performed kinetic experiments using ESI-Mass Spectrometry 
and Ion Mobility Spectrometry (IMS) technologies. 
 G-Quadruplex-ligands as telomerase inhibitor: potentialities of 
the silibinin 
While remaining within the G-quadruplex-forming 
oligonucleotides, it is already known that the formation of this 
structures has important consequences at the cellular level and that 
such structures have been evoked in the control of expression of genes 
involved in the perturbation of telomeric organization4. The structural 
investigation of G-quadruplexes is essential to find the factors 
stabilizing these structures and for the design of G-quadruplex-
binding ligands. So far, the rational design of G-quadruplex-
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interacting compounds has been guided by -stacking and 
electrostatic interactions. 
In this frame, there is a huge interest in a variety of small organic 
molecules able to induce the formation of G-quadruplex in G-rich 
sequences found in telomeres. Based on the wide number of natural 
products as ligands already reported in literature81, we aim to 
investigate the potential activity of silibinin, a flavonolignan isolated 
from the fruits of the milk thistle Silybum marianum82 (Figure 15). 
Silibinin is a prominent component (approximately 30%) of the 
silymarin complex. Structurally it is a diastereoisomeric mixture of 
two flavonolignans, namely silybin A and silybin B in a ratio of 
approximately 1:1, hardly separable (Figure 15). 
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Figure 15. Silybum marianum (Carduus marianus L., Asteraceae; milk thistle) 
depiction in the Leonhart Fuchs herbal (1542); structure of silibinin and its 
diastereoisomers: silybin A and B. 
  
24 
Silibinin is one of the flavonoid antioxidants with multiple 
biological activities mostly related to its radical-scavenging activity. 
Recently, this metabolite has received attention due to its anticancer 
and chemopreventive actions83, as well as hypocholesterolemic, 
cardioprotective, and neuroprotective activities84. In addition to the 
activity of silibinin, other constituents of sylimarin such as isosilybin, 
silychristin and 2,3-dehydrosilybin, have been shown many attractive 
pharmacological properties. In particular, the oxidized form of 
silibinin, the 2,3- dehydrosilybin (DHS), displays major antioxidant 
and anticancer properties than silibinin suggesting that DHS may be 
a useful therapeutic agent85. The pharmacological use of both silibinin 
and DHS in vivo experiments is dramatically limited by factors 
concerning their low solubility and bioavailability86. In order to 
overcome these drawbacks, we developed different synthetic 
strategies for the insertion of suitable chemical modifications in 
attempt to improve their  applications in biomedicine and 
biochemisty87–90. 
Based on biological activities of silibinin and DHS and aiming to 
evaluate their ability to induce inter- or intramolecular G-quadruplex 
structures, it is clear that their stereochemistry may play an 
important role with interesting structural implications. In this 
context, we are focused our attention on two key points: a) the 
separation of silybin A and silybin B from the commercial by HPLC91 
and b) the development of an efficient preparative base-catalysed 
oxidation of silibinin to obtain good yields of DHS92. 
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CHAPTER 2 
Discovery of novel anti-HIV active G-quadruplex-
forming oligonucleotides 
The first stage of the HIV infection is the entry of human 
immunodeficiency virus (HIV) into host cells. This stage involves the 
attachment to host cells and CD4 binding, co-receptor binding, and 
membrane fusion (Figure 1). All of these stages are mediated by viral 
envelope proteins, gp120 and gp41, which are the only viral proteins 
that project from the membrane of the virion1. This interaction is the 
initial event in the viral replicative cycle and consequently is an 
important target for therapeutic intervention. 
 
Figure 1. HIV replication cycle. The targets of approved antiretroviral agents are 
underlined, namely: virus entry, fusion, reverse transcription, integration and 
proteolytic maturation. 
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In this frame, G-quadruplex based aptamers have been 
successfully designed to target the HIV virus at different stages of its 
life cycle. Some examples targeting glycoprotein gp120 of HIV virus, 
have been reported as anti-HIV aptamers among which the ODN 
phosphorothioate ISIS-53202,3 and Hotoda modified sequence R-
95288, both forming tetramolecular G-quadruplex structure4,5. 
Recently, in order to improve aptamers' bioavailability and 
pharmacokinetic profiles, some chemical modifications have been 
described that affect the nucleobases6, the backbone7,8 and 3’ and 5’-
ends, in addition to the introduction of inversion of polarity sites and 
natural or non-nucleosidic linkers9–11. The structural variability of G-
quadruplexes is further increased by these modifications. Moreover, 
in 2011, Di Fabio et. al synthesized a mini-library of 5’-end modified 
d(TGGGAG) oligomers, bearing different aromatic groups at 5’-end 
with potent inhibition of HIV-1 infection12. Surface Plasmon 
Resonance (SPR) assays revealed specific binding to HIV-1 gp120 and 
gp41. Circular dichroism (CD) and Differential scanning calorimetry 
(DSC) studies conducted on these modified oligonucleotides, revealed 
once again, the importance of the aromatic groups at 5’-end for the 
thermal stability of G-quadruplex complexes and therefore for their 
anti-HIV activity. Given the importance of G-quadruplexes forming 
ODNs as potent anti-HIV inhibitors, in order to extend the number of 
modified ODNs and to perform a detailed study of the structure–
activity relationship on modified d(TGGGAG), we synthesized and 
biophysically and biologically characterized a mini-library of new 
d(TGGGAG) oligomers with different type of modification at 5’-end, 
potential inhibitors of HIV infection. In addition in order to improve 
the slow kinetics of tetramolecular G-quadruplex formation, we 
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designed and synthesized new modified bimolecular G-quadruplexes 
(Hairpin ODNs) using the same lead sequence d(TGGGAG). 
2.1. Synthesis, biophysical characterization and anti-HIV activity of 
d(TGGGAG) Quadruplexes bearing hydrophobic tails at the 5'-end 
Aiming at extending the number of more efficient oligonucleotide-
based antivirals, we developed an efficient procedure to synthesize a 
new mini-library of d(TGGGAG) oligomers carrying hydrophobic and 
aromatic groups at the 5’-end by a phosphodiester bond. The choice of 
conjugated groups aim to improve cellular uptake, the half-life of 
these molecules in plasma and especially to stabilize DNA structures 
by hydrophobic interactions. 
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Scheme 1. Phosphoramidite building blocks 1–5 and synthetic scheme for the 
preparation of conjugated oligonucleotides I–V. 
The synthesis of 5′-modified oligomers initially started by the 
convertion of commercially available selected alcohols into the 
corresponding phosphoramidite derivatives (Scheme 1) by reaction 
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with 2-cyanoethyl-N,N-diisopropylaminochloro-phosphoramidite and 
N,N-diisopropylethylamine (DIEA) in dichloromethane anhydrous 
(DCM). The identity of compounds 1–5, all obtained in good yields 
(85%), was confirmed by NMR (1H and 31P) and MS data. 
Simultaneously the scaffold 6 (Scheme 1) was synthesized using 
standard solid phase -cyanoethylphosphoramidite chemistry 
protocols starting from a commercially available DMT-protected 
guanosine functionalized CPG support13,14. Phosphoramidite 
derivatives 1–5 (Figure 1) were exploited in the last coupling step of 
the ODN chain assembly. 
Table 1. Oligonucleotide Characterization 
Sequence (5’-3’) 
MS calcd for [M] 
data (found) 
I p-TGGGAG
 
2077.37 
2078.64 [MH]+ 
2101.23 [MNa]+ 
II p-TGGGAG
N
S
H
N
O
O
CH2CH2
 
2227.42 
2228.25 [MH]+ 
2250.84 [MNa]+ 
III 
p-TGGGAG
H
H
HO
H
 
2205.49 
2206.54 [MH]+ 
2228.28 [MNa]+ 
IV 
p-TGGGAG
H
OH
HO OH  
2341.64 
2342.59 [MH]+ 
2365.87 [MNa]+ 
2380.46 [MK]+ 
V p-TGGGAG  
2119.51 
2120.46 [MH]+ 
2145.21 [MNa]+ 
a: for HPLC conditions see Experimental Session 
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The resulting supports were reacted with triethylamine 
(Et3N)/pyridine (1:1, v/v), at 50°C for 1 h, followed by treatment with 
conc. aq. ammonia at 50°C for 5 h, allowing full deprotection and 
detachment from the solid support of target oligomers I–V. The 
combined filtrates and washings were concentrated in vacuo, 
dissolved in H2O, analyzed and purified by HPLC. The modified 
oligonucleotides were characterized by MALDI-TOF mass 
spectrometry, in all cases giving masses in accordance with the 
expected values (Table 1). 
 CD studies and characterization 
In order to study the influence of the aromatic groups at the 5’-end 
of the oligonucleotide chains on their ability to form G-quadruplex 
structures, a CD analysis was undertaken on oligomers I–V in 
comparison with the corresponding unmodified d(TGGGAG). CD 
spectroscopy can be used to obtain details about the G-quadruplex 
structures by comparing their spectra with those of G-quadruplex 
DNAs with known conformations. Figure 2 shows the CD spectra of 
all oligonucleotides at temperatures ranging from 15 to 90°C in the 
same buffer conditions. Overall CD spectra recorded at 15°C show a 
positive peak at 260 nm and a small negative band around 240 nm. 
These spectral shapes are consistent with the reported spectra of 
other d(TGGGAG) sequences15 and clearly indicate that all of the 
strands fold into a parallel strand structures16. The melting 
temperature values (Table 2) were determined from the CD melting 
profiles for conjugates I–V monitored at 263 nm with an heating rate 
of 1°C/min (Figure 4, bottom). All denaturation curves did not reflect 
an equilibrium process, and the apparent melting temperatures ‘Tm’ 
or ‘T1/2 ’ determined by CD, strongly depend on the rate of heating17. 
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A direct comparison of the CD and DSC data obtained for identical 
samples can be used to rule out the possibility of incompletely formed 
G-quadruplexes before heating and provide a more detailed 
description of the thermal transitions. All heating runs were fully 
irreversible. 
 
Figure 2. CD spectra of I–V. The spectra were collected at 15°C and at steps of 5°C up 
to 90°C in a 10mM potassium phosphate buffer (pH 7.0), supplemented with 200mM 
KCl, at 10µM of single strand. To guide the eye throughout the figures, some 
representative curves are marked with the temperature at which the CD signal was 
recorded. 
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Therefore, neither an extrapolation of the thermodynamic parameters 
G and S from the melting curves nor a deconvolution of the Cp 
curves by statistical mechanic methods were possible. 
Table 2. Thermodynamic parameters for the thermally-induced Quadruplex 
dissociation 
Sequences 
CD DSC 
Tm (°C) ± 1 Tm (°C) ± 1 H°cal (KJmol-1) 
1st 2nd 1st 2nd 1st 2nd 
I Nd 56 nd 61 nd 314 ± 15 
II 46 71 46 74 nd 305 ± 10 
III 33 79 33 90 15 ± 5 124 ± 11 
IV 45 79 45 81 24 ± 15 252 ± 15 
V Nd 76 nd 84 nd 182 ± 10 
†The same sample was splitted in two parts used in parallel for CD and DSC 
analysis. 
Consequently, in these non-equilibrium conditions  only the 
enthalpy change relative to the G-quadruplex dissociation process 
may be directly obtained18. For compound I, DSC runs exhibited a 
broad monophasic peak centred at Tm = 60°C and Hcal = 314 kJ 
mol-1 (Figure 3), which indicates the formation of four G-tetrads, as 
reported elsewhere. The melting temperature of compound I derived 
from the DSC curves was 4°C higher than that obtained from the CD 
results. This difference in the melting temperatures may be ascribed 
to the asymmetry of the calorimetric trace. The CD melting curve of 
compound II shows biphasic behaviour with a first melting point 
centred at 46°C and a second one observed at 71°C (Figure 3, bottom). 
The corresponding DSC curve shows a large asymmetric peak with 
a maximum at 73°C and a small shoulder at 46°C (Figure 3, top). The 
overall calorimetric enthalpy of this peak is 305 kJ mol-1. 
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Biphasic behaviour is observed in the CD melting curve of 
compound III; the first transition is observed at 33°C, and the second 
transition is observed at 79°C. 
 
Figure 3. DSC (top) and CD (bottom) melting profiles of I–V. 
The DSC curve of compound III shows an endothermic peak at 
33°C corresponding to the CD transition and a second, distinct peak 
at 89°C. The calorimetric enthalpies for these two transitions are 15 
and 124 kJ mol-1, respectively. The CD melting profile of compound 
IV exhibits biphasic behaviour, with the first transition at 45°C and a 
second transition at 79°C. The corresponding DSC curve shows an 
initial, smaller peak at 45°C and a second peak at 81°C. The 
calorimetric enthalpies for the two transitions are 24 and 252 kJ mol-
1, respectively. Finally, the CD melting profile of compound V shows a 
single transition at 76°C. The DSC curve of compound V shows 
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monophasic behaviour, with an endothermic peak centred at 84°C 
with a calorimetric enthalpy of 188 kJ mol-1. Several research groups 
have reported that modified G-quadruplex d(TGGGAG) sequences are 
stabilized at increasing melting temperatures relative to the parent 
unmodified sequence12,15. 
Our results (Table 2) are consistent with these reports; however, 
we found that the melting of many of these structures is not a simple 
two-state process, as assumed in previous studies. Although the 
irreversible nature of the melting processes of the studied assemblies 
made a thorough analysis of the <Cp> curves in thermodynamic 
terms difficult, our integrated CD and DSC dissociation studies 
provide a better understanding of the complexities in the melting 
mechanism. The CD melting data for compounds II, III and IV clearly 
show that these G-quadruplex structures deviate from a simple two-
state melting and support the hypothesis that intermediate states 
along the dissociation pathway may exist. Such complex behaviour is 
consistent with the analysis of the DSC thermograms. However, the 
existence of intermediates along the broad melting curve of compound 
I cannot be excluded. It should be noted that the folding/unfolding 
reactions of G-quadruplexes are almost always assumed for 
convenience to be two-state processes, with negligible concentrations 
of any intermediate species along the melting pathway19–21. A 
thermally dependent equilibrium between two G-quadruplex isoforms 
with different stabilities would explain the biphasic melting curves 
observed. Lower thermal stability is generally attributed to flanking 
inter-strand contacts at the edges of the G-quadruplex structures. 
Another interpretation of this biphasic transition observed by CD 
melting curve and DSC profile it has been reported by 
Balasubramaniann and coworkers22, they ascribed a biphasic 
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transition of d(GGGT) to the formation of an high order DNA 
structure23,24, more exactly to interlocked quadruplex dimer by 
d(GGGT). 
 Anti-HIV activity and Surface Plasmon Resonance (SPR): 
directed affinity binding analyses for the HIV envelope.  
Compounds I–V were evaluated for their anti-HIV-1 and -HIV-2 
activities in CEM cell cultures (Table 3). All compounds showed 
pronounced anti-HIV activities, with some preference for HIV-1. This 
inhibitory activity (except compound I) was invariably in the low 
micromolar range [50% effective concentration (EC50): 4.9–10 M for 
HIV-1 and 6.7–32 M for HIV-2]. Compound I was clearly less 
inhibitory (EC50 >8 M for HIV-1 and 69 M for HIV-2). 
Table 3. Antiviral (HIV) and RT activities of test compounds in CEM cell 
cultures. 
Sequences 
EC50a (µM) IC50b(µM) 
HIV-1(IIIB) HIV-2(ROD) RT (Pol.rC.dG) 
I >8 69  18 n. d. 
II 10  4.5 32  0.0 >30 
III 4.9  0.3 6.7  1.9 2.5  0.63 
IV 6.9  1.8 12 9.8 >30 
V 5.4  0.2  8 6.72  0.48 
a50% Effective concentration or compound concentration required to inhibit HIV-
induced cytopathicity by 50% in CEM cell cultures. b50% inhibitory 
concentration required to inhibit the RT reaction by 50% 
A concentration higher than 8 M could not be microscopically 
scored due to unexplained toxicity in the HIV-1-infected (but not HIV-
2-infected) CEM cell cultures. In light of the thermodynamic data and 
biological activity, it is reasonable to conclude that the nature of the 
5’-end modification on the d(TGGGAG) quadruplexes played only a 
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minor role in the anti-HIV activity. Because the conjugated G-
quadruplexes may inhibit HIV entry into its target cells due to their 
negative charge, conjugates II–V were also evaluated for their affinity 
to HIV envelope gp120 and gp41, as well as human serum albumin 
(HSA) as a control, by SPR technology (Table 4) and for their 
inhibitory effect against HIV-1 reverse transcriptase (RT). 
The biosensor chips for the SPR analyses were loaded with 3531 
RU gp120, 3091 RU gp41, or 3333 RU HSA and exposed to 1 OD/ml of 
the compounds. A binding signal was recorded for each of the 
compounds against the three proteins. However, the binding 
amplitudes measured after compound exposure to the protein for 120 
s differed significantly depending on the nature of the compound and 
the glycoprotein evaluated.  
Table 4. Interaction of the quadruplex derivatives with viral and human 
glycoproteins 
Sequences 
Amplitude of the SPR signal (RU)a 
HIV-1 gp120 HIV-1 gp41 HSAb 
II 0.4 4.0 13 
III 8.7 28 45 
IV 4.7 35 6.0 
V 0.1 21 21 
aAmplitude of the SPR signal was measured after 120 sec exposure of the 
compounds to the glycoproteins. bHuman Serum Albumin. 
The compounds III and IV showed a clear binding capacity 
(amplitude range: 4.7–8.7 RU) to gp120 whereas II and V showed 
poor, if any binding. Compounds III, IV and V were by far superior for 
binding to gp41, and compound III showed the strongest binding to 
HSA (Table 4).  
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Compounds III and V bound to HSA better than to gp41. In the 
HIV-1 RT experiments, II, III, IV and V showed varying inhibitory 
activities (I was not evaluated). Their IC50 values were in the range 
2.5–69 M, respectively, when using poly rC.dG as the 
template/primer and radio-labeled [3H] dGTP as the substrate (Table 
3). Considering all of the SPR data, there does not appear to be any 
selectivity for gp120 or gp41 binding compared with HSA binding. 
Also, no correlation between anti-HIV-1 and anti-RT activity was 
found. Therefore, it remains unclear whether selective binding to the 
HIV envelope or RT inhibition represents a mechanism for the 
selective antiviral action of these conjugates. The affinity of the 
synthetic oligonucleotides (II–V) for HSA is an interesting finding 
because the use of albumin as a versatile drug carrier in anti-HIV 
strategy is increasing. In fact, many albumin-based formulations have 
received market approval or are being evaluated in clinical trials25. 
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2.1.2 Experimental Session 
General procedures. Starting compounds for the synthesis of 
phosphoramidites1-5 were all purchased from Sigma-Aldrich. TLC 
analyses were carried out on silica gel plates from Merck (Kieselgel 
60, F254). Reaction products were visualized on TLC plates by UV 
light and then by treatment with a H2SO4/AcOH aqueous solution. 
For column chromatography, silica gel from Merck (Kieselgel 40, 
0.063-0.200 mm) was used. NMR spectra were recorded in CDCl3 with 
a Bruker WM 400 spectrometer. The chemical shifts (δ) are given in 
ppm with respect to the residual solvent signal (7.26 ppm), and the 
coupling constants (J) are in Hz. 31P NMR spectra were recorded at 
161.98 MHz on a Bruker WM-400 spectrometer using 85% H3PO4 as 
an external standard. MALDI TOF mass spectrometric analyses were 
performed on a PerSeptive Biosystems Voyager–De Pro MALDI mass 
spectrometer in the linear mode using a picolinic/3–
hydroxypicolinic/sinapinic acid mixture as the matrix. For the ESI 
MS analyses, a Waters Micromass ZQ instrument equipped with an 
Electrospray source was used in the positive mode. HPLC analyses 
were performed on an Agilent Technologies 1200 series instrument 
equipped with a UV detector. The crude material was analysed and 
purified by HPLC on a Nucleogel SAX column (Macherey–Nagel, 
1000–8/46) or Phenomenex RP18 column [LUNA, 5μm C18(2), 10.0 × 
250 mm]. Desalting was carried out by gel filtration chromatography 
on a Sephadex G25 column eluted with H2O/EtOH 4:1 (v/v). 
General procedure for the Preparation of Phosphoramidite 1–5. 1.26 
mmol of alcohol was dissolved in 10 mL of anhydrous 
dichloromethane, and 880 μL DIEA (5.05 mmol) and 565 μL 2-
cyanoethyl-N,N-diisopropylamino-chlorophosphoramidite (2.52 mmol) 
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were added under argon. After 30 minutes, the solution was diluted 
with ethyl acetate, and the organic phase was washed twice with 
brine and then concentrated. Silica gel chromatography of the residue 
(eluent hexane/ethyl acetate) afforded the desired compounds (1-5). 
2-napthol-[O-(2-cyanoethyl)-N,N′-diisopropylphosphoramidite] (1): 
Starting from 2-napthol (181 mg, 1.26 mmol) and following the 
general procedure, the compound 1 was obtained (368 mg, 85 % yield); 
Compound 1 1H NMR (CDCl3, 400 MHz): δ 7.58 (3H, overlapped 
signals, H-4, H-8 and H-5), 7.15 (2H, overlapped signals, H-7 and H-
9), 7.17 (1H, m, H-1), 7.04 (1H, d, J = 8.5 Hz, H-3), 3.73 (2H, m, 
OCH2CH2CN), 3.56 (2H, m, N[CH(CH3)2]2), 2.46 (2H, t, J = 8.0 Hz, 
OCH2CH2CN), 1.04 (6H, d, J = 8.0 Hz, N[CH(CH3)2]2), 0.98 (6H, d, J = 
8.0 Hz, N[CH(CH3)2]2); 13C NMR (CDCl3, 75 MHz): δ. 151.8, 134.0, 
129.5, 129.1, 127.4, 126.8, 126.0, 124.0, 121.1, 117.4, 114.7, 58.7, 43.4, 
24.2, 24.0, 20.3, 19.9. 31P NMR (CDCl3, 161.98 MHz): δ 149.2. ESI-MS: 
calculated for C20H26NO2P 343.17. Found (positive ions): 344.26 (M-
H)+. 
5-(dimethylamino)-N-(2-hydroxyethyl)-[O-(2-cyanoethyl)-N,N′-
diisopropylphosphoramidite]naphthalene-1-sulfonamide (2): Starting 
from 5-(dimethylamino)-N-(2-hydroxyethyl)naphthalene-1-
sulfonamide (370 mg, 1.26 mmol) and following the general 
procedure, the compound 2 was obtained (620 mg, 81 % yield); 
Compound 2 1H NMR (CDCl3, 400 MHz, 20 °C, mixture of 
enantiomers): δ 8.53 (1H, d, J = 8.4 Hz), 8.30 (1H, d, J = 8.4 Hz), 8.24 
(1H, d, J = 7.2 Hz), 7.53 (2H, m), 7.18 (1H, d, J = 7.6 Hz), 3.75–3.44 
(6H, overlapped signals, OCH2CH2CN, NHCH2CH2O and 
N[CH(CH3)2]2), 3.08 (2H, m, NHCH2CH2O), 2.86 (6H, s, NCH3), 2.55 
(2H, m, OCH2CH2CN), 1.25 (6H, d, J = 6.6 Hz, N[CH(CH3)2]2), 1.04 
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(6H, d, J = 6.7 Hz, N[CH(CH3)2]2). 13C NMR (CDCl3, 75 MHz): δ 151.9, 
130.3, 129.7, 129.4, 128.3, 123.1, 119.6, 118.6, 117.6, 115.1, 62.2, 58.3, 
45.3, 44.1, 42.9, 24.4, 20.1. 31P NMR (CDCl3, 161.98 MHz): δ 151.7. 
ESI-MS: calculated for C34H61N2O5P 608.43. Found (positive ions): 
609.51 (M-H)+. 
β-Estradiol-3-benzoate-17-hydroxy-[O-(2-cyanoethyl)-N,N′-
diisopropylphosphoramidite] (3): Starting from β-Estradiol-3-benzoate 
(475 mg, 1.26 mmol) and following the general procedure, the 
compound 3 was obtained (459 mg, 77 % yield); Compound 3 1H NMR 
(CDCl3, 400 MHz, 20 °C, mixture of diastereoisomers): δ 8.23 (2H, d, J 
= 7.6 Hz), 7.63 (1H, t, J = 7.6 Hz), 7.51 (2H, t, J = 7.6 Hz), 7.33 (1H, 
dd, J = 8.4, 3.2 Hz), 6.97 (1H, d, J = 8.4 Hz), 6.93 (1H, s), 3.80–3.76 
(3H, complex signal, OCH2CH2CN, H-17 of β–estradiol residue), 3.64–
3.58 (2H, complex signal, N[CH(CH3)2]2). 13C NMR (75 MHz, CDCl3): δ 
165.4, 148.6, 138.3, 138.1, 133.4, 130.1, 129.6, 128.5, 126.4, 121.6, 
118.6, 117.8, 83.7, 82.5, 58.4, 57.8, 49.7, 44.1, 43.5, 42.9, 38.4, 37.2, 
36.9, 29.6, 26.9, 26.1, 24.6, 23.2, 20.4, 11.9, 11.7. 31P NMR (161.98 
MHz, CDCl3): δ 150.5, 149.5. 31P NMR (CDCl3, 161.98 MHz): δ 150.5, 
149.5. ESI-MS: calculated for C27H41N2O3P 473.29. Found (positive 
ions): 474.69 (M-H)+. 
3-alpha,7-alpha,12-alpha-tri-O-acethyl-24-hydroxy-[O-(2-cyanoethyl)-
N,N′-diisopropylphosphoramidite]-cholane (4): 3-alpha,7-alpha,12-
alpha-24-tetrahydroxycholane (1.0 g, 2.54 mmol) was dissolved in 
anhydrous pyridine (15 mL), was reacted with DMTCl (1.30 g, 3.05 
mmol). The reaction mixture, left at room temperature overnight 
under stirring, was then diluted with CH3OH and concentrated under 
reduced pressure. The crude was next purified on a silica gel column, 
eluted with DCM containing growing amounts of CH3OH (from 1 to 
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5%) in the presence of a few drops of triethylamine, affording pure 3-
alpha,7-alpha,12-alpha-24-O-DMT-tetrahydroxycholane (1.53 g, 85%). 
The compound thus obtained, dissolved in anhydrous pyridine (15 
mL), was reacted with Ac2O (5 mL). The mixture was left under 
stirring at room temperature 5 h and then quenched by addition of a 
few drops of CH3OH. The mixture, concentrated under reduced 
pressure, was diluted with CHCl3, transferred into a separatory 
funnel, and washed three times with a saturated NaHCO3 aqueous 
solution and then twice with water. The organic phase, dried over 
anhydrous Na2SO4 and filtered, was then concentrated under reduced 
pressure, furnishing the desired product 3-alpha,7-alpha,12-alpha-tri-
O-acethyl-24-O-DMT-cholane, in an almost quantitative yield. A 
solution of iodine (150 mg, 0.55 mmol) in 10 mL of anhydrous CH3OH 
was added to the above product (1.5g, 1.81 mmol). The mixture was 
stirred vigorously at room temperature for 2h, then, sodium 
thiosulfate solution was added to remove excess iodine. The reaction 
mixture was extracted with DCM. The organic phase was combined, 
washed with water, dried over anhydrous Na2SO4, and the solvent 
was removed under reduced pressure. The crude product was purified 
by chromatography on silica gel column (eluent CHCl3/n-hexane, 9:1, 
v/v) to give a desired 3-alpha,7-alpha,12-alpha-tri-O-acethyl-24-
hydroxycholane (1.26 mmol, 69% yield).  
Starting from 3-alpha,7-alpha,12-alpha-tri-O-acethyl-24-
hydroxycholane (660 mg, 1.26 mmol) and following the general 
procedure, the compound 4 was obtained (600 mg, 80 % yield); 
Compound 4 1H NMR (CDCl3, 400 MHz, 20 °C, mixture of 
diastereoisomers): δ 5.02 (1H, br s), 4.90 (1H, br s), 4.58 (1H, m), 4.09 
(2H, t, J = 5.0 Hz), 3.80 (2H, complex signals), 3.58 (4H, complex 
signals), 2.63 (2H, t, J = 6.3 Hz), 2.13 (3H, s), 2.08 (3H, s), 2.05 (3H, s), 
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1.95-0.65 (45H, complex signals). 13C NMR (CDCl3, 75 MHz): δ 169.0, 
169.1, 168.7, 74.2, 73.0, 69.2, 63.8, 60.2, 48.5, 47.6, 43.3, 43.1, 42.3, 
41.2, 40.6, 37.2, 36.6, 36.0, 33.4, 31.3, 30.8, 30.5, 29.7, 28.9, 28.0, 25.4, 
24.4, 23.3, 23.0, 20.02, 18.2, 13.1. 31P NMR (CDCl3, 161.98 MHz): δ 
151.7, 150.7. ESI-MS: calculated for C33H59N2O5P 594.42 Found 
(positive ions): 595.32 (M-H)+. 
1-dodecanol-[O-(2-cyanoethyl)-N,N′-diisopropylphosphoramidite] (5): 
Starting from 1-dodecanol (235 mg, 1.26 mmol) and following the 
general procedure, the compound 5 was obtained (380 mg, 78 % yield); 
Compound 5 1H NMR (CDCl3, 400 MHz, 20 °C, mixture of 
enantiomers): δ 3.80 (2H, m, OCH2CH2CN,), 3.58 (4H, complex 
signals, N[CH(CH3)2]2, OCH2CH2(CH2)9CH3), 2.63 (2H, t, J = 6.3 Hz, 
OCH2CH2CN), 1.56 (2H, m, OCH2CH2(CH2)9CH3), 1.34-1.12 (30H, m, 
N[CH(CH3)2]2, OCH2CH2(CH2)9CH3, 0.87 (3H, t, J = 6.0 Hz). 13C NMR 
(CDCl3, 75 MHz): δ 119.4, 63.7, 58.3, 42.9, 31.9, 31.2, 29.8, 29.6, 29.5, 
26.1, 24.5, 22.6, 20.3, 14.0. 31P NMR (CDCl3, 161.98 MHz): δ 152.9. 
ESI-MS: calculated for C21H43N2O2P 386.31. Found (positive ions): 
387.55 (M-H)+. 
Synthesis and Characterisation of ODNs (I-V). As depicted in Scheme 
1, oligomers I-V were synthesised, starting from functionalised CPG 
support 6 with 0.07-0.08 meq/g initial loading, on which the sequence 
d(TGGGAG) was assembled in a standard manner. Starting with 100 
mg of commercially available CPG-dG support with 0.10 meq/g initial 
loading, and after the assembly of the sequence d(TGGGA), an 
additional coupling with phosphoramidite building blocks 1–5 was 
then performed. Target oligomers I-V were detached from the solid 
support and deprotected by treatment with Et3N/pyridine (1:1, v/v) at 
50 °C for 1 h, followed by treatment with conc. aq. ammonia at 50 °C 
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for 5 h. The combined filtrates and washings were concentrated under 
reduced pressure, re-dissolved in H2O, and analysed and purified by 
HPLC. Purification of the crude conjugated oligonucleotides I-V was 
carried out on Phenomenex RP18 column or RP18 column (LUNA, 
5μm C18(2), 10.0 × 250 mm) using a linear gradient of CH3CN in 0.1 
M AcNH4 in H2O, pH 7.0 from 5% to 100% over 30 min at a flow rate 
of 1.5 mL/min with detection at 260 nm. In all cases 50-80 OD units of 
pure I-V could be on average recovered starting from 100 mg of 
functionalized solid support (average yields 10-25%). 
Quadruplexes Preparation. The quadruplex complexes were obtained 
by dissolving the lyophilized oligonucleotide at a single strand 
concentration of 1×10-4 M in the appropriate buffer. The solution was 
then annealed by heating at 90°C for 5 min and slow cooling to room 
temperature. The buffer used was 10mM potassium phosphate, 
200mM KCl, 0.1mM EDTA at pH 7.0. The concentration of the 
dissolved oligonucleotides I-V was determined by UV measurements 
at 260 nm and at 95°C, using, as the molar extinction coefficients, the 
values calculated by the nearest neighbour model for the sequence 
d(TGGGAG), and the values experimentally calculated for labels 1-3 
(808, 1083, and 703 cm-1 M-1, respectively). 
General procedure for determination of the corresponding ε values for 
1–3 labels. Determination of the ε values at 25°C for labels 1–3 was 
carried out by averaging at least five independent A260 measurements 
of the water soluble samples at different known concentrations (see 
graphics), allowing to determine the following ε data: 808, 1083 and 
703 cm-1 M-1, respectively for 1-naphthyl phosphate disodium salt, 5-
(dimethylamino)-1-naphthalenesulfonic acid and β-estradiol 17-(β-D-
glucuronide) sodium salt which purchased from Sigma-Aldrich. 
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Molar extinction coefficient () in H2O of
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Molar extinction coefficient () in H2O of 
5-(Dimethylamino)-1-naphthalenesulfonic acid. 
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CD Experiments. CD spectra were recorded by a JASCO J-810 
spectropolarimeter equipped with a thermostatically controlled 
accessory (JASCO PTC-348), using a quartz cuvette with a 0.5 cm 
optical path. CD spectra were collected from 220 to 340 nm, at 20 
nm/min, with a response time of 4 s and at 1 nm bandwidth. The CD 
signal of the buffer was subtracted from all CD spectra, corresponding 
to an average of 5 scans. The molar ellipticity was calculated by the 
equation [θ] = 100·θ /cl where θ is the ellipticity value, c is the 
concentration of the single strand (1.0 × 10-5 M), and l is the path 
length of the cell in cm. The thermally-induced dissociation of the 
quadruplexes was studied by monitoring the CD signal at 263 nm 
upon increasing the temperature from 15 to 90°C (heating rate = 
1°C/min). The melting temperatures were calculated from the peaks 
of the first derivative of the CD signal vs T. 
DSC experiments. DSC runs were all performed by a VP-DSC 
calorimeter (MicroCal). All samples, after a degassing process, were 
scanned at a heating rate of 1°C min-1 in the temperature range 20–
120°C in the same experimental conditions adopted for the CD 
experiments. An extra external pressure of about 29 psi was applied 
to the solution to prevent the formation of air bubbles during heating. 
To ensure a complete equilibration of the calorimeter, several 
buffer−buffer heating scans were routinely performed prior to the 
measurement. Only after obtaining invariant buffer−buffer baselines 
samples were scanned. Additional buffer−buffer baselines were 
obtained immediately after the protein scans to double-check for 
uncontrolled drifts in instrumental baseline. For each sample, three 
independent DSC experiments were carried out under the same 
buffer conditions. To obtain the heat capacity Cp curves, buffer–buffer 
base lines were recorded at the same scanning rate and then 
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subtracted from sample curves, as previously described26. In all 
experiments, one or several heating−cooling cycles were carried out to 
determine the reversibility of the denaturation process. To obtain the 
excess heat capacity profiles <ΔCp>, the DSC curves, after 
instrumental baseline correction, were subtracted from a baseline 
obtained by a third-order polynomial fit of the pre- and post- 
transition Cp trends as reported elsewhere27–29. Melting temperatures 
were calculated from the maximum Cp value of the DSC curve. 
Anti-HIV experiments. Inhibition of HIV-1(IIIB)- and HIV-2(ROD)-
induced cytopathicity in CEM cell cultures was measured in 
microliter 96-well plates containing 3 × 105 CEM cells/mL infected 
with 100 CCID50 of HIV for milliliter and containing appropriate 
dilutions of the test compounds. After 4−5 days of incubation at 37°C 
in a CO2-controlled humidified atmosphere, CEM giant (syncytium) 
cell formation was examined microscopically. The EC50 (50% effective 
concentration) was defined as the compound concentration required to 
inhibit HIV-induced giant cell formation by 50%. 
Surface Plasmon Resonance (SPR) analysis. Interaction studies were 
performed on a Biacore T200 instrument (GE Healthcare, Uppsala, 
Sweden) at 25°C in HBS-P (10 mM HEPES, 150 mMNaCl and 0.05% 
surfactant P20; pH 7.4) supplemented with 10mM CaCl2. 
Recombinant HIV-1(IIIB) gp120 (ImmunoDiagnostics Inc., Woburn, 
MA), recombinant HIV-1(HxB2) gp41 (Acris Antibodies GmbH, 
Herford, Germany) and human serum albumin (HSA) (Sigma) were 
covalently immobilized on a CM5 sensor chip in 10mM sodium 
acetate, pH 4, using standard amine coupling chemistry, resulting in 
chip densities of respectively 3531, 3091 and 3333 RU. A reference 
flow cell was used as a control for non-specific binding and refractive 
  
55 
index changes. Samples were injected for 2 minutes at a flow rate of 
45 µl/min and followed by a dissociation phase of 2 minutes. The CM5 
sensor chip surface was regenerated with a single injection of Glycine-
HCl pH = 3. 
HIV-1 reverse transcriptase assay. Enzyme reactions (50 μL in 
volume) were carried out in a 50mM Tris-HCl (pH 7.8) buffer that 
contained 5mM dithiothreitol, 300mM glutathione, 0.5mM EDTA, 
150mM KCl, 5mM MgCl2, 1.25 μg of bovine serum albumin, 0.06% 
Triton X-100, an appropriate concentration of 2.8 μM [3H]dGTP (2 
μCi/assay), varying concentrations of the test compounds, and a fixed 
concentration of poly(rC)/oligo(dG) (0.1 mM). Reactions were initiated 
by the addition of 1 μL of wild-type or mutant RT and were incubated 
for 30 min at 37°C. Reactions were terminated by the addition of 200 
μL of 2 mg/mL yeast RNA, 2 mL of 0.1 M Na4P2O7 (in 1M HCl), and 2 
mL of 10% (v/v) trichloroacetic acid. The solutions were kept on ice for 
30 min, after which the acid-insoluble material was washed and 
analyzed for radioactivity. 
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2.2 Hairpin oligonucleotides forming G-quadruplexes: New aptamers 
with anti-HIV activity 
Even if tetramolecular complexes have recently displayed 
interesting biological properties, and have been proposed for many 
therapeutic applications, their use is limited by unfavourable 
kinetics30. The in vitro formation of a tetramolecular G-quadruplex is 
very slow and may require high ODN and salt concentrations. In 
order to improve the kinetics of G-quadruplex formation, a variety of 
tetra-branched linked d(TGGGAG) ODNs (TEL-ODNs) were reported 
by Piccialli et al. and strong activity was found for some of these 
sequences31,32. 
With the aim to improve the kinetic of G-quadruplex formation 
using d(TGGGAG) as a lead sequence, and therefore to enhance the 
anti-HIV activity of these aptamers, we designed, for the first time, 
bimolecular G-quadruplexes on d(TGGGAG) sequence. Basically, 
these new bimolecular G-quadruplexes diverged from the G-
quadruplexes so far reported, for the number of strands involved in 
the complex, the hexaethylenglycole (HEG) as linker and the number 
of aromatic residues at 5’-end. Here, it is reported the synthesis of 
new Hairpins ODNs with inversion of polarity 3’-3’ and 5’-5’ and some 
5’-end conjugations (I-V, Figure 4) and their biophysical and biological 
characterization. The scaffold of new ODNs is formed by hairpin 
stuctures containing two d(TGGGAG) domains, whose 3’ or 5’-ends 
are joint through a HEG loop (I and V, Figure 4). In addition, the 
synthesis of II-IV, which contain a HEG linker33 in the 3’-3’ inversion 
of polarity site and an aromatic residues at one 5’-end linked by 
phosphodiester linkage were developed. 
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Aromatic phosphoramidate compounds 2-4 were selected on the 
basis of our previously reported data for homologous tetramolecular 
G-quadruplexes, which were efficiently tethered to the d(TGGGAG) 
model sequence by exploiting classical phosphoramidite chemistry. 
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Figure 4. Phosphoramidite building blocks 1–4, modified ODN sequences I–V and 
potential hairpin structure H1–H5. 
ODN tracts were synthesized using standard solid-phase -
cyanoethylphosphoramidite chemistry protocols (in both 3’→5’ and 
5’→3’ directions) on an automated DNA synthesizer, starting from 
commercially available, DMT-protected, nucleoside functionalized 
CPG supports. A CPG solid support that anchors 3’-O-(4,4’-
dimethoxytrityl)-thymidine 5 (Scheme 2) was used to synthesize the 
first DNA tract (synthesis by 5’→3’ direction), leading to 6. 
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Phosphoramidite 1 (Figure 4), commercially available, was then 
exploited to insert a HEG linker unit using classical phosphoramidite 
protocols. 
T 3'DMT
DNA assembly
(5'-3' direction)
TG3AG 3'DMT
coupling with 1
TG3AG p HEG DMT
DNA assembly
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Scheme 2. Synthetic scheme of ODNs I and III – V by standard automated DNA 
synthesis. 
After DMT removal (1% DCA in DCM), the second DNA tract was 
assembled (synthesis by 3’→5’ direction), leading to 8. Spectroscopic 
measurements monitored DMT cation formation, indicating chain 
assembly for each coupling cycle. Compound yields of at least 98% 
were obtained. After detachment and deprotection, the crude material 
was analyzed and then purified by HPLC and gel filtration 
chromatography. Two main peaks were observed in the SAX-HPLC 
profiles (Figure 5B). The fastest eluting peak, attributed to a 12-mer 
single strand, was always accompanied by a major peak that had a 
higher retention time due to its G-quadruplex structure generated 
under HPLC elution conditions. These two peaks, accounting for more 
than 90% of the total integrated area, corresponded to desired I, as 
ascertained by MALDI-TOF MS (Table 5). Subsequently, 
phosphoramidite derivatives 2-4 were exploited in the last coupling 
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step, starting from support 8, to synthesize 5’-conjugated oligomers II-
IV. Target oligomers I-IV were detached from the solid support, 
deprotected and the crude materials were then analyzed and purified 
using HPLC and gel filtration chromatography. 
 
Figure 5. Typical RP-HPLC (A) and SAX (B) profiles of purified and desalted ODNs. 
The modified oligonucleotides were characterized by MALDI-TOF 
MS, in all cases giving masses in accordance with their expected 
values (Table 5). ODN sequence V was obtained from the CPG solid 
support that anchored 5’-O-(4,4’-Dimethoxytrityl)-N-isobutyryl-20-
deoxy-guanosine-3’-[(2-cyanoethyl)-N,N-diisopropyl]- phosphoramidite 
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and previously described procedures (for synthetic scheme see 
Experimental Session). 
Table 5. Oligonucleotide mass characterization and melting temperatures (Tm) of 
the quadruplexes formed by ODNs I–V 
ODN 
sequences 
MS 
calcd for [M]a 
data (found) 
Yield (%)b Tm (°C) 
I 4148.79 / 4150.78 
4150.65 [MH]+; 4172.58 [MNa]+ 
8.8 76.0 ± 0.5 
II 4410.83 / 4412.97 
4412.59 [MH]+; 4434.32 [MNa]+ 
7.0 84.0 ± 0.5 
III 4416.91 / 4419.07 
4418.54 [MH]+; 4440.91 [MNa]+ 
8.2 83.0 ± 0.5 
IV 4399.87 / 4401.99 
4401.52 [MH]+; 4423.84 [MNa]+; 
7.8 83.5 ± 0.5 
V 4148.79 / 4150.78 
4150.88 [MH]+ 4172.46 [MNa]+ 
6.6 75.5 ± 0.5 
d(TGGGAG) — — 41.0 ± 0.5 
aExact mass / Average mass values; bYields calculated on the pure oligonucleotide 
after gel filtration, with respect to the starting functionalization of the supports. 
 CD studies and characterization 
To study the influence of the loops and 5’-end aromatic groups on 
the ability of sequence to form G-quadruplex structures, CD analyses 
was undertaken on oligomers I and V in comparison with a 
corresponding unmodified d(TGGGAG) oligomer. For all sequences, 
the CD spectra at 20°C showed typical, positive bands at 264 nm and 
small negative bands at 243 nm, indicative of parallel-stranded, 
bimolecular G-quadruplex structures (Figure 6). Tm values were 
obtained from the CD melting profiles and are reported in Table 5. 
The melting curves recorded by heating a preformed G-quadruplexes 
did not correspond to equilibrium melting curves (hysteresis 
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phenomenon), and the ‘Tm’ or ‘T1/2’ deduced from these experiments 
depends on the heating rate17. 
 
Figure 6. CD spectra of modified oligonucleotides I–V. 
These data clearly showed that all modified ODNs formed G-
quadruplexes with strongly increased thermal stabilities compared 
with unmodified d(TGGGAG) quadruplex (Table 5). From the data 
analysis, the HEG linker at the 5’-or 3’-end clearly makes the G-
quadruplexes H1 and H5 much more stable than the corresponding 
tetramolecular complexes lacking of HEG bridges (T > 35°C). The 
presence of two aromatic residues at the 5’-end further stabilized the 
resulting G-quadruplexes H2-H4 (T ≈ 8°C) in comparison with un-
conjugated hairpin G-quadruplex H1 and H5 (Figure 7). Noteworthy, 
the different aromatic groups at the 5’-end of conjugates H2-H4 
contributed equally to thermal stabilization, possibly promoting a 
well-packed cluster at the end of the structures. We expected that the 
introduction of aromatic moieties at only one of the hairpin 5’-end 
could lead to the formation of two different populations of conjugated 
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G-quadruplexes, in which the aromatic residues were either in a 
lateral or diagonal position. In all CD profiles, any transition related 
to these two expected H2-H4 populations was observed. 
 
 
Figure 7. CD melting profiles of ODNs H1 (Tm = 76.0 °C; bold line) and H2 (Tm = 84 
°C; dotted line). 
 Anti-HIV activity and Surface Plasmon Resonance (SPR): 
directed affinity binding analyses for the HIV envelope 
Considering anti-HIV activity (Table 6), low micromolar inhibition 
of HIV-1 infection in CEM cell cultures was found for II-IV, but not 
for unconjugated I and V. These favourable selectivity indices 
amounted to >1.0. Anti-HIV-2 activity was markedly less pronounced 
than that for HIV-1. Compound II (containing the phenylbenzyl 2 
moiety) proved to be the most effective derivative with EC50 values as 
low as 0.96 M (HIV-1) and 3.2 M (HIV-2). This compound lacked 
measurable toxicity at 8 M in CEM cell cultures. Interestingly, the 
conjugated G-quadruplexes II-IV were less active than the 
corresponding tetramolecular complexes12, reasonably, because each 
tetrameric G-quadruplex bears four terminal aromatic groups, 
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whereas the dimeric G-quaduplexes (II-IV) contain only two aromatic 
moieties. 
Table 6. Anti-HIV-1 and –HIV-2 activity and cytostatic properties of the test 
compounds I to V in human T-lymphocyte (CEM) cell cultures 
ODN sequences 
EC50a (µM) CC50b (µM) S.I.c 
HIV-1 (IIIB) HIV-2 (ROD)   
I > 8 > 8 > 8 - 
II 0.96  0.24 3.2 0.5 > 8 > 8.3 
III 1.92  1.1 > 8 > 8 > 4.1 
IV 3.4  0.06 6.9  1.6 > 8 > 2.3 
V > 8 > 8 > 8 - 
aEC50, 50% effective concentration or compound concentration required to protect 
CEM cells against the cytopathicity of HIV by 50%; bCC50, 50% cytostatic 
concentration or compound concentration required to reduce CEM cell 
proliferation by 50%; cSelectivity index for HIV-1, calculated as the ratio of 
CC50/EC50. 
Compounds I-V were then evaluated for their binding capacity to 
HIV-1 gp120, gp41 and the albumin (HSA) (Figure 8). Albumin is 
commonly employed as a versatile drug carrier in anti-HIV 
strategies25,34. Un-conjugated compounds I and V did not show 
measurable binding to any of the HIV glycoproteins and HSA. In 
contrast, binding was observed against these three proteins for the 
compounds II-IV. In particular, compound II bound somewhat more 
efficiently than III and IV; however, no compounds showed exclusive 
selectivity for binding to HIV envelope glycoproteins. In fact, when 
the RU values of gp120, gp41 and HSA binding on the sensorchips 
and the molecular weight of the ligands were taken into account, 
binding efficiency of all three ligands were within the same order of 
magnitude. The kon, koff and KD values could not be accurately 
determined since the data could not fit in a 1:1 binding model. 
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Thus, because binding to HIV-1 glycoproteins was only observed 
for the modified G-quadruplexes that also showed anti-HIV activity in 
cell culture, envelope binding might serve as the cause of eventual 
antiviral activity. 
 
Figure 8 . SPR plots of compound I and II–IV interactions with HIV-1(IIIB) gp120, 
HIV-1/HxB2 gp41 and HSA. 
On the other hand, the antiviral activity of these G-quadruplexes 
may be due to the amphiphilic properties as well as the formation of 
multimeric complexes of these ODNs, as recently reported8. 
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However, to further ascertain whether entry (i.e., fusion) is the 
main antiviral target of the compounds, other assays should be 
performed. 
 Serum stability studies 
As efficient anti-HIV therapies require the retention of high drug 
concentrations for prolonged time periods in vivo, we investigated the 
stabilities of hairpin ODNs II-IV in human serum. The bio-stability of 
II-IV sequences were assessed in vitro and compared to unmodified 
d(TGGGAG). As shown in Figure 9, the enhancement in the bio-
stability was observed for all sequences. In particular, I and V proved 
stable for 4 days, while the unmodified sequence was completely 
degraded after 4 h, suggesting the high stabilization effect produced 
by the HEG loop. This serum stability was dramatically enhanced in 
conjugated hairpin ODNs, in particular II, which was stable for at 
least 8 days. 
 
Figure 9. Stability of I–V in Human Serum. 
  
0
20
40
60
80
100
120
0 4h 1d 2d 4d 8d
Incubation Time
R
es
id
ua
l i
nt
ac
t q
ua
dr
up
le
x 
(%
)
I
II
III
IV
V
  
66 
2.2.1 Experimental Session 
General procedures. MALDI-TOF MS analyses were performed on a 
PerSeptiveBiosystems Voyager-De Pro MALDI mass spectrometer in 
the linear mode using a picolinic/3–hydroxypicolinic/sinapinic acid 
mixture matrix. HPLC analyses were performed on an Agilent 
Technologies 1200 series instrument equipped with a UV detector. 
The crude material was purified and analysed using HPLC on a 
Phenomenex RP18 column [LUNA, 5μm C18, 10.0 × 250 mm] and 
Nucleogel SAX column (Macherey-Nagel, 1000–8/46), respectively. 
Desalting was conducted using gel filtration chromatography on a 
Sephadex G10 column, eluted with H2O/EtOH 4:1 (v/v). 
Synthesis and characterization of ODNs (I–V). As depicted in Scheme 
2, oligomers I–IV were synthesised, starting with functionalised CPG 
support 5 with 0.1 meq/g (100 mg) initial loading, on which the 
sequence d(GAG3T) was assembled in a standard manner. After 
coupling with phosphoramidite1, assembly of the second ODN tract 
was then performed. Target oligomers were detached from the solid 
support and deprotected via treatment with conc. aq. NH4OH at 50°C 
for 5 h. The combined filtrates and washings were concentrated under 
reduced pressure, re-dissolved in H2O, and analysed and purified with 
HPLC. Purification of the crude detachments were performed on a 
Phenomenex RP18 column or RP18 column (LUNA, 5μm C18, 10.0 × 
250 mm), using a linear gradient of CH3CN in 0.1 M AcNH4/H2O (pH 
7.0), from 5% to 100% in 30 min, at a flow rate of 1.5 mL/min and 
with detection at 260 nm. HPLC analyses of oligonucleotides I–IV 
was conducted on an analytical anion exchange Nucleogel SAX 
column (Macherey-Nagel, 1000–8/46, 4.6 × 50 mm, 5 μm), adopting 
the following eluents: buffer A, 20 mM KH2PO4/K2HPO4 aq. solution 
(pH = 7.0), containing 20% (v/v) CH3CN; buffer B, 1.0 M KCl, 20 mM 
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KH2PO4/K2HPO4 aq. solution (pH = 7.0), containing 20% (v/v) 
CH3CN, using a linear gradient from 0% to 100% B in 20 min, flow 
rate 0.8 mL/min and detection at λ = 260 nm. In a typical experiment, 
starting from 100 mg of CPG that anchored the first nucleoside, 60 – 
110 OD units (8.8 – 6.6% yields) of purified I–V were obtained (Table 
5). 
Synthetic scheme of V 
G 5'DMT
DNA assembly
(3'-5' direction)
GAG3T 5'DMT
coupling with 1
GAG3T p HEG DMT
DNA assembly
(5'-3' direction)
GAG3T p HEG p TG3AGGAG3T p HEG p TG3AG
detachment
and deprotection
V
3'          5'                      5'           3'3'          5'                      5'           3'
        = CPG; p = phosphodiester bridge; HEG bridge (                                              ).O O O O
4
3'          5'
 
Quadruplex Preparation and CD experiments. CD spectra were 
registered on a JASCO J-715 spectrophotometer equipped with a 
thermoelectrically controlled cuvette holder (JASCO PTC-348) in a 
0.2 cm path length cuvette. The quadruplex complexes (5 x 10-5 M) 
were obtained by dissolving the lyophilised oligonucleotide in an 
appropriate buffer, annealed by heating at 95 °C for 5 min and slowly 
cooled to room temperature. The buffer used was 10 mM potassium 
phosphate, 200mM KCl and 0.1 mM EDTA (pH 7.0). The 
concentrations of dissolved oligonucleotides I – V were determined 
with UV measurements at 260 nm and 90°C, using the calculated 
molar extinction coefficient of d(TGGGAG)2 ε (125,000 cm-1 M-1). CD 
spectra were collected from 200 to 340 nm, at 20 nm/min, with a 
response time of 16 s and at 2 nm bandwidth. The thermal 
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denaturation curves were registered at the λ= 264 nm and a heating 
rate of 0.5°C/min. 
Stability of G-quadruplexes in Human Serum. Unmodified and 
modified sequences were incubated with 93% Human Serum (Lonza) 
at 37°C. Aliquots of 100 pmol were withdrawn at different time points 
and immediately frozen. The solutions were then extracted with 
phenol and ODNs were precipitated with ethanol. Samples were 
analyzed on denaturing (7M urea) 20% polyacrylamide gel and 
visualized by SYBR® Green I (Invitrogen) staining. Equal amounts of 
ODNs before serum incubation were extracted with phenol in parallel 
and loaded as an input control. Gel images were captured using a 
ChemiDoc™ XRS (Bio-Rad), and the electrophoretic bands were 
quantified with Image Lab™ software (Bio-Rad). The signal intensity 
value of an intact quadruplex was set at 1. 
Anti-HIV experiments. Inhibition of HIV-1(IIIB) and HIV-2(ROD)-
induced cytopathicity in CEM cell cultures was measured in 
microtitre 96-well plates containing  3 × 105 CEM cells/mL infected 
with 100 CCID50 of HIV per millilitre and containing appropriate 
dilutions of test compounds. After 4−5 days of incubation at 37°C in a 
CO2-controlled humidified atmosphere, giant CEM (syncytium) cell 
formations were examined microscopically. The EC50 (50% effective 
concentration) was defined as the compound concentration required to 
inhibit HIV-induced, giant cell formation by 50%. 
Surface Plasmon Resonance (SPR) analysis. Interaction studies were 
performed on a Biacore T200 instrument (GE Healthcare, Uppsala, 
Sweden) at 25°C in HBS-P (10mM HEPES, 150mM NaCl and 0.05% 
surfactant P20; pH 7.4) supplemented with 10mM CaCl2. 
Recombinant HIV-1(IIIB) gp120 (ImmunoDiagnostics Inc., Woburn, 
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MA), recombinant HIV-1(HxB2) gp41 (Acris Antibodies GmbH, 
Herford, Germany) and human serum albumin (HSA) (Sigma) were 
covalently immobilised on a CM5 sensor chip in 10 mM sodium 
acetate, pH 4, using standard amine coupling chemistry, resulting in 
chip densities of 3531, 3091 and 3333 RU, respectively. A reference 
flow cell was used as a control for non-specific binding and refractive 
index changes, several buffer blanks were used for double referencing, 
and the blank signals automatically subtracted from the test values. 
Samples were injected for 2 minutes at a flow rate of 45 µl/min and 
followed by a dissociation phase of 2 minutes. Since several samples 
contained DMSO, a DMSO concentration series was also included to 
eliminate the contribution of DMSO to the response signal. The CM5 
sensor chip surface was regenerated with a single injection of Glycine-
HCl pH = 3. 
2.3 General Conclusions and Perspective 
In this chapter, it was described the synthesis of a variety of 
modified aptamers based on “Hotoda sequence” with high anti-HIV 
activity. Biophysical and biological characterization were performed 
on all modified sequences. Particularly, the first mini library of 
d(TGGGAG) ODNs carrying aromatic and hydrophobic tails at the 5’-
end were synthesized via a fully automated, on-line phosphoramidite-
based solid-phase method (Scheme 1). The new ODN 5’-conjugated 
showed anti-HIV activity with some preference for HIV-1, with 
inhibitory activity invariably in the low micromolar range. SPR data, 
did not suggested any selectivity for gp120 or gp41 binding compared 
with HSA binding, yet highlighted the interesting potentialities of 
HSA as a versatile drug carrier in anti-HIV25. 
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The CD and DSC monitored thermal denaturation studies on the 
resulting G-quadruplexes, suggested that the insertion of lipophilic 
residue at the 5’-end, leads always to a stability enhancement of G-
quadruplex complexes (20 <Tm< 40°C). Moreover, a detailed CD and 
DSC analyses indicated a monophasic behaviour for sequences I and 
V, while for ODNs (II–IV) clearly shown that these G-quadruplex 
structures deviate from simple two-state melting, suggesting the 
formation of intermediate states (Figure 3). For all sequences, the CD 
spectra at 20°C showed diagnostic profiles of parallel-stranded 
quadruplex structures. (Figure 2). 
In the second part of this chapter, we also reported the synthesis of 
bimolecular G-quadruplex oligonucleotides based on “Hotoda 
sequence” containing a HEG loop as a 3’-3’ or 5’-5’ inversion of 
polarity site. CD studies assessed that the introduction of a HEG loop, 
produces an improvement of the thermal stability of all hairpin ODNs 
compared to d(TGGGAG) tetramolecular G-quadruplexes and that 
this insertion has no affect on the original parallel folding of the G-
quadruplex structure (Figure 4). This thermal stabilization was 
further increased, once more, by introduction of different aromatic 
residues at the 5’-end of hairpins H1. Moreover, only 5’-conjugated 
hairpins (H2-H4), have proven to exhibit significant anti-HIV activity 
in cell culture (Table 6). Besides the anti-HIV activity, the conjugated 
hairpin G-quadruplexes exhibited interesting properties in terms of 
slight cytotoxicity, favourable CC50/EC50 (selectivity index) ratio and 
increased stability in human serum. Finally, also the 5’-conjugated 
hairpins (H2-H4),  shown a good affinity  for HSA. 
In light of all results, we can confirm that the presence of lipophilic 
residues at the 5’-end is essential for the stability and anti-HIV 
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activity of these G-quadruplexes. These results are in agreement with 
that reported by D’onofrio et al. on the 5’-sugar-conjugated 
d(TGGGAG)15. The conjugation of sugars (polar groups) at the 5’-end 
of d(TGGGAG) cause low thermal stability and no anti-HIV activity 
for  these sequence. Most importantly, we clarified that the major 
stability of the investigated complexes is not directly correlated with 
their pronounced anti-HIV activity. 
Considering the amount of G-quadruplexes formed and able to 
interact with targets (gp120 and gp41), a fundamental prerequisite 
for the biological activity of these sequences, it is evident that their 
thermal stabilities and kinetics of formation are essential. In order to 
achieve a more complete picture of the structure-activity relationships 
of the most active 5’-end modified d(TGGGAG), we have started to 
examine the kinetic aspects of G-quadruplex formation based on these 
sequences by ESI-MS technique, in collaboration with Dr. Valérie 
Gabelica in Inserm/Univ.Bordeaux (see Chapter 4). 
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CHAPTER 3 
Improvement of Solid Phase Synthetic Approach 
Oligonucleotides (ODNs) and nucleotides represent two classes of 
potential therapeutic agents with a broad spectrum of 
pharmacological activities. Desired improvements of certain 
properties, such as cell-specific delivery, cellular uptake efficiency, 
intracellular distribution, and target specificity, can be achieved by 
chemical modifications. Conjugation of ODNs to other molecules such 
as proteins and peptides, saccharides, fluorophores, inhibitors, and 
vitamins offers a feasible way to address these requirements1–3. The 
methods used for the preparation of these molecules fall into two 
major categories: solution and solid phase approaches. The solid 
phase method, in association with combinatorial chemistry 
approaches, is a successful approach for the synthesis of a large 
number of nucleic acid analogues4. An advantage of the solid-
supported method compared with conjugation or derivatization in 
solution is that it is less laborious, among other advantages. In fact, 
on a solid support, the unreacted compounds are usually used in 
considerable excess, and the possible by-products can be removed by 
simple washing. Within this framework, the low loading of the solid 
supports has proven to be a limitation to the different strategies 
proposed, as it strongly restricts the amount of targets that can be 
obtained. 
3.1 Aim of research work 
In these years, many efforts have been made, towards the 
synthesis of new solid supports useful to generate pharmacologically 
interesting libraries of molecules of high purity and in large 
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quantities5–10. The goal of my project was the improvement of the 
more recent solid phase strategy reported by my research group. The 
solid phase methodology at issue, it was reported by De Napoli et al. 
in 2005 (Scheme 1), and was devised to obtain phosphodiester and 
phosphoramidate monoester nucleoside analogues and 5’ and 3’-ODN 
conjugates in extremely pure form using standard phosphotriester 
chemistry7. 
 
Scheme 1. Solid phase methodology to obtain phosphodiester, phosphoramidate 
monoester nucleoside analogues and oligonucleotide conjugates. 
The key step of this strategy was the derivatization of the solid 
support (TG, CPG) with a 3-chloro-4-hydroxyphenylacetic linker, onto 
which the nucleotide is attached through a phosphate triester 
linkage. Due to the structure of the linker, after cleavage from the 
support, the HPLC analyses of the released nucleotides and ODNs 
showed only the desired product. High purity can be obtained due the 
cleavage from the resin of phosphotriester or phosphoramidate diester 
bonds after ammonia treatment, in whereas the nucleoside or ODN 
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anchored by a phosphodiester bond (the unreacted ODN chain) is not 
affected. 
3.2 Results and Discussion 
Aiming to improve the load of the solid support currently available7 
and that is also compatible with phosphoramidite and 
phosphotriester chemistry, we devised a straightforward and efficient 
synthetic protocol to prepare a new support in which the loading of 
the o-chloro-functional group is very high (0.20–0.50meq/g). 
The key step was the derivatisation of commonly used long chain 
amino alkyl (LCAA-CPG and TG) solid supports with N--Fmoc-3-
chloro-L-tyrosine (3-Cl-Tyr). Unlike the 3-chloro-4-hydroxy-
phenylacetic linker, used previously, the 3-chloro-L-tyrosine linker 
not only contains an o-chloro-phenol skeleton but also simultaneously 
has amino and acidic functional groups, which allow a versatile 
elongation of the peptide chain, with a resulting increase of the 
functionalization of the OH groups. In an initial series of 
experiments, we synthesized supports LCAA-CPG (load 0.10meq/g) or 
TG (load 0.29meq/g), with a homopeptide (3-Cl)-Tyr3 following an 
Fmoc protocol, leading to 1a and 1b, respectively (Scheme 2). The 
peptide chain was prepared using DCCI/HOBt (N,N'-
dicyclohexylcarbodiimide/N-hydroxybenzotriazole) as coupling agents, 
with each monomer addition monitored by the Kaiser test11; the yields 
were always in the range of 65–85%, corresponding to 0.19–0.25meq/g 
for 1a and 0.50–0.75 meq/g for 1b. 
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To test the efficiency of these supports in the synthesis of 
phosphodiester and phosphoramidate monoester nucleoside 
analogues, we followed two different methods, as previously reported. 
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Scheme 2. The strategy to obtain CPG or TG with high loading of o-chloro-phenol 
residues. 
In preliminary tests, we chose to synthesize the cholesteryl 
phosphodiester and n-butylamino phosphoramidate of thymidine as 
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nucleotide models. Initially, the 5’-phosphoramidite thymidine 
derivative 2 was anchored to matrices (CPG and TG) by exploiting 
classical phosphoramidite chemistry (Scheme 3). After conversion of 
the phosphite to phosphate triesters, affording supports 3a and 3b,the 
incorporation of the nucleotide, as determined by the DMT test, was 
always in the range of 0.18–0.22meq/g for LCAA- CPG (3a) and 0.25–
0.50meq/g starting from a TG amino resin (3b). Compared with 
previous work, here we have doubled resin loading (0.08–0.10meq/g 
and 0.19–0.22meq/g, resp.). 
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Scheme 3. The feasibility tests of new supports for the solid phase synthesis of 
nucleotide analogues and oligonucleotide conjugates. 
To obtain the phosphodiester thymidine derivative 5 (Scheme 3), 
support 4b was reacted with MSNT [1-(mesitylene-2-sulfonyl)-3-nitro-
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1,2,4-triazole] and cholesterol in pyridine at room temperature (r.t.) 
for 12 hours (h). To prepare the phosphoramidate thymidine 
derivative, support 4a was treated three times with p-tosyl chloride in 
pyridine and then reacted with the n-butylamine dissolved in 
pyridine. As expected, the conjugation efficiency was always in the 
range of 70–80%, leading to supports with 0.13–0.18 meq/g and 0.18–
0.40 meq/g loading for 4a and 4b, respectively. These yields could be 
indirectly evaluated by DMT tests on weighed samples of the support 
after ammonia treatment, determining the amount of un-conjugated 
material left on the solid support. Only nucleosides linked to the 
support through a phosphotriester or phosphoramidate diester 
linkage are easily removed upon basic treatment (28% NH4OH, 50°C, 
5 h), whereas nucleosides anchored through a phosphodiester bond 
are not cleaved from the resin under the same conditions. After DMT 
removal and detachment from the supports, the obtained crude 
material was analyzed by RP-HPLC, and the profiles showed a single 
major peak with an area (85%–91%) similar to values reported 
previously (Figure 1). 
 
Figure 1. SAX-HPLC profile of crude detached 5 (Phenomenex LUNA, 5μm C18, 10.0 
× 250 mm) eluted with a linear gradient from 10 to 100 % B in 30 min, A = H2O, B = 
CH3CN; detection at λ = 260 nm; flow rate 0.8 mL/min. 
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The identity of 5 and 6 was determined by 1H, 31PNMR, and ESI-
MS experiments that were conducted directly on the crude detached 
material. As expected, starting from 30 mg of support 4a or 4b, the 
target nucleotides were recovered as discrete compounds in 2–4 mg 
and 4–9 mg quantities, respectively, in a highly pure form. 
To demonstrate the reliability of the CPG supports for the 
automatic synthesis of ODNs, automated assembly has been explored 
for the synthesis of the ODN chains, adopting the elongation 
directions (3’–5’). Starting from support 8a, a10-mer was synthesized 
(Scheme 3), and after ammonia cleavage and deprotection (6 h, 50°C), 
ion exchange HPLC analysis of the released ODN showed a single 
product corresponding to the desired compound 9. The purity of the 
isolated compound was then checked by HPLC, and its identity was 
determined by MALDI-TOF MS analysis. In a typical experiment, 
starting from 35mg of functionalized support 8a with an average 0.15 
meq/g incorporation of the conjugating residue, 150–200 OD units of 
pure ODNs were isolated after gel filtration. 
3.3 Conclusions and Perspective 
In conclusion, we have reported the synthesis of a new o-chloro-
phenol-functionalized solid support, characterized by a higher loading 
of hydroxyl phenol functions than previously achievable (0.18–
0.22meq/g to CPG and 0.25–0.50 meq/g to TG). This support allows 
the facile and high yield preparation of phosphodiester and 
phosphoramidate monoester nucleosides, as well as other yet 
unexplored classes of phosphodiester and phosphoramidate 
molecules. To test the efficiency of this support, we prepared model 
thymidine analogues conjugated at the 5’-position to cholesterol and 
n-butylamine through phosphodiester and phosphoramidate bridges, 
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respectively. In all cases, the coupling yields and purity of crude 
detached materials were comparable to our previous results, and 
twice as much target was obtained, due to the loading being doubled 
on average. Based on these preliminary studies, the method is 
efficient and very reliable. This synthetic approach can be a starting 
point for the development of a preparative method for obtaining new 
phosphodiester and phosphoramidate nucleotides and oligonucleotide 
conjugates. Further studies are currently in progress to extend this 
solid phase approach to synthesized 3’-conjugates and 5’,3’-
bisconjugates of the well-known d(TGGGAG) sequence (see Chapter 
2). 
3.4 Experimental Session 
Synthesis of supports 1a and 1b. Support 1a: 250 mg of LCAA-CPG-
NH2 (0.10 meq/g, 0.02 mmol) was reacted, at r.t. overnight, with a 
mixture of 109.5 mg (0.25 mmol) of N-α-Fmoc-3-chloro-L-tyrosine, 
51.5 mg (0.25 mmol) of DCCI, 45 µL (0.25 mmol) of DIEA and 38.0 mg 
(0.25 mmol) of N-hydroxybenzotriazole (HOBt·H2O) dissolved in 3 mL 
of anhydrous pyridine. After exhaustive washing with DCM and Et2O, 
the support was dried under reduced pressure and then treated with 
20% piperidine in DMF three times for 5 min. The coupling and Fmoc 
removal were repeated twice more in similar conditions. According to 
the Kaiser test11, the incorporation of the linker was always in the 
range of 65–85%, corresponding to 0.19–0.25 meq/g. After capping the 
unreacted amino functional groups with Ac2O/pyridine (1:1, v/v) for 1 
h at r.t., the support was treated with conc. aq. ammonia (28%) at 
50°C for 1 h. After exhaustive washing with CH3OH, DCM and Et2O, 
the resulting support 1a was dried under reduced pressure. 
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Synthesis of support 1b. 250 mg of TG-NH2 LL (0.29 meq/g, 0.07 
mmol) was reacted, at r.t. overnight, with a mixture of 317.5 mg (0.72 
mmol) of N-3-chloro-Tyrosine acid, 150.0 mg (0.72 mmol) of DCCI, 
126.0 µL of DIEA and 110.0 mg (1.5 mmol) of N-hydroxybenzotriazole 
(HOBt·H2O) dissolved in 5 mL of anhydrous pyridine. After 
exhaustive washing with DCM and Et2O, the support was dried under 
reduced pressure and then treated with 20% piperidine in DMF three 
times for 5 min. The coupling and Fmoc removal were repeated twice 
more in similar conditions. The incorporation of the linker was always 
in the range of 65–85%, corresponding to 0.50–0.75 meq/g, according 
to the Kaiser and Fmoc tests. After capping the unreacted amino 
functional groups with Ac2O/pyridine (1:1, v/v) for 1 h at r.t., the 
support was treated with conc. aq. ammonia (28%) at 50°C for 1 h. 
After exhaustive washing with CH3OH, DCM and Et2O, the resulting 
support 1b was dried under reduced pressure. 
Synthesis of supports 4a, 4b and 8a. Support 4a: 1.1 mL (0.5 mmol) of 
a commonly used ‘activator solution’ (0.45 M tetrazole in CH3CN) was 
added to 0.08 mmol of 5′-O-(2-cyanoethyl)-N,N-
diisopropylphosphoramidite-3′-O-(4,4′-dimethoxytriphenylmethyl)-
thymidine and 250 mg (0.22 meq/g, 0.05 mmol) of support 1a. After 1 
h the support was exhaustively washed with CH3CN and treated (3 
times) with 5 mL of a commonly used “oxidiser” solution 
(I2/pyridine/H2O/THF) for 5 min. After exhaustive washing with 
CH3CN, DCM and Et2O, the resulting support 3a was dried under 
reduced pressure. Incorporation yields of the nucleotides were always 
in the range of 82–99% (0.18–0.22 meq/g), as determined by a 
quantitative DMT test performed on dried and weighed samples of 
support 3a. After the standard capping procedure with Ac2O/pyridine 
(1:1, v/v), the 2-cyanoethyl group from the phosphate was then 
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removed by treatment with 20% piperidine in DMF for 5 min at r.t. (3 
times), resulting in support 4a. 
Support 4b: 4.9 mL (2.2 mmol) of a commonly used ‘activator solution’ 
(0.45 Mtetrazole in CH3CN) was added to 0.35 mmol of the 5′-O-(2-
cyanoethyl)-N,N-diisopropylphosphoramidite-3′-O-(4,4′-
dimethoxytriphenylmethyl)-2′-deoxyribonucleoside and 250 mg (0.55 
meq/g, 0.14 mmol) of support 1b. After 1 h the support was 
exhaustively washed with CH3CN and treated (5 times) with 5 mL of 
a commonly used ‘oxidiser’ solution (I2/pyridine/H2O/THF) for 5 min. 
After exhaustive washing with CH3CN, DCM and Et2O, the resulting 
support was dried under reduced pressure. The complete oxidation of 
the phosphate triester into a phosphate triester, leading to support 
3b, was monitored by 31P NMR of the resin suspended in CDCl3. As is 
typical, a relevant upfield shift of the signal at 137 ppm to two signals 
centred at  -6.5 ppm was observed. After a standard capping 
procedure with Ac2O/pyridine (1:1, v/v), the 2-cyanoethyl group was 
removed from the phosphate by treatment with 20% piperidine in 
DMF for 5 min at r.t. (5 times), resulting in support 4b. Incorporation 
yields of nucleotides, calculated after capping, were always in the 
range of 75–91% (0.40–0.50 meq/g), as determined by a quantitative 
DMT test performed on dried and weighed samples of support 4b. The 
total deprotection of the phosphates was confirmed by a characteristic 
upfield shift in the signal of the 31P NMR spectrum of the solid 
support suspended in CDCl3. 
Support 8a: this support was obtained by following the procedure 
described for the synthesis of support 4a, using 5′-O-(4,4′-
dimethoxytriphenylmethyl)-3′-O-(2-cyanoethyl)-N,N-diisopropyl-
phosphoramidite-thymidine starting from support 1a. 
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Synthesis of thymidine analogue 5. 30 mg (0.40 meq/g, 0.012 mmol) of 
dried support 4b was washed and swelled in anhydrous pyridine and 
then reacted with a mixture of 46 mg (0.12 mmol) of cholesterol and 
36 mg (0.12 mmol) of MSNT in 500 L of anhydrous pyridine for 12 h 
at r.t. After exhaustive washing with pyridine, CH3OH, DCM and 
Et2O, the target analogues were detached from the support by conc. 
aq. ammonia treatment at 50°C for 5 h. The crude material of 5 was 
analysed by HPLC on a C18 Phenomenex LUNA column (5 μm, 10.0 x 
250 mm) eluted with a linear gradient (from 10 to 100% B over 30 
min, A = H2O, B = CH3CN), flow rate = 0.8 mL/min, detection at  = 
260 nm, tR = 16.5 min, HPLC purity 88% (see Figure 1). 1H NMR 
(CD3OD, 400 MHz): 7.79 (1H, s, H-6 T), 6.35 (1H, dd, J = 6.4, 6.4 Hz, 
H-1′ T), 5.32 (1H, m, H-6 cholesterol residue), 4.50 (1H, m, H-3′ T), 
4.04-3.90 (3H, overlapped signals, H-4′ and H2-5′ T), 3.65 (1H, s, H-3 
cholesterol residue), 2.30 (2H, m, H2-2′ T), 2.20-0.65 (complex signals 
of cholesterol residue), 1.94 (3H, s, CH3 T) ppm. 31P NMR (CD3OD, 
161.98 MHz): 2.6 ppm. ESI-MS m/z: 688.51 [(M-H)-]. 
Synthesis of thymidine analogue 6. Synthesis of 6 starting from 4a: 50 
mg (0.22 meq/g, 0.011 mmol) of dried support 4a was washed and 
swelled in anhydrous pyridine. The support was then treated with 1 
mL of a freshly prepared tosyl chloride solution (0.2M TsCl, 0.4M 
NMIm in pyridine) for 15 min at r.t. to generate the active ester, 
followed by addition of 1 mL of the amine solution (0.45M in 
pyridine), with appropriate washing steps in between12. This 
procedure was repeated six times. After exhaustive washing with 
pyridine, CH3OH, DCM and Et2O, the resulting support was dried 
under reduced pressure. The conjugation yields were evaluated by the 
DMT cation test on a weighed sample of the support after ammonia 
treatment (28% NH4OH, 50°C, 5 h). The conjugation yields were 
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always in the range of 65–75%. The target analogue 6 was detached 
from the support by conc. aq. ammonia treatment at 50°C for 5 h. The 
crude material was analysed by HPLC on a C18 Phenomenex LUNA 
column (5μm, 10.0 x 250 mm) eluted with a linear gradient (from 0 to 
100% B over 30 min, A = H2O, B = CH3CN), flow rate = 0.8 mL/min, 
detection at  = 260 nm, tR = 13.6 min, HPLC purity 91%. 
Synthesis of 6 starting from 4b. 30 mg (0.40 meq/g, 0.012 mmol) of 
dried support 4b was washed and swelled in anhydrous pyridine. The 
support was then treated with 2 mL of a freshly prepared tosyl 
chloride solution (0.2M TsCl, 0.4M NMIm in pyridine) for 15 min at 
r.t. to generate the active ester, followed by addition of 1 mL of the n-
butylamine solution (0.45M in pyridine), with appropriate washing 
steps in between. This procedure was repeated ten times. After 
exhaustive washings with pyridine, CH3OH, DCM and Et2O, the 
resulting support was dried under reduced pressure. The conjugation 
yields were evaluated by the DMT cation test on a weighed sample of 
the support after ammonia treatment (28% NH4OH, 50°C, 5 h). The 
conjugation yields were always in the range of 85–90%. The target 
analogue 6 was detached from the support by conc. aq. ammonia 
treatment at 50°C for 5 h. The crude material was analysed by HPLC 
on a C18 Phenomenex LUNA column (5μm, 10.0 x 250 mm) eluted 
with a linear gradient (from 0 to 100% B over 30 min, A = H2O, B = 
CH3CN), flow rate = 0.8 mL/min, detection at  = 260 nm, tR = 13.6 
min, HPLC purity 86%. 1H NMR (CD3OD, 400 MHz) : 7.89 (1H, s, H-
6 T), 6.35 (1H, dd, J = 6.4, 6.4 Hz, H-1′ T), 4.52 (1H, m, H-3′ T), 4.03 
(1H, bs, H-4′ T), 3.96 (2H, bs, H2-5′ T), 2.86 (2H, m, CH2-NH), 2.33-
2.18 (2H, m, H2-2′ T), 1.95 (3H, s, CH3 T), 1.46 (2H, m, CH3-CH2-CH2-
CH2-NH), 1.32 (2H, m, CH3-CH2-CH2-CH2-NH), 0.89 (3H, t, J = 7.2 
  
88 
Hz, CH3 butyl residue) ppm. 31P NMR (CD3OD, 161.98 MHz): 11.0 
ppm. ESI-MS m/z: 376.24 [(M-H)-]. 
Synthesis of oligonucleotide conjugated 9. 50 mg (0.22 meq/g, 0.011 
mmol) of dried support 8a was washed and swelled in anhydrous 
pyridine. The support was then treated with 1 mL of a freshly 
prepared tosyl chloride solution (0.2M TsCl, 0.4M NMIm in pyridine) 
for 15 min at r.t. to generate the active ester, followed by the addition 
of 1 mL of the n-butylamine solution (0.45M in pyridine), with 
appropriate washing steps in between. This procedure was repeated 
six times. After exhaustive washings with pyridine, CH3OH, DCM 
and Et2O, the resulting support was dried under reduced pressure. 
Starting from 25 mg of support, a 10 mer oligodeoxyribonucleotide 
was assembled by the automated standard phosphoramidite 
procedure (DMT off), using commercially available phosphoramidite 
nucleosides. Detachment from the support and deprotection was 
achieved by treatment with conc. aq. ammonia solution (28%, 6 h, 
55°C), and the crude material thus released was then purified by a 
simple gel filtration chromatography on a Sephadex G25 column 
eluted with H2O/EtOH (4:1, v/v). The purity of the isolated compounds 
was then checked by ion exchange HPLC analysis and their identities 
determined by MALDI-TOF mass spectrometry. tR = 31.2 min. 
MALDI-TOF m/z: 3040.63 [(M-H)+] (obsv.), 3038.55 (calcd.).  
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CHAPTER 4 
Kinetic study of G-quadruplex formation by ESI-MS 
Over the years, it was assessed that the knowledge of the energetic 
parameters inherent in G-quadruplex formation is crucial in view of 
their applications as therapeutic agents. It is evident, in fact, that 
both kinetic and thermodynamic factors may be important in 
physiological conditions1. Tetramolecular G-quadruplexes constituted 
from four identical strands arranged in parallel orientation have been 
extensively studied, because they offer a good model system to 
determine the potential folding pathways. In contrast to bi- and 
unimolecular G-quadruplexes, tetramolecular G4 formed by short 
nucleic acid sequences show limited polymorphism and very slow 
kinetic of formation that facilitate experimental studies2. Many 
studies have been conducted to follow the stability and kinetic of G-
quadruplexes formation, using a wide range of methodologies, such as 
UV, circular dichroism (CD), fluorescence, chromatography, native 
PolyAcrilamide Gel Electrophoresis (PAGE), NMR and more recently 
electrospray mass spectrometry (ESI-MS)3,4. Some years ago, 
potential pathways of tetramolecular G-quadruplex formation have 
been reported, overall involve in multiple steps and with the 
formation of some intermediates5,6. In 2010, Gabelica and coworkers7 
reported a kinetic study by ESI-MS that confirmed the formation of 
some intermediates previously proposed by Stefl. Following the 
assembly of G4 complexes by ESI-MS, they proved unambiguously 
the formation of dimers and trimers and reported a pre-equilibrium 
between monomer, dimers, and trimers as potential association 
pathway (Figure 1). 
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Recently many research efforts have been devoted to the design 
and synthesis of modified ODNs, the alteration of chemical 
composition of G-rich strands for example at 3’- or 5’-ends or in the 
backbone, is a successful strategy to improve their therapeutic 
applications. 
 
Figure 1. Potential pathway of G-quadruplex assembly proposed (6), (7) and (28). 
In order to understand the impact of these modifications on the 
kinetic of G4 formation, many studies have been conducted using 
NMR and ESI-MS methodologies. These two techniques, allow to 
follow the association process of these structure, in a more precise 
manner than absorbance by UV or CD. Particular emphasis has been 
directed on the ESI-MS and its application to study the kinetic of G4 
formation and the drug-nucleic acid complexes. By ESI-MS 
experiments it is possible to have much information about the 
number of strands8 and the cations within each structure9,10. 
Moreover the use of this technique is exploit to detect all possible 
intermediate complexes7, to determine the relative equilibrium 
binding constants11 and finally to conduct ligand screening assays12. 
Basically the study of nucleic acids in the gas phase allows to isolate 
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molecules from their environment and to study their intrinsic 
properties, defining the gas phase method as an indirect way to 
understand the solvent effect on folding or binding13. 
4.1 ESI-MS to detect nucleic acids 
Particular interest regarding the study of nucleic acid complexes in 
gas phase, is growing due to the use of electrospray ionization (ESI) 
source, capable to minimize covalent fragmentation and even to 
preserve non-covalent complexes. 
 
Figure 2. Generic electrospray mass spectrometry experiment on nucleic acid 
complexes reported in (11). (a) Sample is prepared by mixing DNA and NH4OAc 
buffer and it is injected in the mass spectrometer via the electrospray source. (b) 
Schematic representation of a hybrid quadrupole-time of flight mass spectrometer. 
The ion trajectory is in blue. 
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ESI is a soft ionization method in which the analyte can be given 
little internal energy during the transfer to the gas phase14. Thanks 
to the soft ionization it is possible to detect non-covalent complexes as 
DNA structures and also to observe interactions between small drug 
molecules and DNA complexes. Double helical duplex15,16 and 
quadruplex17 DNA has been first detected in 1993 by B. Ganem and 
co-workers. 
ESI typically generates protonated and/or deprotonated molecular 
ions of the type (M+nH)n+ and (M-nH)n-, respectively. High charge 
states are often formed, and the charge state distribution depends on 
the molecular mass of the analyte, the solvent conditions in the 
sprayed solution, and ion-source conditions, skimmer voltage 
(collisional-induced desolvation and dissociation). Critical parameters 
in the study of non-covalent complexes are the source or capillary 
temperatures (kept as low as possible), and all acceleration voltages 
in the transfer optics (all cone, skimmer, and lens voltages). 
Usually to high acceleration voltages, the dissociation of non-
covalent complexes can occur. The typical solvent conditions used to 
achieve maximum sensitivity are not always optimal to maintain an 
intact biomolecular complex. A major limitation of ESI-MS, is its low 
salt tolerance, in fact even minute amounts of sodium or potassium 
result in the detection of a wide distribution of non specific adducts on 
the DNA11. Therefore, a majority of non-covalent complexes studied 
by ESI-MS is done in volatile salts like ammonium acetate (NH4OAc). 
Organic solvents such as methanol or acetonitrile may be added to the 
solution to obtain maximum sensitivity and signal stability, but only 
with low percentage in order to preserve the native structure7. 
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Recently, quantitative mass spectrometry determination of 
absolute concentration of complexes from relative peak intensities has 
been described by Gabelica18. This method requires the determination 
of the factor relating the peak intensity of each species, known as 
electrospray response factor (R)19,20and defined in Eq. 1 for compound 
M: 
Eq. 1    IM= RM[M] 
To this aim is used an internal standard (T6) and the mass balance 
equation applied to each complex detected in the electrospray mass 
spectra. Briefly, for each stoichiometry adopted by the sequence, the 
ratio between the area of a peak attributable unambiguously to that 
stoichiometry and the area of a peak of the internal standard, is 
calculated at each time-point. The method for the determination of 
response factors can also be used to study the kinetics involving non-
covalent complexes, following the signals relative to each complex, in 
respect of the internal standard. 
4.2 Aim of research work 
In this frame is focused my research work, the goal of my project 
was to complete the biophysical characterization of the most active 5’-
modified ODNs (Figure 3), synthesized in our laboratories. As 
described in the previous chapter, the thermal stability of these 5’-end 
modified ODNs carried out by CD is not directly correlated with their 
high anti-HIV activity. In order to achieve a more complete picture of 
the relationship between G-quadruplexes formed by 5’-end modified 
ODNs and their pronounced anti-HIV activities, it is necessary to 
explore not only the structural and thermodynamic, but also the 
kinetic aspects of G-quadruplex folding. In this context, we chose to 
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study the kinetics of 5’-end modified G-quadruplex formation by ESI-
MS (Figure 3), taking in advantage of the precious collaboration of 
Valérie Gabelica, Research Director of ARNA Inserm/Univ. Bordeaux 
(France). Valérie Gabelica is a pioneer in the study of non-covalent 
DNA complexes by ESI-MS7. 
 
Figure 3. d(TGGGAG) G-quadruplex and its 5’-end modified with pronounced anti-
HIV activities (on the top). Schematic representation of potential pathway of G-
quadruplexes folding (on the bottom). 
Aiming at investigating the influence of the 5’-end conjugated 
moiety on the kinetics of G4 formation, we have studied the kinetics 
of G-quadruplex formed by 5’-end modified ODNs in comparison with 
that formed by unmodified sequence (Figure 3). From ESI-MS 
experiments we have followed the formation of all possible complexes, 
determining the number of strands and the cations inside each 
complex. In addition to ESI-MS studies, we assessed the molecularity 
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of non-covalent complexes, in particular that of high order DNA 
structures using non-denaturing polyacrylamide gel electrophoresis. 
4.3 Results and Discussion 
All 5’-conjugates d(TGGGAG) endowed with high anti-HIV activity 
(Figure 3, top) are dissolved in water (nuclease-free), and the 1 mM 
stock solutions are stored at -20°C. The modified sequences are 
obtained from synthesis, purification (RP-HPLC) and desalting 
(Sephadex G25) carried out in our laboratory (synthetic strategy 
reported in Chapter 2). The stock concentrations are determined by 
UV absorbance at 260 nm, and measured on an Agilent Cary 100 UV 
spectrophotometer. Before G-quadruplex formation, aqueous stock 
solutions of each sequence, including the unmodified sequence, are 
heated at 80°C for 5 min. Heating, commonly called annealing, is 
required to remove all pre-formed G-quadruplex complexes. 
To study the kinetic of G-quadruplex formation, we recorded ESI-
MS spectra as a function of the time after addition of cation in the 
ODN solutions. These experiments are carried out in NH4OAc (150 
mM) and also using a new buffer developed very recently by Gabelica 
and co-workers10. In order to observe DNA G-quaduplexes with K+ 
ions specifically bound between G-quartets, as occur in physiological 
conditions, they replaced the NH4OAc with trimethylammonium 
acetate (TMAA), doping the solution with potassium chloride (KCl) at 
concentration up to 1 mM. The TMA ion is too large to fit between G-
quartets, hence, only K+ ions can coordinate. Before the ESI-MS 
experiments, aiming to follow G4 association pathway, we looked for a 
proper concentration of stock solution and time-scale in which the 
kinetics are representative. The concentration chosen is 600 μM, 
fixing as a T0 the time of addition of cation, we monitored the kinetics 
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of formation for each sample over 14 days. At each time point, an 
aliquot of the sample is diluted to 20 μM, final single–strand 
concentration, and injected in the ESI-MS. For the preparation of a 
stock solution in NH4OAc, the solution 1 mM in single-stranded of all 
sequences is diluted to 600 μM (final concentration of stock solution) 
adding NH4OAc in a final concentration of 150 mM. The single strand 
d(T6) is added in each stock solution to serve as internal standard. All 
kinetics experiments are carried out with the sample at room 
temperature. Quadruplex formation is initiated by the addition of 
NH4OAc (final concentration: 150 mM). We therefore assume that, 
once formed, all complexes formed resist the dilution step. The signal 
intensity of the reference is used to normalize the intensity variations 
of each signals, and to deduce their respective response factors. 
We firstly studied the unmodified sequence I, in order to have a 
kinetic reference of G-quadruplex formed without 5’-end moiety. In 
Figure 4 is reported as typical ESI-MS spectra, the spectra of 
d(TGGGAG) (I) recorded after 1 day. The monomer is detected mainly 
at charges state 2- (m/z=934.93) with some sodium ions non-
specifically bound, but no ammonium ions bound. Sodium is a 
common contamination in DNA samples. Dimer and trimer are also 
detected, like the monomer with a non-specific sodium adducts, 
issuing respectively at m/z=1246.99 and m/z=1402.83. A tetramer is 
unambiguously detected at the charge state 5- (m/z=1503.69) and 4-. 
(m/z=1884.16). As shown in the spectra (Figure 4), G-quadruplexes 
capture different number of ammonium ions. The internal standard, 
d(T6) (m/z=880.36) is detected only in the monomeric form as properly 
supposed. An unexpected result is the detection of an octameric specie 
predominantly at charge states 7- (m/z=2153.54). 
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In these years, an increased number of papers has reported the 
existence of higher order DNA structures formed by multimerization 
of G-quadruplex units21,22. 
 
Figure 4. Electrospray mass spectra of d(TGGGAG) (20 μM in 150 mM NH4OAc) 
recorded after 1 day from ammonium acetate addition. M (single strand, ss) for 
monomer, D for dimer, T for trimer, Q for tetramer, O for octamer. 
In particular, very recently, exactly for d(TGGGAG), it is observed 
by NMR data, the formation of high order than G-quadruplex 
structures23 confirming the octamer detected by ESI-MS. In addition, 
in 2011, Borbone et al. described a novel dimerization pathway of two 
tetramolecular G-quadruplex subunits obtained by head-to-head 
stacking24,25. This dimerization pathway stimulate many questions 
regarding the type of interaction involved in the formation of detected 
[d(TGGGAG)4]2 and 5’-end [d(TGGGAG)4]2 octamers. All modified 
sequences showed almost the same spectra profile of d(TGGGAG), in 
terms of type of complexes and relative charge states. By using a 
recent Gabelica’s mathematical method18, the relative ESI-MS 
response of each component of the mixture can be determined and 
therefore the concentration relative to each complex. 
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Figure 5 shows the time evolution of the concentration (μM) of 
monomer, dimer, trimer, tetramer and octamer for sequences (I-IV), 
unfortunately two of these modified ODNs, V and VI, aggregated 
already at 600 μM in water solution, preventing to follow their kinetic 
association pathways. 
 
Figure 5. Time evolution of the concentration (μM) of monomer, dimer, trimer, 
tetramer and octamer for sequences I–IV. 
From ESI-MS data, we observed that the single strand (M) is very 
quickly converted into a dimer (D), both tetramer (Q) and octamer (O) 
species began to form quite quickly (up to 1 day) and continued to 
increase up to 14 days reaching the plateau (Figure 5). The formation 
of octamer begins simultaneously to tetramer, but in any cases 
remains lower than that of tetramer. The detection of these complexes 
for long time scales confirmed that, once formed, they are stable to 
the dilution step (600 μM to 20 μM). 
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Figure 7 shows PAGE experiments on the I–IV sequences loading in 
both conditions ( “–” and ”+”), d(T6) is used as a single-stranded 6-mer 
marker and d(TG4T) annealed in 0.1 M potassium buffer is used as a 
tetramolecular G-quadruplex marker, [d(TG4T)]4. For all ODNs 
loading in water condition (“–”), the more intense band is that related 
to the single strand (ss) in agreement with the fastest migration. For 
I, II and III (“+”), it is observed a retarded migration respect to the 
[d(TG4T)]4 G4 reference. We therefore assigned the slow migrating 
PAGE bands to octameric self-assembly structures. The sequence IV 
showed an evident smearing in terms of intensity of band in 
agreement with the slow kinetic observed by ESI-MS (Figure 7). 
4.3.2 Ion Mobility Spectrometry for the detection of high order 
structures 
Ion Mobility Spectrometry (IMS) is a high resolution technique 
that provides indications on the tridimensional oligonucleotide 
structure of the studied ions. This technique allows to separate ions 
with identical mass-to-charge ratio due to their different mobility in 
the drift tube. The mobility of ions is the quantity that describes how 
quickly the ion moves through a drift cell filled with a high pressure 
of buffer gas under the influence of a weak electric field26. 
Interestingly, the use of IMS allows to have information about the 
shape of species detected depending on the their drift time27.  In the 
drift tube, complexes with compact conformation such as G-
quadruplexes travel more quickly and with small collision cross 
sections (CCS) than large extended ions, like single-strand, that drift 
slowly and with large CCS (Figure 8). The collision cross sections are 
a measure of the surface of the ion that is exposed to collision with 
the bath gas. 
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Figure 8. Representation of the ions in the drift tube in function of their different 
shape. 
 Preliminary experiments on IMS 
In order to confirm the molecularity and to determine the 
compactness of detected complexes, we tested all sequences on 
IMS, paying attention to octamer complexes .In Figure 9 is 
reported a representative example of the Driftscope spectrum 
characterized by a 2D-graph with the mass spectrum (top of 
panel) and the drift time in the ion mobility (bottom of panel). 
 
Figure 9. Representation of the contribution of O8- in comparison with that of Q4- in 
the Driftscope spectrum. 
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As described, at each ion detected by ESI-MS corresponds an 
unique drift time. Particular attention, it has been addressed on 
octamer signals, thanks to IMS it has been possible to distinguish the 
octamer at the charge state 8- from the more abundant tetramer at 
the charge state 4-, even if they have the same m/z ratio. In Figure 9, 
it is reported the contribute of octamer respect to that more abundant 
of tetramer. From preliminary results obtained, we observed for all 
sequences (I–IV) the same distribution of complexes seen by ESI-MS 
(LCT mass spectrometer) but an additional consistent amount of 
octamer. 
4.4 Conclusions and Prespective  
The kinetic ESI-MS studies on modified d(TGGGAG), confirmed 
the formation of some intermediates as earlier reported for 
unmodified tetramolecular G-quadruplexes2,28. The association 
pathway of G-quadruplex folding, based on modified d(TGGGAG), 
revealed a pre-equilibrium between single-strand, dimer and trimer 
that occurs before the G4 formation, in agreement with the 
mechanism for tetramer formation reported by Gabelica in 20107. 
From preliminary kinetic results obtained by ESI-MS in 150 mM 
NH4OAc, it seems that the kinetics of all modified sequences do not 
deviate from that of unmodified d(TGGGAG), suggesting that the 
aromatic moieties at 5’-end of d(TGGGAG) do not improve the 
kinetics of G4 formation. Moreover it has been observed that all 
sequences, including unmodified sequence, already at 600 μM in 
NH4OAc formed simultaneously to G-quadruplex complex also a high 
order G4 structures identified as octamers. In addition, by Ion 
Mobility Spectrometry experiments conducted in the same 
experimental conditions of LCT-Waters (kinetic ESI-MS 
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experiments), it has been observed that the amount of octamer 
formed is not insignificant and thereby it is very interesting. 
These finding open the door to future studies that aim to the 
understanding of the dimerization phenomenon (how happen and if is 
relevant for therapeutic activity), especially for 5’-end modified 
sequences endowed with high anti-HIV activity. Finally, by using of a 
new sample preparation method (TMAA/KCl mixture), we detected 
the number of potassium ions specifically coordinated to the G-
quaduplexes formed by all sequences (3K+), and presumably, the 
number of quartets involved (4 quartets). 
In light of recent IMS studies performed on all 5’-modified 
d(TGGGAG) (Figure 3), comparison studies between the experimental 
data (CCS) obtained by IMS and CCS developed by theory models are 
in progress. 
4.5 Experiment Session 
Preparation of samples. Stock solutions were prepared at 1 mM in 
water and stored at -20°C. The stock concentrations were determined 
by UV absorbance at 260 nm measured on an Agilent Cary 100 UV 
spectrophotometer. Water was nuclease-free grade from Ambion 
(Applied Biosystems, Lennik, Belgium). Ammonium acetate 
(NH4OAc, Ultra for Molecular Biology, Fluka), trimethylammonium 
acetate (TMAA, Ultra for UPLC, Fluka) and potassium (KCl, 
999.999%, Sigma) were purchased from Sigma-Aldrich (Saint-
Quentin Fallavier, France). Annealing experiments were performed 
at 80°C heating for 5 min and then a fast cooling to 20°C were carried 
out. Stock solutions of 600 μM of each ODN were obtained by diluition 
of the samples in 150 mM NH4OAc or 150 mM TMAA and 1 mM KCl 
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buffers. For all kinetics experiments, 50 μM d(T6) (monoisotopic mass 
1762.318 Da) was added to each stock solution in order to follow the 
intensities of the reactant (single strand, ss), and the complexes 
(dimer, trimer, tetramer and octamer) relative to that of the 
reference. The solutions were stored at 20°C for MS measurements 
performed in 14 days. The samples are agitated, loaded into the 
syringe and the spray is initiated in few minutes.  
Electrospray Mass Spectrometry. Native ESI-MS spectra were 
obtained using a LCT Premier mass spectrometer (Waters, Man- 
chester, U.K.). The electrospray ion source was operated in negative 
ion mode and the voltage is set to 2200 V. The desolvation 
temperature is 60°C, and the gas temperature is 40°C. In all 
experiments provided in NH4OAc it have been recorded, three spectra 
at different voltage ( 50 V, 100 V, 200 V) to be sure of soft condition of 
analysis. The source pressure is increased to 45 mbar (measured by a 
Center Two probe, Oerlikon Leybold Vacuum, Cologne, Germany). 
The sample cone voltage in TMAA/KCl experiments is 200 V. At this 
voltage TMA adducts on the mass spectra are totally avoided, but the 
K+ stoichiometry is not affected. The syringe injection rate is 200 
μL/h. Shown MS spectra is the sum of 3 min accumulations (1 scan 
per 1.1 s). The voltage of spectra chosen to fit the kinetics, was that 
one for the best compromise to observe the single strand, tetramer 
and octamer. The spectra were smoothed (mean function, 2  15 
channels), background-substracted (polynomial order = 99, 0.1% 
below curve, tolerance 0.010), centroided (peak width 15 channels, 
reconstructed area of the top 80% of the peak), and recalibrated using 
the reference as a lock mass [d(T6)]2- monoisotopic peak at m/z = 
880.153.  
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Native PolyAcrylamide Gel Electrophoresis (PAGE). The molecular 
size of structures were probed using native polyacrylamide gel 
electrophoresis. ODN samples (50 μM), obtained by diluting the 
annealed stock solutions just before the experiment, were loaded on a 
15% polyacrylamide gel supplemented with 100 mM of KCl. Sucrose 
(10 %) was added just before loading. The gel was pre-run for about 
30 min before loading samples. The gel was run at 26°C at constant 
voltage (110 V) for 2.5 h. The bands were visualized by UV shadowing 
and after ‘Syber green’ coloration. 
Sample preparation. To achieve complete G4 formation, high 
concentrations of samples are necessary. After heating at 80°C for 5 
min, to the water stock solution of samples were added 100 mM KCl 
(4.5 mM final concentration of oligos). In parallel, the samples in 
single–stranded condition, are prepared only by annealing in pure 
water. 
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CHAPTER 5 
Silibinin: biomolecule as potential G-quadruplex-
ligand 
Nucleic acid G-quadruplexes are non canonical secondary 
structures formed in particular G-rich sequences in presence of 
monovalent cations1. G-quadruplex structures have been identified in 
telomeric DNA and RNA sequences2–4 as well as in the promoter 
regions of many proto-oncogenes such as c-myc 5, Bcl-2 6, VEGF 7, 
KRAS 8, c-kit 9,10 and RET 11,12. 
The formation of G-quadruplex structures can have important 
consequences at the cellular level and particularly, in the inhibition of 
telomere extension by the telomerase enzyme, which is up-regulated 
in cancer cells11. These findings have stimulated the study of G-
quadruplexes as important targets for cancer drug discovery. A 
general consensus is that G-quadruplex-ligands stabilizing G-
quadruplex structures could pave the way for the discovery of novel 
anti-cancer agents13. In this frame, the number of known G-
quadruplex-ligands has grown rapidly over the past few years. The 
binding between G4 and ligands can occur in many ways and it is not 
yet clear how can be regulated. In most cases, the quadruplex-
stabilization occurs, via stacking and electrostatic interactions 
resulting in the binding of the ligand (usually a flat aromatic 
molecule) with G-quartets14. 
Many molecules with these characteristics have been reported as 
telomerase inhibitors: anthraquinones15, 3,6-disubstituted acridines16, 
trisubstitutedacridines17, porphyrins18, and triazines19. 
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One of the most promising compounds of this series is represented 
by BRACO-19, a 3,6,9-trisubstituted acridine20 (Figure 1). 
 
Figure 1. Some structures of G-quadruplex ligands. 
In these years, numerous natural compounds have been found to 
inhibit telomerase, which amoung berberine21 and Telomestatin22 
(Figure 1), and some flavonoids (Quercetin, Genistein and Apigenin; 
Figure 2)23,24. Flavonoids have been known for a long time to exert 
multiple biological effects (bioflavonoids), ranging from their famous 
antioxidant properties to anti-inflammatory, anti-microbial and anti-
cancer properties25. 
Relevant examples of telomerase inhibitors within the flavonoid 
family, are two soluble derivatives of Quercetin reported by Kerr26 
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and D’Alarcao27. In particular QC12, synthesized by Kerr has been 
subjected to phase I of clinical trials. 
 
Figure 2. Flavonoids exhibiting anti-telomerase activity. 
Among these anti-telomerase flavonoids, is included the activity of 
silibinin28 a flavolignan found in silymarin, isolated from the fruits of 
the milk thistle Silybum marianum (L.) Gaertn. (Carduus marianus 
L., Asteraceae; milk thistle)29,30 . This metabolite is present in nature 
as diastereoisomeric mixture of two flavonolignans, namely silybin A 
and silybin B in a ratio of approximately 1:1, hardly separable31 
(Figure 3). 
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Figure 3. Silibinin and its two diastereoisomers (silybin A and B). 
Over the years different modes of numbering for silibinin have 
been proposed30. In this thesis we used a systematic numbering as 
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shown in Figure 3. Silibinin is the major biologically active 
constituent of silymarin, exhibiting multiple biological activities. 
Unfortunately, the pharmacological use in vivo of silibinin is 
dramatically limited for its content in nature as diastereoisomeric 
mixture hardly separable, and for its low water solubility32. In recent 
years, many efforts have been made to overcome these limitations, in 
particular, two water soluble derivatives of silibinin, well-known as 
FlavobionTM and LegalonTM, endowed with high hepatoprotective 
activities are used in chronic liver diseases caused by oxidative 
stress33 (such as alcoholic and non-alcoholic fatty liver diseases or 
drug- and chemically-induced hepatic toxicity). 
 
Figure 4. Chemical structures of natural components of silymarin complex. 
In addition, in the ‘90s in order to maximize oral bioavailability of 
silibinin, the formulation most commonly employed in 
pharmacokinetic trials has been changed with a mixture of silibinin 
  
118 
and phosphatidylcholine old by Indena SpA (Milan, Italy) as 
Siliphos®, or IdB 1016. Barzaghi and co-workers, reported 
pharmacokinetic studies on silybin-phosphatidylcholine complex34. 
Silibinin has received attention also thanks to its alternative 
beneficial activities, which mostly include anticancer and 
chemopreventive actions35 as well as hepatoprotective36, 
neuroprotective37 and antiviral activities38. Based upon these 
promising results, silibinin has been tested in human cancer patients 
in phase I-II of clinical trials39. In this frame, in addition to silibinin, 
other constituents of sylimarin such as isosilybin (1c, 1d), silychristin 
(1e) and 2,3-dehydrosilybin (1f) (Figure 4), have shown attractive 
pharmacological properties. In particular, the oxidized form of 
silibinin, the 2,3- dehydrosilybin (DHS), displays major antioxidant40 
and anticancer properties than silibinin suggesting that DHS may be 
useful therapeutically41. Unfortunately, the use of DHS as 
therapeutic agent is rather restricted by its low content in silymarin 
complex, too low to study the biological activities. 
5.1 Aim of research work 
In order to better understand the G-quadruplex molecular 
recognition and further enhance the drug design, detailed information 
about quadruplex-ligand complexes are crucial. Because the 
specificity of the interactions between ligands and G-quadruplexes 
(involved in gene regulation), is a main concern in the determination 
of biological activity of these compounds, in my PhD project we 
focused our attention on the study of silibinin and its derivatives as 
potential new selective ligands for G-quadruplex structures. Silibinin 
is a diastereoisomeric mixture of two flavonolignans, namely silybin A 
and silybin B in a approximately 1:1 ratio. The stereochemistry of this 
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metabolite plays an extremely important role in its pharmacological 
activities with interesting structural implications. 
New data on the pharmacological activity related to the pure 
flavonolignans have reported that two silybin diastereomers (A and 
B) exhibit different biological activities most likely regulated by 
stereospecific mechanism of action42,43. 
Based on this structural limitation of silibinin (diastereoisomeric 
mixture) and aiming to investigate its ability to bind G-quadruplex 
structures, we developed a new, simple and fast HPLC method to 
obtain the two diastereoisomers of silibinin, silybin A and B in pure 
form and in great amount44. In addition, in order to test also the 
ability of DHS to bind G-quadruplex structures, we carried out a 
base-catalyzed oxidation of silybin A and B promoted by microwave 
(MW), obtaining the pure enantiomers DHS A and B, in very brief 
times and with high yields45. The potentialities of these pure 
compounds(silybin A and B, DHS A and B), will be analyzed in the 
near future. 
While remaining within of chemistry of silibinin, we also dealt 
with the low water solubility of silibinin that dramatically limits its 
pharmacological use46. In this frame, we developed a synthetic 
strategy to obtain new silibinin derivatives linking suitable chemical 
modifications able to improve its applications in biomedicine and 
biochemisty47–49. 
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5.2 A rapid and simple chromatographic separation of diastereomers 
of silibinin and their oxidation to produce 2,3-dehydrosilybin 
enantiomers in an optically pure form. 
A major problem hampering studies of optically pure silibinin is 
the extremely complicated separation of its diastereoisomers. This 
problem has been approached over the years by several research 
groups through the use of HPLC methods. Recently, a preparative 
HPLC method for the separation of silybin A, silybin B and other 
silymarin congeners in larger quantities was described50,51. A multi-
faceted approach has been proposed by Kren et al. in which the 
chromatographic separation is performed on the mixture of the two 
diastereoisomers suitably modified by chemical or enzymatic 
methods52,53. Generally, these methods require special expertise in 
both organic synthesis and enzymatic kinetic resolutions. By a careful 
analysis of the studies cited, it is evident that a rapid and less 
laborious method for the separation of silibinin is still required.  
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Scheme 1. Separation of two diastereoisomers of silibinin (1A and 1B) and their 
oxidation to 2,3-dehydrosilybin A (2A) and 2,3-dehydrosilybin B (2B). 
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Initially we developed a rapid and preparative separation (gram-
scale amounts) of the diastereoisomers of silibinin using preparative 
HPLC (Scheme 1) and their oxidation to produce enantiomers of 2,3-
dehydrosilybin in a very pure form using our optimised procedure54. 
Previous investigations have shown that the solubility of silibinin in 
THF at 25°C (greater than 140–150 mg/mL) is considerably greater 
than in H2O or MeOH (0.05–1.5 mg/mL)51, allowing for the injection of 
large quantities of analyte. The key point of our approach is 
dissolving the sample in THF, an alternative solvent to H2O or MeOH 
in which silibinin has a very low solubility. Various types of HPLC 
conditions (columns, flow and mobile phases) were evaluated; the 
optimum chromatographic conditions for the separation of both 
silybin A and B were characterized by using a Phenomenex Gemini 
C18-110A preparative column (10-μm particle size, 250 mm × 21.2 
mmi.d.), as a mobile phase a ternary mixture of H2O/MeOH/MeCN 
(60:35:5, v/v/v) and 0.1% TFA. In preliminary studies, we also used 
DMSO, to better dissolve the silibinin, but it resulted in poor 
resolution under all the conditions tested. To attain the highest 
quantity of pure silybin A and silybin B and to avoid poor resolution 
due to the expansion of their chromatographic peaks, 500 µL 
injections containing 70 mg of silibinin were used. Better resolution 
was observed in all injections performed dissolving the sample in 
THF and then mixing with an equal volume of the eluent solution 
(Figure 5). The resolution of silybin A and silybin B was high enough 
to obtain pooled fractions containing practically pure single isomers. 
Using groups of 10 injections each time, fractions of silybin A (tR = 
67.5 min) and silybin B (tR = 74.5 min) were collected, and after 
removal of the mobile phase under reduced pressure, amorphous 
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colourless powders of silybin A (300 mg) and silybin B (315 mg) were 
obtained by drying under vacuum. 
 
Figure 5. Prep-HPLC profile of the silibinin. Silybin A (1A, tR = 67.5 min) and silybin 
B (1B, tR = 74.5 min). Conditions: Phenomenex Gemini C18-110A preparative column 
(10 μm particle size, 250 mm × 21.2 mmi.d.), eluted with H2O/MeOH/MeCN (60:35:5, 
v/v/v) containing 0.1% of TFA; flow 12 mL/min, monitored at 288 nm. 500 µL aliquot 
of 140 mg/mL of the silibinin solution was mixed with 500 µL of the eluent solution 
and then injected. 
To make the procedure quicker and to maximise the functionality 
of our instruments, we carried out the injections in sequence every 40 
min (Figure 6). 
 
Figure 6. HPLC profile of sequential injections. 
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Thus, we were able to obtain approximately 1 g for both 
diastereoisomers in a very pure form in less than a week. The purified 
products, whose HPLC purity was higher than 98%, were fully 
characterised by NMR (1H, 13C) (tables in Exprimental Session), CD 
(Figure 7a in Experimental Session), ESI MS and [α]D. The 
confirmation of two specific structures was also obtained by 
comparing the NMR and CD data with those published in the 
literature55,56. 
Afterwards, diastereoisomers1A and 1B were treated with 
potassium acetate (AcOK) in DMF at 80°C to produce 2A and 2B 
(Scheme 1). In our procedure, a 0.1 M solution of pure silybin A (1A) 
or silybin B (1B) was treated with anhydrous AcOK in DMF at 80°C 
for 2 h. The crude mixture was purified by chromatography on a silica 
gel column (eluent: CHCl3/acetone, 80:20, v/v) to yield 2A and 2B in 
good yields, and the HPLC purity was greater than 98%. The purified 
products were fully characterised by NMR (1H, 13C) (tables in 
Exprimental Session), CD (Figure 7b in Experimental Session), ESI 
MS and [α]D. The obtained data were compared with those published 
in the literature57. 
5.2.1 Experimental Session 
The preparative HPLC method was performed with a Shimadzu 
LC-8A PLC system equipped with a Shimadzu SCL-10A VP System 
control and Shimadzu SPD-10A VP UV-VIS Detector. A Phenomenex 
Gemini C18-110A preparative column (10-μm particle size, 250 mm × 
21.2 mmi.d.) was used, and the mobile phase of H2O/MeOH/MeCN 
(60:35:5, v/v/v), containing 0.1% of TFA, was delivered isocratically at 
12 mL/min. The chromatograms were monitored at 288 nm. The 
HPLC system was controlled by LC Real Time Analysis software 
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(Shimadzu Corporation). The silibinin solution was prepared by 
dissolving and sonicating the accurately weighed compound in THF. 
The obtained solution (ca 140 mg/mL) was then applied to Nylon 
filters (pore size = 0.45 µm). A 500 µL volume of the silibinin solution 
was mixed with 500 µL of the mobile phase and then applied to the 
chromatographic system. Silybin A and silybin B peaks were collected 
manually. 
The analysis was performed with a Waters 1525 HPLC equipped 
with a binary gradient pump and a Waters 2996 Photodiode Array 
Detector using a RP18 column Phenomenex LUNA (5-μm particle 
size, 10.0 mm × 250 mmi.d.). The mobile phase of H2O/MeOH, 
containing 0.01% acetic acid (50:50, v/v), was delivered isocratically at 
0.8 mL/min. The chromatograms were monitored at 288 nm. 
Standard solutions of silybin A, silybin B, 2,3-dehydrosilybin A and 
2,3-dehydrosilybin B were prepared by dissolving the accurately 
weighed standard compounds in THF to yield final concentrations of 5 
mg/mL. A 25-µL volume of each analyte was applied to the 
chromatographic system for the determination of purity. 
(2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-
(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl]chroman-4-one 
(Silybin A, 1A): colourless, amorphous powder; mp. 161–162; [α]25D 
+14.5 (c 0.20, acetone); CD spectra see Figure 7a; ESI MS (negative 
ions) m/z 481.51 (calcd for C25H21NO10 481.11). 
(2R,3R)-3,5,7-trihydroxy-2-[(2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-2-
(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl]chroman-4-one 
(Silybin B, 1B): colourless, amorphous powder; mp. 157-159; [α]25D –
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11.2 (c 0.24, acetone); CD spectra see Figure 7a. ESI MS (negative 
ions) m/z 481.17 (calcd for C25H21NO10 481.11). 
3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-
(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl]chroman-4-one 
(2,3-dehydrosilybin A, 2A): mp. decompose at 200 °C (decomp.); [α]25D 
–22.8 (c 0.18, MeOH); CD analysis see Figure 7b. ESI MS (negative 
ions) m/z 479.23 (calcd for C25H19NO10 479.10). 
3,5,7-trihydroxy-2-[(2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-2-
(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl]chroman-4-one 
(2,3-dehydrosilybin B, 2B): [α]25D +23.0 (c = 0.14, MeOH); CD analysis 
see Figure 7b. ESI MS (negative ions) m/z 479.41 (calcd for 
C25H19NO10 479.10). 
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Table: 1H NMR data of silybin A (1A), silybin B (1B) and 2,3-dehydrosilybin (2) 
position 1A 1B 2 
H-2 5.06 d (11.3) 5.06 d (11.3) – 
H-3 4.60 d (11.1) 4.59 d (11.0) – 
OH-3 not obs. not obs. 9.54 s 
OH-5 11.88 s 11.70 s 12.7 s 
H-6 5.89 d (1.8) 5.90 d (2.1) 6.20 d (2.0) 
OH-7 10.84 s 10.30 s not obs. 
H-8 5.84 d (1.8) 5.86 d (2.0) 6.46 d (2.0) 
H-2' 7.07 d (1.4) 7.07 d (1.8) 7.66 d (2.2) 
H-5' 6.96 d (8.3) 6.96 d (8.3) 7.12 d (8.8) 
H-6' 7.01 dd (8.4, 1.6) 7.07 dd (8.1, 1.6) 7.76 dd (8.8, 2.2) 
H-2'' 6.99 d (1.5) 7.06 d (1.5) 7.06 d (2.1) 
OH-4'' 9.15 s 9.10 s 9.15 s 
H-5'' 6.79 d (8.1) 6.79 d (8.0) 6.85 d (8.1) 
H-6'' 6.85 dd (8.1, 1.4) 6.84 dd (8.4, 1.7) 6.88 dd (8.0, 2.0) 
H-7'' 4.89 d (7.9) 4.90 d (7.9) 4.97 d (8.0) 
H-8'' 4.16 ddd (6.9, 3.9, 2.7) 
4.15 ddd (6.8, 3.9, 
2.5) 
4.27 ddd (8.0, 4.3, 
2.5) 
H-9''a 3.52 dd (12.3, 2.4) 3.52 dd (12.0, 2.4) 3.56 ddd (12.3, 4.9, 2.5) 
H-9''b 3.33 dd (12.3, 3.9) 3.33 dd (12.0, 3.9) 3.37 ddd (12.3, 5.0, 4.5) 
OH-9'' not obs. not obs. not obs. 
OCH3 3.76 s 3.77 s 3.80 s 
NMR spectra were recorded in DMSO-d6, on Bruker WM-400 
Table: 13C NMR data of silybin A (1A), silybin B (1B) and 2,3-dehydrosilybin (2) 
position type 1A 1B 2 
C-2 CH 82.6 82.5 145.8 
C-3 CH 71.4 71.5 136.3 
C-4 C 197.6 197.7 176.0 
C-4a C 100.4 100.4 103.1 
C-5 C 163.3 163.3 160.7 
C-6 CH 96.1 96.1 98.3 
C-7 C 167.1 166.9 164.1 
C-8 CH 95.1 95.1 93.6 
C-8a C 162.5 162.5 156.3 
C-1' C 130.1 130.1 123.8 
C-2' CH 116.5 116.6 116.2 
C-3' C 143.3 143.2 143.4 
C-4' C 143.7 143.6 145.1 
C-5' CH 116.3 116.3 116.8 
C-6' CH 121.3 121.1 121.3 
C-1'' C 127.5 127.5 127.3 
C-2'' CH 111.8 111.7 111.9 
C-3'' C 147.6 147.7 147.3 
C-4'' C 147.0 147.0 147.1 
C-5'' CH 115.3 115.3 115.4 
C-6'' CH 120.5 120.5 120.2 
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Figure 7. (a) CD spectra at 25°C of the silybin A (bold line) and silybin B (dotted line) 
at 21 M in MeOH; (b) CD spectra at 25°C of the 2,3-dehydrosilybin A (dotted line) 
and 2,3-dehydrosilybin B (bold line) at 19.3 M in MeOH. 
  
C-7'' CH 75.9 75.9 75.9 
C-8'' CH 78.1 78.1 78.6 
C-9'' CH2 60.2 60.2 60.1 
OCH3 CH3 55.7 55.7 55.8 
NMR spectra were recorded in DMSO-d6, on Bruker WM-400 
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5.3 Microwave-assisted oxidation of Silibinin: a simple and 
preparative method for the synthesis of improved radical scavengers 
Recently it has been reported that, the 2,3-dehydrosilybin, 
(oxidation product of silibinin) present in traces in silymarin extract, 
shows more potent antioxidant activity than its parent compound. 
This compound also appeared to be more effective than silibinin in 
biological assays comparing their antitumour and antiproliferative 
potencies40, and shown also positive effects against some skin diseases 
(e.g., psoriasis and atopic eczema)58. 
Years ago, the biological activity of 2,3-dehydrosilybin was 
basically related to the biological activity of silibinin and silymarin 
because of its difficult isolation. Therefore, many methods to 
synthesize 2,3-dehydrosilybin are reported in literature, including 
treatment with H2O2 in a solution of NaHCO359 or with N-
methylglucamine57. Very recently, my research group reported this 
oxidation using pyridine at reflux54, attended by an alternate 
approach described by Křen and co-worker employed potassium 
acetate in DMF at 50°C60. In this paper, they reported also the 
formation of an interesting byproduct, obtained from alkaline 
treatment of silibinin, the hemiacetal 3 (Scheme 2). 
This compound was first isolated and characterised by Křen, et al. 
and was found to be a more potent antioxidant than either silibinin or 
2,3-deydrosilibin. Nevertheless, little is known about its biological 
properties, as to date it has been obtained only as an undesired side 
product. All methods just described for 2,3-dehydrosilybin 
preparation, provide at most the 50% yield. A new preparative 
oxidation of silibinin and silybin is developed, exploring the use of 
microwave heating (MW) that enhances reaction rates and in many 
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cases improves product yield61. We have also developed a preparative 
purification method to isolate 2,3-dehydrosilbin 2 and hemiacetal 3, 
compounds with remarkable antioxidant activity that continue to 
spark much interest. 
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Scheme 2. Base-catalysed oxidation of silibinin1. 
Firstly, it was examined the effect of several solvents in our 
procedure, 1,4-dioxane, THF, MeOH, pyridine and DMF, exploring 
also the utility of their mixtures. Progressively, it was investigated 
the effect of two bases, AcOK and TEA (potassium acetate and 
trietylamine). Reactions were monitored by RP-HPLC (Figure 8) and 
quenched by removing the solvent under reduced pressure. The 
strength of the bases chosen is significant because exposure to strong 
bases, such as alkali metal hydroxides, leads to the rapid 
decomposition of silybin. Reaction yields were calculated by weighing 
the products obtained after chromatographic purification over a pre-
packed RP-18 column. Products were eluted with a ternary mixture of 
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CH3OH/CH3CN/H2O containing increasing proportions of CH3CN. 
The formation of product 3 was not observed under conventional 
heating. The best reaction yields were obtained when the solvent was 
DMF (78%), consistent with previous reports. Yields from reactions in 
other solvents never exceeded 60% (Table 1). 
 
Figure 8. A typical HPLC profile of a reaction under MW heating: analytical 
Phenomenex LUNA RP-18 column (5 μm particle size, 10.0 mm × 250 mmi.d.), 
eluting with H2O/CH3CN (10 to 100% in 50 min), flow rate 1.0 mL/min, monitored at 
254 and 288 nm. 
The purified product 2 was fully characterised by NMR (1H, 13C) 
and ESI-MS analysis, and these data were compared with published 
results to confirm the structure. The purity of 2 was greater than 97% 
in all cases, as determined by analytical HPLC. 
The base-catalysed oxidation of silibinin was subsequently carried 
out under microwave heating. We varied several conditions (solvent, 
temperature, time) and all reactions were carried out in a minimum 
volume of solvent. As expected, reaction yields (Table 1) were very low 
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in slightly polar solvents with low dielectric constants, such as THF 
and 1,4-dioxane (yields ≤25%). 
Similar results were obtained using solvent mixtures (see Table 2) 
composed of CH3OH and H2O, which have high dielectric constants. 
.Table 1. Base catalyzed oxidation of silibinin exploiting the classical 
heating method (oil bath). 
Base 
(3 equiv.) 
Solvent Temperature 
(°C) 
Time 
(hours) 
Yield (%) 
[2]       [3] 
KOAc THF reflux 24 25       -- 
KOAc THF reflux 48 40       -- 
TEA THF reflux 24 25       -- 
TEA THF reflux 48 40       -- 
KOAc dioxane reflux 24 25       -- 
KOAc dioxane reflux 48 50       -- 
TEA dioxane reflux 24 25       -- 
TEA dioxane reflux 48 45       -- 
KOAc DMF 80 0.5 78       -- 
      -- pyridine 95 100 60 (51)    --(<10) 
n.r.= no reaction, was observed degradation of the reaction mixture. 
In some cases the harsh reaction conditions led to rapid and 
substantial decomposition of starting material and the formation of a 
brown and insoluble residue. When the reaction was conducted in 1,4-
dioxane:MeOH (8:2, v/v) at 80°C in the presence of AcOK, we 
observed partial degradation of silibinin and the formation of pitchy 
and insoluble brown material (ca. 40 wt. %). Reactions in DMF or 
pyridine gave very interesting results. Conducting the reaction in 
DMF at 50°C led to the formation of 2 and 3 in 70% and 15% yield, 
respectively, within 30 minutes. When the reaction was carried out in 
pyridine, 2 and 3 were formed in variable yields depending on the 
reaction temperature. At 110°C, the product distribution favoured 
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formation of 3 (62%) over 2 (32%). At a slightly lower temperature 
(100°C), formation of product 2 (28%) predominated over 3 (18%). 
All reactions were monitored by RP-HPLC (Figure 8) and were 
quenched by removing the solvent under reduced pressure. In all 
cases, the yield of 3 (15–62%) was improved over previously reported 
yields57. We subjected pure silybins A and B to the MW oxidation 
conditions. Heating in DMF at 50°C gave 2,3-dehydrosilybins A and B 
in average yields of 72%. 
Table 2. Base catalyzed oxidation of silibinin exploiting the heating promoted by 
microwave (MW). 
Base 
(3 equiv.) Solvent 
Temperature 
(° C) 
Time 
(hour) 
Yield (%) 
[2]       [3] 
KOAc THF 50 1.5 15       -- 
KOAc THF/H2O (9:1, v/v) 50 1.5 18       -- 
-- THF/TEA (2:1, v/v) 60 2.5 25       -- 
-- THF/TEA (1:1, v/v) 60 2.5 25       -- 
KOAc dioxane/CH3OH (8:2, v/v) 110 0.5 n.r. 
KOAc dioxane/CH3OH (8:2, v/v) 90 0.5 n.r. 
KOAc dioxane/ CH3OH (8:2, v/v) 80 0.5 20       5 
TEA dioxane/ CH3OH (8:2, v/v) 80 0.5 20       5 
KOAc dioxane/ CH3OH (8:2, v/v) 50 10 35       -- 
KOAc DMF 50 0.16 70      15 
-- pyridine 150 1.5 n.r. 
-- pyridine 110 3.5 32       62 
-- pyridine 100 3.5 28       18 
n.r.= no reaction, was observed degradation of the reaction mixture. 
Conducting the MW oxidation in pyridine at 110 °C gave good 
yields of the corresponding hemiacetals. Crude products were purified 
on a pre-packed RP-18 column, eluting with a ternary mixture of 
CH3OH/CH3CN/H2O containing increasing proportions of CH3CN. 
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The purified products 2 and 3 were fully characterised by NMR (1H, 
13C) and ESI MS analysis, and these data were compared with 
published results to confirm the structures57. The purity of products 
was greater than 97% in all cases, as determined by analytical HPLC. 
5.3.1 Experimental Session 
General procedure for HPLC analysis: HPLC analysis was performed 
using a Waters 1525 HPLC equipped with a binary gradient pump 
and a Waters 2996 Photodiode Array Detector using a Phenomenex 
LUNA RP18 column (5-μm particle size, 10.0 mm × 250 mmi.d.). The 
column was eluted with H2O/CH3CN (10 to 100% in 50 min), flow rate 
1.5 mL/min, monitored at 254 and 288 nm. 
General purification procedure: The crude material (1 g) was purified 
by chromatography over a pre-packed column RP-18 (Biotage® KP-C-
18-HS 25 g) on a Biotage® Isolera Spektra one eluting with a ternary 
mixture of CH3OH/CH3CN/H2O containing increasing proportions of 
CH3CN (from 4:1:5 to 4:3:3, v/v/v). The flow rate was 25 mL/min. 
General procedure for oxidation under conventional heating: A 
solution of silibinin1 (1.0 g, 2.1 mmol) and base (KOAc or TEA, 6.22 
mmol) in an appropriate solvent (15 mL for 1,4-dioxane, THF or their 
mixture; 8 mL for DMF; 6 mL for pyridine) was heated to reflux. The 
reaction mixture was quenched by removal of the solvent in vacuo. 
The crude product was purified by chromatography over a pre-packed 
RP-18 column. 
General procedure for oxidation under MW heating: All irradiation 
experiments were carried out in a dedicated CEM-Explorer and CEM 
Discover monomode microwave apparatus, operating at a frequency of 
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2.45 GHz with continuous irradiation power from 0 to 300 W using 
the standard maximum power absorbance level of 300 W. A solution 
of silibinin 1 (1.0 g, 2.1 mmol) and base (6.22 mmol) in an appropriate 
solvent (8 mL for THF, THF/H2O, 1,4-dioxane/MeOH and 4 mL for 
pyridine and DMF) was placed in a 10 mL glass tube. The tube was 
sealed with a Teflon septum, placed in the microwave cavity and 
irradiated. Initial microwave irradiation used the minimum wattage 
required to ramp the temperature from room temperature to the 
desired temperature. The reaction mixture was held at this 
temperature for the required time. After the irradiation period, the 
reaction vessel was cooled rapidly to ambient temperature by gas jet 
cooling. 
5.4 Conclusions and Prespective 
In conclusion, we have reported a simple and robust purification 
HPLC method to obtain two diastereoisomers of silibinin in a very 
pure form. The described preparative HPLC method is effective in 
obtaining gram-scale amounts of the standards silybin A and silybin 
B in short times and with minimal effort. In addition in order to test 
the biological activity of DHS, we have developed an efficient new 
preparative base-catalysed oxidation of silibinin. The oxidation is 
carried out under conventional heating in comparison with microwave 
(MW). The MW procedure gave a rapid access to good yields of 2,3-
dehydrosilybin 2 and hemiacetal 3 in minimum solvent volumes 
(Table 2). The optimised conditions were then used to oxidize optically 
pure silybin A and B to 2,3-dehydrosilybin A and B, respectively. All 
purified products were fully characterised by NMR (1H, 13C), CD, [α]D 
and ESI MS analyses. Access to significant quantities of these 
compounds will facilitate the evaluation of their specific 
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pharmacological properties, that was not possible before. Thanks to 
the optimization of oxidation conditions promoted by microwave (MW) 
heating, we intend to extend this method to obtain modified DHS 
starting from the synthesis of water soluble silybin analogues. 
5.5 New silibinin analogues with improved bioavailability  
As previously alluded, the therapeutic efficiency of silibinin is 
rather limited by its low bioavailability and water solubility. 
Typically, silibinin is administered orally and this method of 
administration, limits the efficacy of the natural product because of 
its poor absorption and short half-life in the body62. In order to reach 
their target tissues, cells, and organelles for their desired therapeutic 
effects a number of physical and chemical approaches by which 
accomplish these difficult challenges have been proposed63. The most 
important is Siliphos® (IdB 1016), a silybin-phosphatidylcholine 
complex34 developed in 1990 by Indena SpA (Milan, Italy). 
Only a few modifications have been introduced in these years; 
these most simply alter the chemical and physicochemical properties 
of the natural metabolite enhancing its biological efficacy, in vivo 
stability, low bioavailability and overall uptake33,52,54,64–67. Generally 
tissue- and cell- specific drug targeting can only be achieved by 
employing carrier-drug complexes or conjugates that contain a ligand 
recognized by a receptor on the target cell. Carbohydrate-based 
conjugates allow targeting of a certain class of cell membrane 
receptors that are referred to as lectins that recognize a specific 
carbohydrate motif and internalize their ligands by endocytosis68. 
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5.5.1 Synthesis of new silybins and evaluation of their antioxidant 
properties 
Aiming to exploit a readily available natural product as a scaffold 
for chemical diversification, we considered silybin A and B as 
versatile starting materials. Starting from a pure form of silybin A 
and B easily obtained by HPLC method described before (see 
Paragraph 5.2), it was developed a successful synthetic strategy to 
obtain a variety of silybin derivatives bearing different substituents, 
including some of charged groups at the C(9") position. The 
antioxidant activity of these derivatives and also of silybin A and B 
were evaluated in vitro assays. We chose to insert the modifications 
at the C(9"), because it has been reported that this functional position 
is not responsible for antioxidant and antiradical action of this 
metabolite54,69. By modifying this position for both diastereoisomers of 
silibinin (silybin A and B), we generated a series of new and more 
polar analogues that could be useful models for chemical 
diversification (Scheme 3). 
 
Scheme 3. Reagents and conditions: a) DMTCl, pyridine, 50°C, overnight. b) Ac2O, 
pyridine, 25°C, overnight. c) 5% formic acid in CH2Cl2, 25°C, 30 min. d) SO3·Et3N, 
DMF, 25°, 30 min.; NH4OH/MeOH, 25°C, 30 min. e) TPP, DPPA, THF, 25°C, 5h; 
0.1M HCl/EtOH 1 : 4, 50°C, 20 min. f) H2, C/Pd, MeOH, 25°C, overnight. g) 4-
nitrophenyl dichlorophosphate, pyridine, 0°C, 40 min.; NH4OH/MeOH, 25°C, 30 min. 
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The synthesis of the key silybin intermediates 2A or 2B starting 
from silybin A and B respectively (Scheme 3) provided using an 
efficient orthogonal protection strategy, protecting the HO−C(3,5,7,4”) 
functional groups with acetyl (Ac) while the HO−C(9") with 
dimethoxytriphenylmethyl group (DMT). The modifications 
introduced at the C(9") position included the sulfate, phosphodiester, 
amino, and azide functional groups. The phosphodiester and amino 
functionalities were chosen in order to prepare a useful silybin-based 
scaffold for generating a library of C(9")−modified compounds, such as 
phosphodiesters, amides, urethanes, and sulfonamides. 
Purified silybin A (1A) (Scheme 3) was first converted into 
C(9")−ODMT ether by a reaction with 4,4’-
dimethoxytriphenylmethylchloride (DMTCl) after the HO−C(3,5,7,4") 
functionalities were completely acetylated. The successive treatment 
with 5% formic acid in CH2Cl2 allowed for the removal of the DMT 
protecting group, leading to 2A. Starting from 2A, the silybin 
analogues 3A, 4A, 5A, and 6A were obtained in a few steps with good 
overall yields. To introduce the sulfate group, compound 2A was 
reacted with SO3·Et3N and then treated with concentrated aqueous 
ammonia in MeOH, allowing for the full deprotection of acetyl groups 
and leading to the desired compound 3A. The silybin derivative 4A 
was prepared starting from the key intermediate 2A, which was first 
converted into the corresponding C(9")−azido derivative by the 
Mitsunobu reaction after deacetylation. The derivative 5A was 
obtained by catalytic hydrogenolysis of the C(9")−azido functionality 
of 4A. The reaction of 2A with 4-nitrophenyl dichlorophosphate in 
pyridine and subsequent deacetylation generated compound 6A. In all 
cases, the intermediate compounds and final derivatives were purified 
by silica gel chromatography and then fully characterized by 1H-NMR 
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(and also 31P-NMR in the case of 6A) and MALDI-MS. With the same 
pattern of reactions, compounds 3B−6B were obtained from silybin B 
(1B) via the intermediate 2B, which corresponds to compound 2A. The 
antioxidant activity of each substance was assessed using the 2,2-
diphenyl-1-picryl-hydrazyl-hydrate (DPPH) free radical assay. The 
DPPH free radical method is an antioxidant assay based on electron 
transfer that produces a violet solution in ethanol70. This free radical, 
which is stable at room temperature, is reduced in the presence of an 
antioxidant molecule, giving rise to a colorless ethanol solution. The 
use of the DPPH  assay provides an easy and rapid way to evaluate 
antioxidant activity of a variety of molecules by spectrophotometry71. 
The new compounds 3A−6A and 3B−6B were tested for their free 
radical scavenging ability in a comparison with their parent 
compounds 1A and 1B (Table 3), silibinin (mixture 1A/1B, 1:1) and 
butylated hydroxyl anisole (BHA), which was used as standard 
antioxidant. 
Table 3. Radical-Scavenging data of silibinin, silybin A and B, DHS A and B and 
their analogues. 
Compound DPPH IC50 (M) 
silibinin  392  ±  8 
silybin A (1A) 425 ± 5 
silybin B (1B) 446 ± 7 
silybin A−9"-O-sulphate sodium salt (3A) 165 ± 8 
silybin B−9"-O-sulphate sodium salt (3B) 189 ± 3 
9"-Azide-silybin A (4A) 667 ± 26 
9"-Azide-silybin B (4B) 657 ± 18 
9"-Amine-silybin A (5A) 32 ± 2 
9"-Amine-silybin A (5B) 33 ± 1 
silybin A−9"-O-(4-nitrophenyl)-phosphate sodium salt (6A) 604 ± 15 
silybin B−9"-O-(4-nitrophenyl)-phosphate sodium salt (6B) 591 ± 18 
BHA 198 ± 4 
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Silybin A and B showed antioxidant activities that were absolutely 
comparable to each other (425 and 446 M, respectively) slightly 
higher than that of the 1:1 mixture (Silibinin, 392 M), and more 
than double than that of the BHA standard (198 M). Foti et al. 
recently have reported kinetic measurements by DPPH assay to 
demonstrate that the reaction between phenols and DPPH occurs in 
alcohols by electron transfer from the phenoxide anions to DPPH72. 
The presence of oxidized groups in the molecules reduces their 
ability to donate electrons or hydrogen atoms and thus their 
reactivity toward the radical. According to these studies, the 
oxidation of C(9") of silybin to azide derivatives (4A and 4B, with IC50 
values of 667 and 657 M, respectively) or to p-nitrophosphate 
derivatives (6A and 6B, with IC50 values of 604 and 591 M, 
respectively) further reduced their radical scavenging properties. 
Significant improvement of this property compared to silibinin and 
BHA was observed for both sulphate derivatives 3A and 3B (IC50 
values of 165 and 189 M, respectively) and, especially for in both 
amine derivatives 5A and 5B (IC50 values of 32 and 33 M, 
respectively, Table 3). Upon reaction with DPPH, silybin derivatives 
gave a very complex reaction mixture composed mostly of insoluble 
brownish precipitates. These are probably polymers (radical−initiated 
polymerization) and non−identified products of lower molecular 
weight. 
5.5.1.1 Experimental Session 
All the reagents were of the highest quality of those commercially 
available and they were used as received. Anal. TLC was performed 
on precoated alumina plates with Merck Silica Gel 60 F254 as the 
adsorbent. Reaction products were visualized on TLC plates by UV 
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light followed by treatment with 5% H2SO4 ethanolic solution and 
then by heating to 130°C. For column chromatography, silica gel from 
Merck (Kieselgel 40, 0.063−0.200 mm) was used. NMR spectra were 
recorded on Varian INOVA-500 FT NMR spectrometer (at 499.710 
and 125.663 MHz for 1H and 13C, resp.), at 25°C;  in ppm, J in Hz. 
Peak assignments have been carried out on the basis of standard 1H-
1H COSY, HMBC, and HSQC experiments. 31P-NMR spectra were 
recorded on a Bruker WM-400 spectrometer (at 161.98 MHz, using 
85% H3PO4 as external standard). For the ESI-MS analyses, a Waters 
Micromass ZQ Instrument, equipped with an electrospray source, was 
used. MALDI TOF mass spectrometric analyses were performed on a 
PerSeptive Biosystems Voyager−De Pro MALDI mass spectrometer. 
General procedure for the preparation of 3,5,7,4”-O-tetra-acetyl-
silybin A (2A) and 3,5,7,4”-O-tetra-acetyl-silybin B (2B). Purified 
silybin A (1A, 350 mg, 700 mol) was evaporated several times with 
anhydrous THF and dissolved in anhydrous pyridine (3 ml) before 
reaction with DMTCl (450 mg, 133 mol). The reaction mixture was 
left at 50°C overnight under stirring and was then diluted with 
MeOH and concentrated under reduced pressure. The basic 
ingredient in its natural state was next purified on a silica gel column 
and eluted with CHCl3 containing increasing amounts of MeOH (from 
0 to 5%) in the presence of a few drops of TEA, affording pure 9"-O-
(4,4’-dimethoxytriphenylmethyl)-silybin A as an amorphous solid 
(0.45 g, 600 mol) in 88% yield. Rf = 0.5 (CHCl3/MeOH 90 : 10). 
9"-O-(4,4’-dimethoxytriphenylmethyl)-silybin A (0.38 g, 470 mol), 
was dissolved in anhydrous pyridine (2.2 ml) and reacted with acetic 
anhydride (1 ml, 11 mmol). The mixture was left under stirring at 
room temperature overnight and then concentrated under reduced 
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pressure. The basic ingredient was then diluted with CHCl3, 
transferred into a separatory funnel, washed three times with a 
saturated NaHCO3 aqueous solution, and washed then twice with 
H2O. The organic phase was dried over anhydrous Na2SO4, filtered 
and concentrated under reduced pressure to produce pure 3,5,7,4"-O-
tetra-acetyl-9"-O-(4,4’-dimethoxytriphenylmethyl)-silybin A as a pale 
amorphous solid (0.42 g, 426 mol) in 91% yield. Rf = 0.5 
(hexane/AcOEt 90 : 10). To a solution of 3,5,7,4”-O-tetra-acetyl-9"-O-
(4,4’-dimethoxytriphenylmethyl)-silybin A (0.42 g, 426 mol) in 
CH2Cl2 (5 ml), 5% formic acid in CH2Cl2 (8 ml) was added. The 
mixture was stirred for 30 min before the mixture was extracted with 
CHCl3 (25 ml), washed with 10% NaHCO3 solution, dried over 
Na2SO4, and then concentrated in vacuo. The basic material was next 
purified on a silica gel column and eluting with hexane containing 
increasing amounts of AcOEt (from 50 to 70%) to afford pure 3,5,7,4"-
O-tetra-acetyl-silybin A (2A) (220 mg, 340 mol) as a pale amorphous 
solid in 80% yield. 
Compound 2A: Rf = 0.6 (CHCl3/CH3OH, 90:10, v/v). The 1H NMR 
(500 MHz, CDCl3, room temperature) δ  7.09-6.96 (6H, overlapped 
signals, H-2', H-6', H-5', H-2", H-5", H-6"), 6.74 (1H, s, H-8), 6.56 (1H, 
s, H-6), 5.66 (1H, d,J= 12.5 Hz, H-3), 5.32 (1H, d,J= 12.5 Hz, H-2), 
4.99 (1H, d,J= 8.0 Hz, H-7"), 3.99 (1H, m, H-8"), 3.80-3.77 (4H, 
complex signals, OCH3, H-9"a), 3.49 (1H, dd,J= 2.0 Hz, J= 9.5 Hz, H-
9"b), 2.32, 2.26, 2.23, 1.98 (12H, s, CH3 of the acetyl groups) ppm.ESI-
MS: 649.18 ([M – H]+, C33H30O14; 650.16). 
The same procedure was used to obtain 2B starting from silybin B 
(1B). 
Compound 2B: Rf = 0.6 (CHCl3/CH3OH, 90:10, v/v). The 1H NMR 
(500 MHz, CDCl3, room temperature) δ  7.04-6.93 (6H, overlapped 
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signals, H-2’, H-6’, H-5’, H-2”, H-5”, H-6”), 6.76 (1H, s, H-8), 6.55 (1H, 
s, H-6), 5.64 (1H, d,J= 12.5 Hz, H-3), 5.30 (1H, d,J= 12.5 Hz, H-2), 
4.97 (1H, d,J= 8.0 Hz, H-7”), 3.99 (1H, m, H-8”), 3.80-3.77 (4H, 
complex signals, OCH3, H-9”a), 3.49 (1H, dd,J= 2.0 Hz, J= 9.5 Hz, H-
9”b), 2.34, 2.24, 2.22, 1.99 (12H, s, CH3 of the acetyl groups) ppm.ESI-
MS: 649.21 ([M – H]+, C33H30O14; 650.16). 
General procedures for the preparation of silybin analogues 3A, 4A, 
5A, 6A and respective isomers (3B, 4B, 5B, 6B). 
Synthesis of silybin A-9"-O-sulphate sodium salt (3A). Compound 2A 
(20 mg, 31 mol) was dissolved in anhydrous DMF (200 l) and 
reacted a sulphur trioxide triethylamine complex (6 mg, 33 mol). 
After 30 min, the reaction mixture was quenched with H2O and then 
concentrated under reduced pressure. The crude extract was next 
purified on a silica gel column using with CHCl3/MeOH 97 : 3 as the 
eluent to afford  pure 3,5,7,4”-O-tetra-acetyl-9"-O-sulphate silybin A 
(17 mg, 24 mol) in 78% yield. 3,5,7,4”-O-tetra-acetyl-9"-O-sulphate 
silybin A was successively treated with 0.4 ml conc. aq. ammonia in 
MeOH 50:50 at 25°C for 30 min. The concentrated mixture was 
purified on a silica gel column and eluted with CHCl3/MeOH 80:20, 
and then the compound was converted into the corresponding sodium 
salt (3A) by cation exchange on a DOWEX (Na+ form) resin to afford a 
homogeneous sample (10 mg, 17 mol) in 70% yield. Rf = 0.5 
(CHCl3/MeOH 70 : 30). ESI-MS: 583.05 ([M – H]−, C25H21NaO13S; 
584.06). The same procedure was used to obtain the silybin B-9"-O-
sulphate isomer as a sodium salt (3B). 
Compound 3A: Rf = 0.5 (CHCl3/MeOH 70 : 30). ESI-MS: 583.07 ([M 
– H]−, C25H21NaO13S; 584.06).The 1H NMR (500 MHz, CDCl3, room 
temperature) δ  7.10 (1H, br s, H-2’), 7.04 (m, 1H, H-2”), 7.03 (1H, m, 
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H-5’), 6.96 (1H, m, H-6’), 6.90 (1H, m, H-6”), 6.83 (1H, m, H-5”), 5.92 
(1H, s, H-8), 5.89 (1H, s, H-6), 4.95 (1H, d, J = 12.4 Hz, H-2), 4.78 (1H, 
d, J = 7.9 Hz, H-7”), 4.49 (1H, d, J = 12.4 Hz, H-3), 4.24 (1H, m, H-8”), 
4.16 (1H, m, H-9”a), 3.90 (1H, m, H-9”b), 3.87 (3H, s, OCH3).ESI-MS: 
583.05 ([M – H]−, C25H21NaO13S; 584.06). 
Compound 3B: Rf = 0.5 (CHCl3/CH3OH, 70:30, v/v). The 1H NMR 
(500 MHz, CDCl3, room temperature) δ  7.12 (1H, br s, H-2’), 7.04 (1H, 
m, H-2”), 7.02 (1H, m, H-5’), 6.96 (1H,m, H-6’), 6.91 (1H, m, H-6”), 
6.83 (1H, m, H-5”), 5.92 (1H, s, H-8), 5.89 (1H, s, H-6), 4.95 (1H, d, J = 
12.5 Hz, H-2), 4.78 (1H, d, J = 8.0 Hz, H-7”), 4.49 (1H, d, J = 12.5 Hz, 
H-3), 4.24 (1H, m, H-8”), 4.15 (1H, m, H-9”a), 3.91 (1H, m, H-9”b), 
3.85 (3H, s, OCH3).ESI-MS: 583.07 ([M – H]−, C25H21NaO13S; 584.06). 
Synthesis of 9"-azide-silybin A (4A). 40 mg (60 mol) of 2A and 15 mg 
(0.30 mol) of triphenylphosphine were dissolved in 0.8 ml of 
anhydrous THF at 0°C and then treated with a mixture of 15 µL (7 
mol) of DEAD and 15 µL (8 mol) of diphenylphosphorylazide 
(DPPA) in anhydrous THF. After 10 min, the reaction temperature 
was raised to 25°C and the reaction was stirred for 5 h. The crude 
extract was concentrated under reduced pressure and purified by 
silica gel chromatography with hexane containing increasing amounts 
of AcOEt (from 40 to 50%), as the eluent to afford 30 mg (48 mol, 
78%) of pure 3,5,7-O-three-acetyl-9"-azide-silybin. The obtained 
compound was treated with 0.8 ml of HCl conc./EtOH 10:40, at 50°C 
for 20 min. The crude mixture was diluted with AcOEt, transferred to 
a separatory funnel, washed with a saturated NaHCO3 aqueous 
solution, and washed twice with H2O. The organic phase was dried 
over anhydrous Na2SO4 and filtered prior to concentration under 
reduced pressure and purification using on TLC eluting with 
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CHCl3/MeOH 92:8 was used as the eluent to pure 4A (21 mg, 40 mol) 
as a homogeneous solid in 84% yield. 
Compound 4A: Rf = 0.4 (CHCl3/MeOH 90 : 10). 1H-NMR (500 MHz, 
CD3OD): 6.95 (1H, d, J = 8.0, H−5), 6.94 (1H, brs, H−2’), 6.90 (1H, d, J 
= 8.5, H−5”), 6.89 (1H, brs, H−2”), 6.87 (1H, brd, J = 8.5, H−6”); 6.78 
(1H, brd, J = 8.0, H−6’), 5.93 (1H, brs, H−8), 5.88 (1H, brs, H−6), 5.02 
(1H, d, J = 12.5, H−2), 4.89 (1H, brd, J = 8.0, H−C7”), 4.56 (1H, d, J = 
12.5, H−3), 4.13 − 4.15 (1H, m, H−C8”), 3.89 (3H, s, OCH3), 3.54 (1H, 
brd, J = 13.0, CH2a-9”); 3.13 (1H, dd, J = 4.0, J = 13.0, CH2b-9”). ESI-
MS:  530.49 [M + Na]+, 508.16 ([M + H]+, C25H21N3O9; calc. 507.13). 
The same procedure was used to obtain the 9"-azide-silybin B (4B) 
isomer. 
Compound 4B: Rf= 0.4 (CHCl3/MeOH 90:10). 1H-NMR (500 MHz, 
CD3OD): 6.93 (1H, d, J = 8.0, H−5’), 6.91 (1H, brs, H−2’), 6.88 (1H, d, 
J = 8.5, H−5”), 6.85 (1H, brs, H−2”), 6.83 (1H, brd, J = 8.5, H−6”), 6.78 
(1H, brd, J = 8.0, H−6’), 5.91 (1H, brs, H−8), 5.85 (1H, brs, H−6), 5.02 
(1H, d, J = 12.5, H−2), 4.82 (1H, brd, J = 8.0, H−7”), 4.52 (1H, d, J = 
12.5, H−3), 4.09 − 4.12 (1H, m, H−8”), 3.82 (3H, s, OCH3), 3.51 (1H, 
brd, J = 13.0, CH2a-9”), 3.15 (1H, dd, J = 4.0, J = 13.0, CH2b-9”). ESI-
MS: 530.37 [M + Na]+, 546.52 [M + K]+, 508.15 ([M + H]+, C25H21N3O9; 
calc. 507.13). 
Synthesis of 9"-amine-silybin A (5A). The silybin derivative 4A (30 
mg, 54 mol) was dissolved with stirring in MeOH (0.80 ml). 10% 
Pd/C (2.0 mg) was added as a catalyst, the flask was evacuated and 
an atmosphere of hydrogen was secured. The mixture was stirred 
overnight under hydrogen balloon pressure (reaction complete 
according to TLC). The mixture was filtered through a plug of silica 
and was washed with AcOEt, concentrated under reduced pressure 
and then purified using TLC with CHCl3/MeOH 80:20 as the eluent to 
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pure 5A (15 mg, 31 mol) as a homogeneous solid in 62% yield. Rf = 
0.4 (CHCl3/MeOH 80 : 20). ESI-MS (MALDI-TOF): 480.13 ([M – H]−, 
C25H23NO9; calc. 481.14). The same procedure was used to obtain the 
9"-amine-silybin B (5B) isomer. 
Compound 5A: Rf = 0.4 (CHCl3/CH3OH, 80:20, v/v). 1H NMR (500 
MHz, CDCl3, room temperature) δ7.11 (1H, s, H-2’), 7.05 (1H, m, H-
6’), 7.02 (1H, m, H-5’), 6.99 (1H, s, H-2”), 6.88 (1H, m, H-6”), 6.85 (1H, 
m, H-5”), 5.87 (1H, s, H-8), 5.84 (1H, s, H-6), 4.94 (1H, d, J = 12.5 Hz,  
H-2), 4.74 (1H, d, J = 8.1 Hz, H-7”), 4.47 (1H, d, J = 12.5 Hz, H-3), 
4.13 (1H, d, J = 8.1 Hz, H-8”), 3.86 (3H, s, OCH3), 2.83, 2.68 (1H, m, 
H-9”a, H-9”b). ESI-MS: 482.12 ([M – H]+, C25H23NO9; calc. 481.14). 
Compound 5B: Rf = 0.4 (CHCl3/CH3OH, 80:20, v/v). 1H NMR (500 
MHz, CDCl3, room temperature) δ7.11 (1H, s, H-2’), 7.05 (1H, m, H-
6’), 7.02 (1H, m, H-5’), 6.99 (1H, s, H-2”), 6.88 (1H, m, H-6”), 6.85 (1H, 
m, H-5”), 5.87 (1H, s, H-8), 5.84 (s1H,, H-6), 4.94 (1H, d, J = 12.4 Hz,  
H-2), 4.74 (1H, d, J = 8.0 Hz, H-7”), 4.47 (1H, d, J = 12.4 Hz, H-3), 
4.13 (1H, d, J = 8.0 Hz, H-8”), 3.86 (3H, s, OCH3), 2.83, 2.68 (2H, m, 
H-9”a, H-9”b).ESI-MS: 480.13 [M – H]−, C25H23NO9; calc. 481.14. 
Synthesis of silybin A-9"-O-(4-nitrophenyl)-phosphate sodium salt 
(6A). Compound 2A (25 mg, 39 mol) was dissolved in anhydrous 
pyridine (0.5 ml) and reacted with 4-nitrophenyl dichlorophosphate 
(10 mg, 4.2 mol). The reaction was left under stirring at 0°C for 40 
min and monitored by TLC using CHCl3/MeOH 90:10. The reaction 
mixture was quenched with H2O, stirred at 0°C for 20 min, then 
concentrated under reduced pressure, and finally purified using TLC 
eluting with CHCl3/MeOH 95:5 as the eluent to pure (3,5,7,4"-O-tetra-
acetyl)-silybin A-9"-O-(4-nitrophenyl)-phosphate (25 mg, 30 mol) in 
80% yield. The NMR spectra of this compound showed dramatic line 
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broadening, which is diagnostic of slow equilibrium on the NMR time 
scale. This could suggest a strong propensity toward aggregation in 
CDCl3. The obtained compound was treated with 0.5 ml conc. aq. 
ammonia in MeOH (1:1) at 25°C for 30 min. The reaction mixture was 
concentrated under reduced pressure and then purified on TLC 
eluting with CHCl3/MeOH 70:30  as the eluent to afford pure 6A (14 
mg, 21 mol) in 67% yield. Compound 6A was converted into the 
corresponding sodium salt by cation exchange on a DOWEX (Na+ 
form) resin to obtain a homogeneous sample. 
Compound 6A: Rf = 0.4 (CHCl3/MeOH 70 : 30). 1H-NMR (500 MHz, 
CDCl3,): 8.00 − 8.02 (2H, m, m−protons of 4−nitrophenyl moiety), 7.52 
− 7.55 (1H, m, H−6’), 7.58 − 7.62 (1H, m, H−6”), 7.40 − 7.42 (2H, m, 
o−protons of 4−nitrophenyl moiety), 6.95 (1H, s, H−2’), 6.78 − 6.81 
(1H, m, H−5’), 6.76 − 6.79 (1H, m, H−2”), 6.72 − 6.76 (1H, m, H−5”), 
6.51 (1H, s, H−8), 6.24 (1H, s, H−6), 4.91 (1H, d, J = 8.0, H−7”), 4.19 
(1H, d, J = 8.0, H−8”), 4.20 − 4.22 (1H, m, CH2a-9”), 3.84 (3H, s, 
OCH3), 3.76 − 3.79 (1H, m, CH2b-9”). 31P-NMR (CD3OD, 161 MHz): 
−4.8. ESI-MS: 682.13 ([M – H]−, C31H26NO15P; calc. 683.10). 
The same procedure was used to obtain the silybin B-9"-O-(4-
nitrophenyl)-phosphate isomer as a sodium salt (6B). 
Compound 6B: Rf = 0.4 (CHCl3/MeOH 70 : 30). 1H-NMR (500 MHz, 
CDCl3): 8.08 (2H, complex signals, m−protons of 4−nitrophenyl 
moiety), 7.53 − 7.54 (1H, m, H−6’), 7.58 − 7.62 (1H, m, H−C6”), 7.40 
(2H, complex signals, o−protons of 4−nitrophenyl moiety), 6.95 (1H, s, 
H−2’), 6.78 − 6.81 (1H, m, H−5’), 6.78 (1H, s, H−2”), 6.72 − 6.75 (1H, 
m, H−5”), 6.51 (1H, s, H−8), 6.24 (1H, s, H−6), 4.91 (1H, d, J = 8.0, 
H−7”), 4.19 (1H, d, J = 8.0, H−8”), 4.20 − 4.23 (1H, m, CH2a-9”), 3.84 
(3H, s, OCH3), 3.75 − 3.80 (1H, m, CH2b-9”). 31P-NMR (CD3OD, 161 
MHz): –4.8. ESI-MS: 682.11 ([M – H]−, C31H26NO15P; calc. 683.10). 
  
147 
Assessing free radical scavenging activity using the DPPH method. 
The measurement of the DPPH radical scavenging activity was 
performed according to methodology described by Brand−Williams et 
al.70. Briefly, the antioxidant in methanol (0.1 ml) was added to 2.4 ml 
of methanolic DPPH solution (25 mg/L). The reaction mixture was 
covered and left in the dark at room temperature. The absorbance at 
517 nm was recorded spectrophotometrically (HP 8452A, 
Hewlett−Packard GmbH) after 0.5, 1, 3, 15, 30, and 60 min and 
thereafter every hour until the steady state was achieved. Each 
antioxidant was prepared in duplicate for each of at least three 
concentrations and averaged. Butylated hydroxyl anisole (BHA) was 
used as a standard antioxidant. The amount of sample required to 
decrease the initial DPPH concentration by 50% (EC50) was calculated 
by linear regression of the remaining DPPH (%) vs the sample 
concentration. When DPPH reacts with an antioxidant compound, 
which can donate hydrogen, it is reduced. The changes in color (from 
deep violet to light yellow) were read [Absorbance (Abs)] at 517 nm 
after 100 min of reaction using a UV−VIS spectrophotometer (DU 
800; Beckman Coulter, Fullerton, CA, USA). The mixture of ethanol 
(3.3 ml) and the sample (0.5 ml) served as blanks. The control 
solution was prepared by mixing ethanol (3.5 ml) and DPPH radical 
solution (0.3 ml). 
The percentage of scavenging activity (AA%) was determined 
according to Mensor et al.73: 
AA% = 100 – (Abssample− Absblank) x 100/Abscontrol) 
Statistical analysis. The experiments for each substance were done in 
triplicate. The results were expressed as decrease in percentage 
relative to control values and compared by one−way ANOVA and 
Tukey's test. 
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Differences were considered statistically significant if p < 0.05. The 
poor superoxide radical scavenging capacity of silybin was previously 
reported69. 
5.5.2 New silibinin scaffold for chemical diversification: synthesis of 
novel 9”-silibinin conjugates 
Aiming to improve the bioavailability, the delivery as well as the 
biological activity of silibinin, we developed an efficient synthetic 
procedure to obtain new 9"-silibinin conjugates with different labels. 
Particularly, we have selected some molecules known for their ability 
as molecular carriers (steroids, bile acids)74,75, radical scavengers 
(nucleosides)76,77, and capable to improve water solubility (as 
polyether)78,79. The introduction of these labels occur through a 
phosphate group that confers also great pharmaceutical and 
pharmacokinetic benefits to the molecule. Therefore we chose to start 
from the new 9"-phosphoramidite building block 3 (Scheme 4) which 
could be transformed into a series of conjugates using a solution-
phase parallel array protocol and exploiting standard and reliable 
phosphoramidite chemistry80. We initially converted silibinin 1 into 
9"-ODMT intermediate 2, using a synthetic approach described in the 
previous section (see Paragraph 5.5.1), then this compound 2 has been 
converted into the corresponding phosphoramidite derivatives 3. 
Thus intermediate 3, whose synthesis has recently been optimized 
by my research group54; was obtained using 2-cyanoethyl-N,N-
diisopropylamino-chlorophosphoramidite reagent with DIEA (N,N-
diisopropylethylamine) in anhydrous DCM (dichloromethane). In 
these preliminary studies, silibinin used as starting material was a 
mixture of its diastereoisomers, the derivatives 3 were obtained as a 
mixture of two diastereoisomers, not separable by chromatography, 
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and the 1H and 31P NMR spectra appeared like those of a single 
compound. 
After purification the identity of compounds 3, obtained in good 
yields (65%), was confirmed by NMR (1H, 13C and 31P) and HRMS-ESI 
data81. Afterwards the group of molecules chosen for their peculiar 
properties have been selected also because having a free hydroxyl 
group (A-E, Scheme 4) that  provides an easily coupling with the key 
intermediate 3. 
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Scheme 4. Synthesis of 9"-phosphodiester silibinin conjugates 5 (A-E). *yields 
calculated from starting product 3. 
While A, B and C are commercially available, D and E were 
efficiently obtained starting from 2’-deoxyadenosine and 3α,7α,12α,24-
tetrahydroxycholane, respectively. Exploiting the different reactivity 
of hydroxyl groups we used the tert-butyldimethylsilyl group 
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(TBDMS) for the transient protection of the primary OH moiety while 
all other groups were protected with acetyl (Ac). 2’-deoxyguanosine 
and 3α,7α,12α,24-tetrahydroxycholane were protected by reactions 
with TBDMS-chloride (TBDMSCl) and DMTCl respectively82,83. The 
products were acetylated by acetic anhydride to yield fully protected 
products. Finally, the TBDMS group was cleaved by 
triethylaminetrihydrofluoride (Et3N·3HF) and dichloroacetic acid 
(DCA) to yield N2-acetyl-2’,3’-O-di-acetyl-deoxyguanosine (D) and 
3α,7α,12α-O-tri-acetyl-24-hydroxycholane (E) in overall yields of 80 
and 75% respectively. The coupling of 3 with A-E (Scheme 4) was 
carried out by using the classic coupling reagent (0.1M tetrazole in 
acetonitrile) subsequently, the treatment with 5.5M tert-butyl 
hydroperoxide solution in decane, led to phosphotriesters 4 (A-E). 
After purification by flash chromatography, the derivatives 4 were 
treated with conc. aq. ammonia and MeOH (1:1, v:v) at room 
temperature, allowing the full deprotection from acetyl and 
cyanoethyl groups and generating the desired phosphodiester 
derivatives 5 (A-E) in good yields (Scheme 4). All final derivatives 5 
(A-E) were purified by flash chromatography and then characterized 
by NMR (1H and 31P) and MS analyses. All the intermediates and 
final derivatives were obtained as a mixture of two diastereoisomers, 
that we failed to separate by chromatography, and the NMR spectra 
of many of them appeared like those of a single compound. 
5.5.2.2 Experimental Session 
General procedure for the preparation of phosphoramidite 3: To 240.0 
mg (0.37 mmol) of 3,5,7,4"-O-tetra-acetyl-silibinin (2) dissolved in 
anhydrous dichloromethane (5 mL), DIEA (390 µL, 2.22 mmol) and 2-
cyanoethyl-N,N-diisopropylamino-chlorophosphoramidite (107 µL, 
0.48 mmol) were added under argon. After 30 min the solution was 
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diluted with AcOEt and the organic phase was washed twice with 
brine and then concentrated. Silica gel chromatography of the residue 
(eluent n-hexane:ethyl acetate, 3:7, v:v, in the presence of 1% of 
triethylamine), afforded desired compound 3 (205.0 mg, 0.24 mmol) in 
a 65% yield. Rf = 0.8 (n-hexane:ethyl acetate, 3:7, v:v). 
Compound 3: 1H NMR (CDCl3, 500 MHz, room temperature, 
mixture of diastereoisomers): δ 7.11-6.90 (6H, overlapped signals, H-
2’, H-6’, H-5’, H-2”, H-5”, H-6”), 6.81 (1H, s, H-8), 6.58 (1H, s, H-6), 
5.66 (1H, d, J = 11.6 Hz, H-3), 5.37 (1H, d, J = 11.6 Hz, H-2), 5.03 (1H, 
d, J = 7.6 Hz, H-7”), 4.13 (1H, m, H-8”), 3.90-3.60 (9H, complex 
signals, OCH3, H-9”, OCH2CH2CN, N[CH(CH3)2]2 ), 2.65 (2H, complex 
signals, OCH2CH2CN), 2.37, 2.32, 2.29, 2.04 (12H, s for each, CH3 of 
acetyl groups) 1.25-1.15 (12H, complex signals, N[CH(CH3)2]2) ppm. 
13C NMR (CDCl3, 125 MHz, room temperature, mixture of 
diastereoisomers): δ 185.3 (C-4), 169.1 (C-7), 168.7, 167.8 (CO of 
acetyl groups), 162.5 (C-5), 156.3 (C-8a), 151.4 (C-3”), 144.3 (C-4”), 
143.6 (C-4’), 140.2 (C-3’), 134.8 (C-1’), 123.0 (C-1”), 120.8 (C-6’), 119.9 
(C-6”), 119.8, 117.6, 117.2 (C-2’, C-5’, OCH2CH2CN), 116.2 (C-5”), 
111.4, 111.2, 110.6, 108.9 (C-6, C-8, C-2”, C-4a), 81.0 (C-2), 76.2 (C-8”), 
75.8 (C-7”), 73.3, 73.1 (C-3), 62.6, 62.2 (C-9”), 58.8, 58.5 
(OCH2CH2CN), 56.0 (OCH3), 43.3, 43.1 (N[CH(CH3)2]2), 24.5 
(N[CH(CH3)2]2), 21.1, 20.9, 20.7, 20.4 (CH3 of acetyl groups), 19.9 
(OCH2CH2CN) ppm. 31P NMR (CDCl3, 161.98 MHz): δ 152.9, 150.2 
ppm. HRMS (ESI-MS - positive ions): m/z calcd for C42H47N2O15P = 
850.2714; Found: [MH]+ = 851.2788; [MNa]+ = 873.2606. 
General procedure for the synthesis of conjugates 5 (A-E): 
derivative 3 (150 mg, 0.22 mmol) and the select compound A-E (0.21 
mmol, previously dried and kept under reduced pressure, were 
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reacted with a 0.45M tetrazole solution in anhydrous CH3CN (1.0 mL, 
0.45 mmol). The reaction was left under stirring at room temperature 
and monitored by TLC in the eluent system n-hexane: AcOEt, 1:1, v:v. 
After 1h, a 5.5M tert-butyl hydroperoxide (t-BuOOH) solution in 
decane (100 μL) was added to the mixture and left under stirring at 
room temperature. After 30 minutes the reaction mixture was diluted 
with CHCl3, transferred into a separatory funnel, washed three times 
with water, concentrated under reduced pressure, and purified by 
flash chromatography eluted with n-hexane: AcOEt, 7:3, v:v, affording 
pure 4 (A-E) as yellow-brown amorphous powder. The next treatment 
with conc. aq. ammonia in CH3OH (1:1, v:v) to 1h at room 
temperature, allowed full deprotection from acetyl and 2-cyanoethyl 
groups. The concentrated mixture was then purified on a silica gel 
column, eluted with CHCl3/CH3OH containing growing amounts of 
CH3OH. Compounds thus obtained 5 (A-E) were converted into the 
corresponding sodium salts by cation exchange on a DOWEX (Na+ 
form) resin to have a homogeneous samples in good yield (55-72%).  
Compound 5A: NMR spectra of this compound showed dramatic 
line broadening, diagnostic of a slow equilibrium on the NMR time 
scale, which could suggest a strong propensity toward aggregation in 
CDCl3. 1H NMR (CDCl3, 500 MHz, room temperature, mixture of 
diastereoisomers): δ 7.02-6.60 (6H, complex signals), 5.85 (2H, br s), 
5.59 (1H, dd, J = 11.9 and 11.7 Hz), 5.11 (2H, complex signals), 4.78 
(1H, br s), 4.04 (1H, br signal), 3.95-3.63 (6H, complex signals), 2.05 
(2H, br signal), 1.92-0.99 (26H, complex signals), 0.85 (3H, br s), 0.79 
(3H, d, J = 4.8 Hz), 0.74 (6H, br s), 0.55 (3H, s) ppm. 31P NMR (CDCl3, 
161.98 MHz): δ –0.83 ppm. HRMS (MALDI-TOF, negative ions) 
m/zcalcd for C52H66O13P = 929.4246, found 929.4246 [M – H]-. 
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Compound 5B: 1H NMR (CD3OD, 500 MHz, room temperature, 
mixture of diastereoisomers): δ 7.11-6.72 (6H, complex signals), 5.91 
(1H, d, J = 1.5 Hz), 5.85 (1H, m), 4.98-4.75 (2H, complex signal), 4.41 
(1H, d, J = 11.5 Hz), 4.21-4.05 (5H, m), 3.88-3.68 (24H, complex 
signals) ppm. 31P NMR (CDCl3, 161.98 MHz): δ 3.1 ppm. HRMS 
(MALDI-TOF, negative ions) m/zcalcd for C36H44O18P = 795.2271, 
found 795.2271 [M – H]-. 
Compound 5C: 1H NMR (CD3OD, 500 MHz, room temperature, 
mixture of diastereoisomers): δ 7.79 (1H, s), 7.11-6.72 (6H, complex 
signals), 6.41 (1H, dd, J = 6.8 and 6.8 Hz), 5.91 (1H, d, J = 1.5 Hz), 
5.85 (1H, m), 4.97-4.74 (2H, complex signal), 4.65 (1H, m), 4.41 (1H, d, 
J = 11.5 Hz), 4.22-4.10 (4H, m), 4.00-3.85 (5H, complex signals), 2.44 
(2H, m), 1.99 (3H, s) ppm. 31P NMR (CDCl3, 161.98 MHz): δ 3.3 ppm. 
HRMS (MALDI-TOF) m/zcalcd for C35H34N2O17P = 785.1600, found 
785.1602 [M – H]-. 
Compound 5D: 1H NMR (CD3OD, 500 MHz, room temperature, 
mixture of diastereoisomers): δ8.56 (1H, s), 8.29 (1H, s), 7.11-6.72 
(6H, complex signals), 6.05 (1H,d, J=6.0 Hz), 5.91 (1H, d, J = 1.5 Hz), 
5.85 (1H, m), 4.90 (2H, complex signals), 4.63 (1H, m), 4.54 (1H, m), 
4.41 (1H, d, J = 11.5 Hz), 4.35 (1H, m),4.20 (2H, m), 4.21-4.05 (3H, m), 
3.88-3.68 (3H, s) ppm. 31P NMR (CDCl3, 161.98 MHz): δ 3.1 ppm. 
HRMS (MALDI-TOF) m/zcalcd for C35H33N5O16P = 810.1665 found 
810.1666 [M – H]-. 
Compound 5E: 1H NMR (CD3OD, 500 MHz, room temperature, 
mixture of diastereoisomers): δ 7.08-6.81 (6H, complex signals), 5.95-
5.89 (2H, m), 5.07 (1H, m), 4.97 (1H, m), 4.52 (2H, m), 4.24 (1H, m), 
4.06 (1H, m), 3.95-3.68 (7H, complex signals), 3.30 (1H, m), 2.01-0.70 
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(33H, complex signals) ppm. 31P NMR (CDCl3, 161.98 MHz): 4.3 
ppm. ESI-MS (positive ions): m/z calcd for C49H63O16P = 938.39; 
Found: [MH]+ = 939.48; [MNa]+ = 961.37. HRMS (MALDI-TOF, 
negative ions) m/z calcd for C49H62O16P = 937.3781, found 937.3782 [M 
– H]-. 
5.5.3 New silibinin glyco-conjugates: Synthesis and evaluation of 
antioxidant properties 
As previously described, therapeutic efficiency of silibinin is rather 
limited by its low bioavailability that limited its affectivity33. In this 
contest, it has been reported, for the quercetin, natural product 
endowed with potent antioxidant activitiy, that the therapeutic 
absorption of its modified quercetin glycoside, is more efficient than 
the quercetin aglycon, ascribing this benefit to the hydrophilic 
character of saccharide moieties that increase the water solubility of 
the aglycon, and enhance its bioavailability27,84,85. Moreover, the 
presence of hydroxyl groups brings the possibility of prodrug 
approach making possible the improvement of its pharmaceutical, 
pharmacokinetic and/or pharmacodynamic properties86. 
Starting from these considerations, we synthesized and biologically 
characterized, new 9''–silibinin conjugates connecting the mono- and 
di-saccharide residues to hydroxyl anomeric position through 
phosphodiester bond (Scheme 5). In our approach 9''-phosphoramidite 
1 (see Paragraph 5.5.2) has been used as silibinin substrate and 1-OH 
full protected mono- and di-saccharide derivatives (2–5, Scheme 5) 
chosen as sugar starting materials. We initially converted full 
acetylated mono and di-saccharides into 1-OH derivatives by a 
reaction with benzylamine in THF at room temperature87,88. 
Thus compounds 2–5 (Scheme 5) were coupled with derivative 1 
using 0.45 M tetrazole in CH3CN/DCM (1:1, v:v). After the treatment 
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with 5.5 M tert-butyl hydroperoxide solution in decane and 
subsequently with conc. aq. Ammonia/MeOH (1:1, v:v) at room 
temperature, the phosphodiester derivatives 6–9 were obtained in 
good yields. 
 
Scheme 5. General structures of new silibinin glyco-conjugates (top); synthesis of new 
9"-glyco-silibinin analogues (bottom). 
All compounds were then converted into the corresponding 
sodium salts by cation exchange on a DOWEX (Na+ form) resin to 
have crystalline samples. The crude materials were then subjected to 
the purification step, by reverse phase analysis (RP-18 HPLC), using 
a variety of columns and elution conditions, but unfortunately the 
mixture of diastereoisomers was too much complicated to be purified. 
In the end new silibinin analogues (6–9) were eluted onto Sep-Pak 
C18 cartridge and were obtained as a mixture of diastereoisomers, as 
observed 31P NMR analysis. The NMR analysis has proved very 
complex, in fact 1H and 31P NMR spectra of all compound showed 
dramatic line broadening, already at 5.0 mg/mL (ca. 7.0 mM), 
diagnostic of a slow equilibrium on the NMR time scale, which could 
suggest a strong propensity toward aggregation in H2O. This 
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drawback has not allowed a complete and detailed NMR 
characterization of the new derivatives. In this preliminary study we 
show the values of the 31P NMR and ESI-MS mass spectra signals 
(see Experimental Session). 
In order to evaluate their antioxidant activity, all silibinin 
derivatives were subjected to 2,2-diphenyl-1-picrylhydrazyl (DPPH) 
free radical scavenging assay89 and the Xanthine oxidase (XO) 
inhibition models assay (Table 4). 
Table 4. Free Radical Scavenging capacity (DPPH) and Xanthine Oxidase Inhibition 
(X – XO) 
Samples IC50 (M)a Cell viability (%)b 
 DPPH 
scavenging 
 after induction 
of oxidative stress 
silibinin-9"- phosphoryl-D-
glucopyranoside (6) 
301.7 ± 15.1 89.2 ± 3.1 42.7 ± 3.2 
silibinin-9”- phosphoryl-D-
mannopyranoside (7) 
108.0 ± 3.2 89.5 ± 2.3 42.3 ± 4.2 
silibinin-9"- phosphoryl-D-
galactopyranoside (8) 
233.0 ± 14.0 84.1 ± 2.4 42.8 ± 3.6 
silibinin-9"- phosphoryl-D-
lactopyranoside (9) 
154.7 ± 6.2 91.8 ± 2.1 48.4 ± 3.8 
silibinin 392.2 ± 7.8 45.3 ± 2.5 42.4 ± 2.9 
2,3-dehydrosilybin 27.0 ± 0.8 - - 
quercetin 0.31 ± 0.01 - - 
a. IC50 values (defined as concentrations that inhibites activity by 50%) were 
calculated using data obtained from at least three independent experiments. 
b. (Mean ± SD from three separate experiments run in duplicate, at 10, 25, 50, 100, 
and 200 µM). 
 
The DPPH test is a non-enzymatic method currently used to 
provide basic information on the scavenging potential of stable free 
radicals in vitro. On the other hand XO is considered to be the most 
important biological source of free radicals. Many references reveal 
cerebral microvascular injury resulting from XO production of 
superoxide free radicals90. XO inhibition is thereby implicated as 
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useful approach in treating cerebrovascular pathological changes or 
Central Nervous System (CNS) diseases91,92. From the DPPH assay 
shown in Table 4, we observed that introducing any sugar moieties in 
9" position did not led to a significant reduction of quenching 
properties. For comparison purposes, the antioxidant activities of 2,3-
dihydrosilybin and quercetin were evaluated as controls. In particular 
the new silibinin derivatives (6–9) showed DPPH radical scavenging 
activities similar to that of the silibinin 1, confirming that the 
introduction in 9'' of the sugar moiety did not influence the radical 
scavenging activity of this metabolite69,93. In basal conditions, the pre-
incubation of MKN28 cells with 6–9 and silibinin lead to two different 
results (Table 4). In fact, 6–9 analogues don’t affect cell viability, 
while Silibinin induced a cell death of about 50%, also at the lower 
dose used. The evaluation of cell viability in MKN28 cultured cells 
after incubation with 6–9 and silibinin, and the subsequent induction 
of oxidative stress, have shown that these molecules protect from cell 
death under oxidative stress, at least as the silibinin. 
5.5.3.1 Experimental Session 
General procedure for the synthesis of conjugates (6–9): 
phosphoramidite 1 (150 mg, 0.18 mmol) and the select saccharide 
compound 2 - 5 (0.19 mmol, previously dried and kept under reduced 
pressure, were reacted with a 0.45 M tetrazole solution in anhydrous 
CH3CN (1.0 mL, 0.45 mmol). The reaction was left under stirring at 
room temperature and monitored by TLC in the eluent system 1:2 n-
hexane:AcOEt, (v:v). After 1h, a 5.5 M tert-butyl hydroperoxide (tert-
BuOOH) solution in decane (70 μL, 0.40 mmol) was added to the 
mixture and left under stirring at room temperature. After 30 
minutes the reaction mixture was diluted with CHCl3, transferred 
into a separatory funnel, washed three times with water and dried 
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under reduced pressure. The next treatment with TEA/pyridine (1:1, 
v/v) to 1 h at 50°C and then with aq. ammonia (28%)/CH3OH (1:1, v:v) 
for 1 h at room temperature, allowed full deprotection from acetyl and 
2-cyanoethyl groups. The dried mixtures were purified by a Sep-Pak 
C18 Cartridge and then converted into the corresponding sodium 
salts by cation exchange on a DOWEX (Na+ form) resin to have a 
homogeneous samples in good yield (60-72%). 
Compound 6 (brown powder, 88.1 mg, 68%): 31P NMR (161.98 
MHz, D2O, room temperature, mixture of diastereoisomers) δ 2.9, 1.4, 
0.8. HRMS (MALDI-TOF, negative ions) m/zcalcd for C31H32O18P = 
723.1332, found 723.1332 [M – H]-. 
Compound 7 (brown powder, 94.0 mg, 72%): 31P NMR (161.98 
MHz, D2O, room temperature, mixture of diastereoisomers)δ1.3, 0.9, 
0.7. HRMS (MALDI-TOF, negative ions) m/zcalcd for C31H32O18P = 
723.1332, found 723.1333 [M – H]-. 
Compound 8 (brown powder, 82.3 mg, 63%): 31P NMR (161.98 
MHz, D2O, room temperature, mixture of diastereoisomers)δ 2.4, 1.6, 
1.1, 0.8. HRMS (MALDI-TOF, negative ions) m/zcalcd for C31H32O18P 
= 723.1332, found 723.1333 [M – H]-. 
Compound 9 (brown powder, 104.8 mg, 60%): 31P NMR (161.98 
MHz, D2O, room temperature, mixture of diastereoisomers)δ 1.1, 0.8. 
HRMS (MALDI-TOF, negative ions) m/zcalcd for C37H42O23P = 
885.1860, found 885.1859 [M – H]-. 
DPPH radical scavenging activity assay. The antioxidant activities of 
the compounds was assessed by examining their abilities to scavenge 
the 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical. DPPH solution 
(20 mg/mL) was prepared in methanol. The compounds was dissolved 
in methanol to prepare the stock solution (1 mM). Freshly prepared 
DPPH solution was taken in test tubes and analogue solutions (1 
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mM–1 M) were added to every test tube so that the final volume was 
2.25 mL and after 10 min, the absorbance was read at 515 nm. 
Quercetin and 2,3-dehydrosilybin were used as a reference standards 
and dissolved in methanol to make the stock solution with the same 
concentration (1 mM). 
Xanthine Oxidase Inhibition Assay. Oxidative stress was induced by 
incubating MKN28 cells with XO (10-100 mU/mL) in the presence of 
its substrate xanthine (X) (1 mM) for periods of up to 3 h. We 
examined the effect of Silibinin and of our analogues (6–9) on X – XO 
induced cell damage. In particular, cells were incubated with serum 
free medium (control) for 1 - 48 h; with serum free medium for 1–48 h 
and then with X (1 mM) – XO (50 mM) for 2 h (X – XO control); with 
6–9 and silibinin (10 – 200 µM) for 1–48 h and then, after washing, 
with X (1 mM) – XO (50 mM) for 2 h. Subsequently, we determined 
cell viability by [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazoliumbromide] MTT assay in MKN28 cultured cells. 
5.5.4 General Conclusions 
In conclusion in order to enhance water solubility and 
bioavailability of silibinin, we developed efficient protocols for the 
synthesis of new 9"-silibinin derivatives conjugated to a broad array 
of groups. Firstly, we generated a series of new and more polar 
analogues of silybin, useful models for chemical diversification 
(sulfate, phosphodiester, NH2, and N3 functional group) (Paragraph 
5.5.1, Scheme 3). The antioxidant activities of these analogues were 
evaluated using the DPPH assay. The results revealed that the 
amino-derivatives of silybin A and B (5A and 5B) are much more 
active than other derivatives and both sulfate derivatives (3A and 3B) 
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exhibit significant improvement of antioxidant activity compared to 
that of silibinin and BHA (Table 3). 
Subsequently, in the preceding paragraphs 5.5.2 and 5.5.3, it has 
been reported a simpler synthetic strategy that leads to a key 
building block of silibinin (Scheme 6), useful for a variety of 
modifications following a reliable and well-known phosphoramidite 
chemistry. Basically we synthesized new 9"-phosphodiester silibinin 
derivatives conjugating at the key intermediate, molecular carrier 
(steroids, bile acids), improved water solubility groups (polyethers), 
radical scavenger (nucleosides), and polar molecules as saccharides 
(Scheme 6). 
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Scheme 6. Graphical abstract of 9"-phosphodiester silibinin analogues starting from a 
phosphoramidite building block. 
The antioxidant activity of new silibinin glyco-conjugates was 
evaluated by DDPH and Xanthine oxidase (XO) inhibition model 
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assays. DPPH assays showed that the scavenging activities of 
silibinin glyco-conjugates (6–9) were similar to that of the silibinin 
confirming that the introduction of the sugar moiety in 9"position, 
had little effect on radical scavenging activity of this metabolite. 
From Xanthine oxidase (XO) assays in basal conditions, the pre-
incubation of MKN28 cells with silibinin and its glyco-analogues, 
showed that silibinin induce a cell death of about 50% also at the 
lower dose used, in contrast with the analogues that have not affect 
on the cell viability. Indeed, from the evaluation of cell viability in 
MKN28 cultured cells after the induction of oxidative stress, it results 
that these glyco-conjugates (6–9), protect from cell death after 
induction of oxidative stress, at least as silibinin. Moreover the glyco-
conjugates showed a water solubility well above that of silibinin, in 
fact it was possible to prepare solutions of about 70 mg/mL of 
analogues in water. These data encourage our future studies that are 
aimed to improve this synthetic strategy to realize libraries of 
optically pure glyco-conjugated silibinin and 2,3-dehydrosylibin 
derivatives. 
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Abbreviations 
Ac: acetyl 
Ac2O: acetic anhydride 
AcK: potassium acetate 
AcOEt: ethyl acetate 
AcOH: acetic acid 
BHA: hydroxyl anisole 
CCS: Collision Cross Section  
CD: Circular Dicroism  
AcCN: acetonitrile 
CPG: Controlled Pore Glass  
DBB: 3,4-dibenzyloxybenzyl 
DCA: dichloroacetic acid  
DCCI: N,N-dicyclohesylcarbodiimide 
DCM: dichloromethane 
DEAD: diethyl azodicarboxylate 
DHS: 2,3-dehydrosilybin 
DIEA: N,N-diisopropylethylamine 
DMAP: 4-(dimethylamino)pyridine 
DMF: N,N-dimethylformamide  
DMSO: dimethylsulfoxide 
DMT: 4,4-dimethoxy-triphenylmethyl 
DPPA:  diphenylphosphorylazide 
DPPH: 2,2-diphenyl-1-picrylhydrazyl 
DSC: Differential Scanning Calorimetry 
EDTA: Ethylenediaminetetraacetic acid 
ESI-MS: Electrospray Ionization Mass Spectrometry 
Et2O: ethyl etere 
  
EtOH: ethanol 
G4: G-quadruplex 
HEG: hexaethylene glycol 
HOBT: N-hydroxybenzotriazole  
HPLC: High Performance Liquid Chromatography 
HSA: Human Serum Albumin 
IN: integrase 
IMS: Ion Mobility Spectrometry 
LC-MS: Liquid Chromatography-Mass Spectrometry  
MALDI-TOF: Matrix Assisted Laser Desorption Ionizzation-Time of 
Flight 
MeOH: methanol 
MW: microwave 
MSNT: 1-(2-mesitilensolfonil)-3-nitro-1,2,4,triazolo 
NMIm: N-methyl-imidazole 
NMR: Nuclear Magnetic Resonance 
ODNs: oligodeoxynucleotides 
PAGE: PolyAcrylamide Gel Electrophoresis 
Py: pyridine 
RT: Reverse Transcriptase 
RP-HPLC: Reverse Phase HPLC  
RU: Response Unit 
SELEX: systematic evolution of ligands by exponential enrichment 
SPR: Surface Plasmon Resonance 
TBDMS: tert-butyldimethylsilyl 
TEA:  triethylamine 
TFA: trifluoroacetic acid 
TG: tentagel  
THF: tetrahydrofurane 
  
TLC: Thin Layer Chromatography  
Tm: Thermal Melting 
TMAA: trimethylammonium acetate 
TsCl: p-toluenesulfonyl chloride 
XO: Xanthine Oxidase 
  
  
 
